Establishment of reference intervals for kaolin-activated TEG and the STA compact automated analyzer for dogs and coagulation response in a canine model of endotoxemia by Eralp Inan, Oya
O
Y
A
 
E
R
A
L
P
 
I
N
A
N
 
 
 
 
 
 
C
O
A
G
U
L
A
T
I
O
N
-
T
E
G
-
S
T
A
 
C
O
M
P
A
C
T
-
E
N
D
O
T
O
X
E
M
I
A
-
D
O
G
VVB VVB LAUFERSWEILER VERLAG
édition scientifique
9 7 8 3 8 3 5 9 5 8 4 9 4
VVB LAUFERSWEILER VERLAG
STAUFENBERGRING 15
D-35396 GIESSEN
Tel: 0641-5599888 Fax: -5599890
redaktion@doktorverlag.de
www.doktorverlag.de
VVB LAUFERSWEILER VERLAG
édition scientifique
ISBN: 978-3-8359-5849-4
Establishment of Reference Intervals for  Kaolin-
activated TEG  and the STA Compact Automated
Analyzer for Dogs and Coagulation Response 
in a Canine Model of Endotoxemia
Oya Eralp Inan 
INAUGURAL-DISSERTATION zur Erlangung des Grades eines Dr. med. vet.
beim Fachbereich Veterinärmedizin der Justus-Liebig-Universität Gießen
Das Werk ist in allen seinen Teilen urheberrechtlich geschützt. 
Jede Verwertung ist ohne schriftliche Zustimmung des Autors 
oder des Verlages unzulässig. Das gilt insbesondere für 
Vervielfältigungen, Übersetzungen, Mikroverfilmungen
 und die Einspeicherung in und Verarbeitung durch 
elektronische Systeme.
1. Auflage 2011
All rights reserved. No part of this publication may be
 reproduced, stored in a retrieval system, or transmitted, 
in any form or by any means, electronic, mechanical, 
photocopying, recording, or otherwise, without the prior 
written permission of the Author or the Publishers.
st1  Edition 2011
©  2011 by VVB LAUFERSWEILER VERLAG, Giessen
Printed in Germany 
VVB LAUFERSWEILER VERLAG
STAUFENBERGRING 15, D-35396 GIESSEN
Tel: 0641-5599888 Fax: 0641-5599890 
email: redaktion@doktorverlag.de
www.doktorverlag.de
édition  scientifique
 Aus dem Klinikum Veterinärmedizin, Klinik für Kleintiere, klinische 
Pathophysiologie und klinische Laboratoriumsdiagnostik 
der Justus-Liebig-Universität Gießen 
Betreuer: Prof. Dr. Andreas Moritz 
 
 
Establishment of Reference Intervals for Kaolin‐activated TEG  
and the STA Compact Automated Analyzer for Dogs and  
Coagulation Response in a Canine Model of Endotoxemia 
 
 
 
INAUGURAL‐DISSERTATION 
zur Erlangung des Grades eines 
Dr. med. vet. 
beim Fachbereich Veterinärmedizin 
der Justus-Liebig-Universität Gießen 
 
 
 
 
eingereicht von 
 
Oya Eralp Inan 
Tierärztin aus Schwelm/Deutschland 
 
 
Gießen, 2011

Imprimatur 
Mit Genehmigung des Fachbereichs Veterinärmedizin der 
 Justus-Liebig-Universität Gießen. 
 
 
Dekan: Prof. Dr. Dr. h.c. Martin Kramer 
 
 
 
Gutachter: Prof. Dr. Andreas Moritz 
         Prof. Dr. Georgios Scheiner - Bobis  
 
 
 
 
 
Tag der Disputation: 12. Dezember 2011
4 
Table of contents 
 
Abbrevations           8 
1. Preface           11 
2. Introduction          13 
2.1. Physiology of the coagulation process      13 
2.1.1. Primary hemostasis         13 
2.1.2 Secondary hemostasis        14 
2.1.3. Tertiary hemostasis         15 
2.1.4 Natural inhibitors of hemostasis       16 
2.2. Pathologies of the coagulation process      17 
2.2.1. Hereditary coagulopathies        17 
2.2.2. Acquired coagulopathies        19 
2.2.3. Hemostasis, sepsis and DIC       20 
2.3. Diagnostic tests          21 
2.3.1. Primary hemostasis         22 
2.3.2. Secondary hemostasis         23 
2.3.3. Tertiary hemostasis          25 
2.3.4. Assessment of thrombophilia and heparin effects    26 
2.3.5. Global tests (Thromboelastography)      27 
2.4. Reference intervals for coagulation assays in dogs    30 
3. Material and Methods         32 
3.1. Establishment of reference intervals for TEG and variables reflecting 
       secondary and tertiary hemostasis run on the STA compact analyzer  32 
3.1.1. Evaluation of repeatability, interferences and the effect of anticoagulant 32 
3.1.1.1. Repeatability of the TEG analysis      32 
3.1.1.2. Effect of anticoagulant in TEG analysis      33 
3.1.1.3. Effect of hemolysis on TEG analysis      33 
5 
3.1.1.4. Repeatability of the variables assayed on the STA compact   34 
3.1.1.5. Impact of hemolysis and lipemia on the variables measured on  
            the STA compact         34 
3.1.2. Establishment of reference intervals      35 
3.1.2.1. Sampling          36 
3.1.2.2. Method – TEG         37 
3.1.2.3. Default settings and methods of human assays applied at the STA  
            compact          38 
3.1.2.4. Validation of human assays on the STA compact    41 
3.1.2.5. Modification of test methods applied at the STA compact   41 
3.2. Evaluation of the impact of endotoxemia on the coagulation process  42 
3.2.1. Sampling          44 
4. Statistics           45 
4.1. Statistical analysis for calculation of reference intervals for kaolin-activated 
      TEG and coagulation variables       45 
4.1.1. Statistical analysis for the assessment of repeatability, interferences 
         and effect of anticoagulant        45 
4.1.1.1. Repeatability of the TEG analysis      45 
4.1.1.2. Impact of anticoagulant and sex on TEG analysis    45 
4.1.1.3. Effect of hemolysis on TEG analysis      46 
4.1.1.4. Influence of sex and repeatability of the variables assayed  
            on the STA compact        46 
4.1.1.5. Impact of hemolysis and lipemia on the variables measured on  
            the STA compact         46 
4.1.2. Statistical analysis for calculation of reference intervals   47 
4.2. Statistical analysis for the evaluation of the impact of endotoxemia 
       on the coagulation process        47 
5. Results           48 
 
6 
5.1. Establishment of reference intervals for TEG and variables reflecting 
       secondary and tertiary hemostasis run on the STA compact   48 
5.1.1. Repeatability, interferences and the effect of anticoagulant   48 
5.1.1.1. Repeatability of  TEG analysis       48 
5.1.1.2. Effect of anticoagulant in TEG analysis      48 
5.1.1.3. Effect of hemolysis on TEG results      49 
5.1.1.4. Repeatability of variables assayed on the STA compact   51 
5.1.1.5. Impact of hemolysis and lipemia on variables measured on  
             the STA compact         52 
5.1.2. Results for reference intervals       55 
5.2. Evaluation of the impact of endotoxemia on the coagulation process  60 
6. Discussion           68 
6.1. Establishment of reference intervals for TEG and variables reflecting 
       secondary and tertiary hemostasis run on the STA compact   68 
6.1.1. Repeatability, interferences and the effect of anticoagulant   68 
6.1.1.1. Repeatability of TEG analysis       68 
6.1.1.2. Impact of anticoagulant in TEG analysis     68 
6.1.1.3. Effect of hemolysis on TEG results      69 
6.1.1.4. Repeatability of variables assayed on the STA compact   72 
6.1.1.5. Impact of hemolysis and lipemia on variables measured on  
            the STA compact         73 
6.1.2. Reference intervals         74 
6.2. Evaluation of impact of endotoxemia on the coagulation process  81 
7. Summary           87 
 Objective           87 
 Material and Methods         87 
 Statistics           88 
 Results           89 
 Conclusion           90 
7 
8. Zusammenfassung         91 
 Ziel der Studie          91 
 Material und Methoden         91 
 Statistik           92 
 Ergebnisse           93 
 Schlussfolgerung          95 
Reference List          96 
Acknowledgements         119 
  
  
8 
Abbrevations 
 
ACT  activated clotting time 
ADP  adenosinediphophate 
anti-FXa anti-activated factor X 
APC  activated protein C 
APCR  activated protein C resistance 
aPTT  activated partial thromboplastin time 
AT  antithrombin 
avWD  acquired von Willebrand disease 
α2AP  α-2-antiplasmin 
BMBT  buccal mucosal bleeding time 
CBC  complete blood count 
CHS  Chediak-Higashi syndrome 
CV  coefficient of variation 
deg  degree 
DIC  disseminated intravascular coagulation 
DSH  domestic shorthair 
FVIII  factor VIII 
FV/FVa factor V/activated factor V  
FVII/FVIIa factor VII/activated factor VII 
FVIII/FVIIIa factor VIII/activated factor VIII 
FIX/FIXa factor IX/activated factor IX 
FX/FXa factor X/activated factor X 
FXII/FXIIa factor XII/activated factor XII 
FXIII/FXIIIa factor XIII/activated factor XIII 
FDP  fibrin degradation product 
GT  Glanzmann thrombostenia 
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HC  heparin cofactor II 
HF  freeze-thawing hemolysis 
HK  high molecular weight kininogen 
HM  mechanical hemolysis 
IMT  immune mediated thrombocytopenia 
K  kallikrein 
LMWH low molecular weight heparin 
LPS  lipopolysaccharide 
min  minute 
mm  millimeter 
MPC  mean platelet component concentration 
MPM  mean platelet mass 
MPV  mean platelet volume 
NO  nitric oxide 
OSPT  one stage prothrombin time 
PAF  platelet activating factor 
PAI  plasminogen activator inhibitor 
PC  protein C 
PCDW platelet component distribution width 
PGI2  prostacycline 
PK  prekallikrein 
PLT  platelet 
pNA  para-nitroaniline 
PS  Protein S 
PT  prothrombin time 
TAFI  thrombin activable fibrinolysis inhibitor 
TEG  thromboelastography 
TF  tissue-factor 
TFPI  tissue-factor pathway inhibitor 
10 
TM  thrombomodulin 
tPA  tissue plasminogen activator 
TT  thrombin time 
TXA2  thromboxane A2 
WBC  white blood cell 
vWD  von Willebrand disease 
vWf  von Willebrand factor   
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1. Preface 
 
In the past 50 years, several risk factors for developing venous thrombosis have been 
described in people.1 In veterinary medicine, knowledge of factors predisposing to 
thrombophilia is limited and subject of current investigations. In 1854 the German 
pathologist Rudolf Virchow stated the related factors leading to hypercoagulable 
states.1 So these hypercoagulable states may be causes of venous thrombosis, arterial 
thrombosis and thromboembolism, leading to organ failure.1 Disorders associated 
with hypercoagulation may be acquired or hereditary.1 In people, many hereditary 
disorders have been detected but reported disorders in animals are generally 
acquired and caused by other underlying diseases.1,2 Early diagnosis might provide a 
rapid treament. There are several routine laboratory tests including coagulation 
times (prothrombin time, activated partial thromboplastin time), fibrinogen, and 
platelet count used in veterinary medicine to diagnose hypocoagulatory states 
(bleeding tendency), but only rare tests for detection of hypercoagulable states. 
Techniques like thromboelastography give qualitative information about all phases 
of the coagulation process including the clot formation and breakdown and also the 
stability of the clot itself. In people3 and dogs4, thromboelastography has been used 
to detect both hypo- and hypercoagulability. Thromboelastographic evaluations of 
hypercoagulability has been performed in dogs with neoplasia, disseminated 
intravascular coagulation (DIC), immune mediated hemolytic anemia (IMHA), 
parvoviral enteritis and treatment with deracoxib.5-9 In this study it was also of 
interest to detect an early coagulation response in a canine model of endotoxemia by 
measuring antithrombin (AT), protein C (PC), protein S (PS), activated protein C 
(APC) response, plasminogen (PLG), factor VIII (FVIII) and fibrin degradation 
products (FDPs). Therefore, using these parameters for dogs, test methods have to be 
evaluated and reference ranges are needed. However, reference ranges for 
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coagulation parameters in dogs have been mainly established for routine coagulation 
parameters. Furthermore, even for the routine coagulation panel it is generally 
agreed upon that analyzer- and method-specific reference intervals have to be 
established. 
 
The current study has two aims: 
1) The establishment of reference ranges for kaolin-activated TEG (TEG® 5000 
Thrombelastograph, Haemonetics Corporation; formerly Haemoscope 
Corporation; Braintree, MA, USA) variables R, K, angle α, MA and G and for 
the variables one-stage prothrombin time (OSPT), activated partial 
thromboplastin time (aPTT), thrombin time (TT), antithrombin (AT) , 
fibrinogen plasma concentration, PC, PS, PLG, APC-ratio, FVIII, D-dimer and 
anti-factor Xa (anti-FXa) measured with the benchtop analyzer STA Compact 
(STA Compact®, Roche Diagnostics GmbH, Mannheim, Germany). Also 
repeatability and interferences such as hemolysis and lipemia were assessed 
before developing the reference intervals.  
2) In the second part of the study, it was of interest to characterize the early 
response of the coagulation system to low-dose lipopolysacharide (LPS) 
application in healthy dogs compared to a placebo (saline) as reflected by 
dynamic alterations of variables reflecting secondary and tertiary hemostasis, 
natural inhibitors of coagulation as well as TEG measurements.  
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2. Introduction 
 
2.1. Physiology of the coagulation process 
Hemostasis is the mechanism to control blood loss (minor or major) arising from 
vascular or tissue trauma. Also fibrinolysis, the physiological remove of the clot, is 
initiated with the activation of coagulation and is a part of this mechanism. The 
hemostatic system is a finely balanced mechanism. A reduced clotting activity, is 
called hypocoagulation or the adverse, hypercoagulation, can lead to 
pathophysiological states thrombosis or thromboembolism.10 Under physiological 
conditions, coagulation does not occur in blood circulation, because clotting factors 
are circulating in inactive forms and other required components are in the 
extravascular area (tissues).10,11 There are different types and a variety of proteins 
(coagulation proteins) included in the coagulation process.10 When extravascular 
components get into the blood stream, the coagulation process is initiated with a 
series of activations (cellular and enzymatic) and cell surface changes.  
Traditionally, the hemostatic system has been divided into 3 stages: primary 
hemostasis, secondary hemostasis and tertiary hemostasis, including fibrinolysis and 
natural anticoagulants.12 
 
2.1.1. Primary hemostasis 
The primary hemostasis is the phase responsible for creating the primary platelet 
plug. Here, the reactions take place with vascular endothelium components, platelets 
and von Willebrand factor (vWf).12 The normal vascular endothelium is inhibiting the 
coagulation process by synthesis of antagonists of platelet activation including nitric 
oxide (NO) and prostacyclin (PGI2). But after vascular injury, vasoconstriction 
develops, so blood flow is slowed down and blood loss is delayed. Folllowing 
platelet adhesion, activation and aggregation, the primary platelet plug is formed at 
the corrupted vessel wall. With the adhesion of platelets to the collagen fibers in the 
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exposed subendothelium, platelets bind to collagen. The process of platelet adhesion 
is influenced by the shear rate. In regions with high shear rate (such as small and 
medium sized arteries), the initial adhesion takes place via collagen and vWf.12 In 
regions of low shear rate (such as venes or large arteries) the platelet adhesion is 
mediated by fibrinogen.12 The adhesion activates platelets and their shape changes 
lead to an increase of their surface contact. Activated platelets stimulate the 
aggregation of other platelets. The most important aggregating agent is thrombin 
which is formed by the coagulation pathway from prothrombin (factor II).12 vWf and 
fibrinogen together also mediate platelet aggregation. The primary platelet plug is 
formed and needs to be stabilized by fibrin. Primarily, the aim of secondary 
hemostasis is to form fibrin by thrombin.  
 
2.1.2. Secondary hemostasis 
Secondary hemostasis is composed of the coagulation cascade, resulting in fibrin 
formation. The coagulation cascade includes three pathways: the intrinsic pathway, 
the extrinsic pathway, and the common pathway.12 The cause for calling it “extrinsic” 
is the fact that the components of this pathway are provided from the extravascular 
area.10,12 This classification of the coagulation cascade does not correspond to in vivo 
conditions, but is helpful for the interpretation of laboratory tests.13,14 The extrinsic 
pathway is initiated by a trauma and leads to the release of tissue factor (TF) from 
different tissues like organ capsules and mucous membranes, which activates factor 
VII (FVII, prothrombin).10 Pathological conditions like inflammation can result in 
expression of TF by other type of cells.10 The activated FVII (FVIIa)-TF complex 
activates factor X (FX) and this is the intersection point with the intrinsic pathway, 
followed by the common pathway. The intrinsic pathway is initiated primarily by 
thrombin (small amount), which is formed by the exstrinsic pathway.12 The tissue 
factor pathway inhibitor (TFPI) inhibits the mechanism initiated by TF. The small 
amount of thrombin initiates the intrinsic pathway through the activation of FXI. FXI 
is also activated by an auto-activation with the activation of factor XII (FXII) by the 
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high molecular weight kininogen (HK)-prekallikrein (PK) complex (contact 
pathway).10,12,15 This action leads also to the conversion of PK into kallikrein (K), 
which then is responsible for the convertion of HK into bradykinin.12 Bradykinin 
leads to the release of tissue plasminogen activator (tPA).16 This phase is more 
important with its anticoagulant and profibrinolytic effects than its coagulation 
effects.10 After the activation of factor XI (FXI), activated FXI (FXIa) activates factor IX 
(FIX). The activated FIX (FIXa)-activated factor VIII (FVIIIa) complex interacts with 
calcium and platelets (tenase complex) for the activation of FX (the intersection 
point).12 Some studies suggests that the intrinsic pathway, i.e. the contact pathway 
plays a role in thrombus formation and also does not correspond to in vivo 
conditions.10,17,18  
At the intersection point the common pathway begins and an activated FX (FXa)-
activated factor V (FVa) complex is formed.12 This complex interacts with calcium 
and platelet phospholipid (prothrombinase complex) and transforms fibrinogen to 
fibrin by the development of thrombin (large amount) from prothrombin.10,12  
Thrombin activates also FVIII, which is responsible for the formation of cross-linked 
fibrin polymers from fibrin polymers together with calcium.12 FVIII is only activated 
if there is a certain amount of fibrin polymers.19 Thrombin is one of the most 
important component of hemostasis, which is not only  responsible for the 
coagulation but has also an antithrombotic effect.10,20 The large amount of thrombin, 
needed for fibrin formation, is supplied by the associated mechanism of the extrinsic 
and intrinsic pathway.21 The plasma half-life of thrombin is very short.10,22  
 
2.1.3. Tertiary hemostasis  
The tertiary hemostasis is the fibrinolysis part of coagulation. The aim of this process 
is to form plasmin for the clot dissolution.12,23 
Plasminogen is cleaved to plasmin by tPA.10,12 At this time, plasminogen is bound to 
the fibrin at the clot.10,12 Kallikrein and FVIIa activates plasminogen directly, but 
urokinase and FXII are also activators.10,12 Activated protein C (APC) induces the 
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activation of plasmin. Plasminogen activation inhibitor PAI is a inhibitor of plasmin 
due to its blocking effect on APC.24 The plasmin in circulation is inhibited by α2-
antiplasmin (α2AP).24 Fibrin degradation by plasminogen results in the formation of 
fibrin degradation products (FDPs). D-dimer are FDPs, which only appear by the 
degradation with plasminogen.13,25  
 
2.1.4. Natural inhibitors of hemostasis   
There are a variety of inhibitors with different effects. As mentioned before, NO and 
PGI2 are natural inhibitors efficient in primary hemostasis by inhibition of platelet 
function.10,12  
Another natural anticoagulant is antithrombin (AT). It is efficient together with its 
cofactor heparin.10 Thrombin is inhibited by AT with the stimulation of heparin. For 
this reason heparin is used as an antithrombotic agent.10,26,27 AT-heparin complex has 
also an inhibiting effect against a variety of proteases like FXIIa, FXIa, K, FIXa and 
FVIIa.10 
Heparin cofactor II (HC) is a specific thrombin antagonist. HC inhibits thrombin, 
however, HC deficiency is not associated with a of risk for thrombosis.10,26 It is 
thought that HC is the primary involved in the process of wound healing and 
inflammation.10,26 
Tissue factor pathway inhibitor (TFPI) is an inhibitor of TF-FVIIa and FXa, which 
exists on cell surfaces and platelets.10,28 FXa-activated factor V (FVa) complex is 
resistant to TFPI inhibition.10,29 Recent studies indicate that protein S (PS) has a 
cofactor role for TFPI.10,30 
Protein C (PC) is an inhibitor of thrombin, which is produced in the liver.10 PC is 
activated by PS and molecules of endothelial cells, but for an effective inhibition of 
thrombin, activated protein C (APC) needs thrombomodulin (TM).10,31 APC inhibits 
thrombin formation by blocking of FVIIIa and FVa whereupon PS is recquired as a 
cofactor. PS is also a cofactor for TFPI which is necessary for the inhibition of FXa.10,30 
But when FVIII is bound to vWf, it it is not inhibited by APC.10,31 Furthermore, 
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cleaving of FV by APC is more efficient on endothelial surfaces.10,32 Activated PC-PS 
also activates plasminogen activator inhibitor 1 (PAI-1), which is an inhibitor of 
plasminogen activators and effects tPA.10,31  
As in all physiologic processes, there is also a counter regulation of the inhibition of 
fibrinolysis. 
One of the fibrinolysis inhibitors is the thrombin activated fibrinolytic inhibitor 
(TAFI) which prevents the fibrin clot from fibrinolysis. TAFI is activated by thrombin 
(large amount) and plasmin.10 TAFI changes the structure of fibrin and blocks the 
binding of plasminogen to fibrin.10  
Another inhibitor of fibrinolysis is α2AP which inhibits plasminogen, as mentioned 
before.10 However, plasminogen bound to fibrin in a plasminogen-fibrin complex is 
resistant to α2AP inhibition.10  
 
2.2. Pathologies of the coagulation process  
Hemostatic disorders can be inherited or acquired. Acquired disorders are the most 
common hemostatic problems.10 
 
2.2.1. Hereditary coagulopathies 
Hereditary coagulopathies include disturbances of primary and secondary 
hemostasis. One of the most often seen hemostatic defects in people33,34 and in 
dogs33,35 is von Willebrand disease (vWD). Clinical signs associated with vWD are 
those typically observed in disorders of primary hemostasis, like epistaxis, petechia, 
hematuria and a prolonged bleeding time after trauma. Clinical signs and diagnosis 
can change in relation to the defect of vWf.33,34,35-39 Clinical signs are best known for 
dogs33,35,40-45, but the disease has been also detected in other animals.33,46-51 
An inherited thrombocytopenia can seen with the grey collie syndrome associated 
with disturbances in neutrophils, reticulocytes and platelets.52 Some dog breeds have 
a thrombocytopenia without clinical signs like Greyhounds and Cavalier King 
Charles Spaniels.53-56 Other inherited disorders are Glanzmann thrombosthenia (GT) 
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and Chediak-Higashi-Syndrom (CHS). Here, the diseases are arising from platelet 
function disorders.54,57-59 A thrombopathy like the Scott syndrome in people has been 
reported in a German Shepherd dog family.54,56,60 Hemophilia A is the most common 
hereditary coagulation disorder in animals.61 The aetiology of the disorder is a 
deficiency or functional problem of FVIII and FIX.61,62 Hemophilia A is not a breed 
specific disorder, however, it is often seen in German Shepherd dogs.61,63 The disease 
can be seen in severe or mild form.61 In mild forms no clinical signs are present and 
disorders can only recognized after a trauma or surgery. Otherwise in more serious 
cases, hematoms or other spontaneous hemorrhages can be seen.61 Also hemophilia B 
is an important coagulapathy which is not as often seen as hemophilia A.61 Here the 
cause is a deficiency or functional problem of FIX.61,62 Clinical signs are the same as 
for hemophilia A.61  
All of the remaining factor deficiencies identified in animals like fibrinogen, 
prothrombin, FVII, FX, FXI, FXII and contact factor defects are rare and are generally 
breed specific or have been seen in a family.61 One of this disorders is a hereditary 
fibrinogen defect reported in dogs, cats, goats and sheep.61,64,65 Acquired 
hypofibrinogenemia arising from pathological conditions is more commonly seen.61 
Hereditary prothrombin deficiency have been reported in few cases.61,64 FVII 
deficiencies have been reported in Beagles, Deerhounds and in a Alaskan Klee 
Klai.61,66,67 FX deficiencies have been reported in dogs and a domestic shorthair (DSH) 
cat, whereat this FX deficiency is only a partial one, because the absence of FX can 
lead to death.61,64,68,69 FXI deficiency has been reported in dogs, cattle and DSH 
cats.61,70-72 FXII, PK and HK defects have been detected in dogs, cats (purebred and 
DSH) and horses.61,64,73-76 Deficiencies of all vitamin K dependent factors due to defect 
in vitamin K decarboxylase have been described in cats, sheep and in Labrador 
retrievers.61,77-79 All these problems lead to mild to severe bleeding disorders.61  
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2.2.2. Acquired coagulopathies 
Acquired coagulaopathies are much more commonly seen disorders than hereditary 
ones. Platelet disorders and acquired coagulation deficiencies can be caused by a 
variety of infectious diseases.80 
Platelet disorders may result from thrombocytopenia, thrombocytopathia or 
thrombocytosis. Thrombocytopenia can occur due to decreased platelet production, 
platelet destruction, increased consumption or blood loss. Bone marrow disturbances 
like neoplasia or leukemia may result in low production of platelets.24,53 The 
destruction of thrombocytes has a variety of mechanisms, one of them is immune-
mediated thrombocytopenia (IMT). Further aetiology includes neoplasia, drugs, bone 
marrow disorders or inflammatory processes.24,53,81,82 Infectious diseases including 
parasites such as Babesia canis infection, some bacterial infections like leptospirosis, 
salmonellosis, or rickettsial infections like Ehrlichia canis,Anaplasma platys, Anaplasma 
phagocytophilum or Rickettsia rickettsii and viral diseases like canine distemper virus 
(CDV), herpes virus, infectious canine hepatitis or parvovirus infection in dogs can 
all be associated with thrombocytopenia.24,53,84-87 The consumption of platelets is 
generally caused by DIC, thrombotic thrombocytopenic purpura (TTP) which is well 
known in people but rarely described in animals (pigs) and hemolytic uremic 
syndrome (HUS).53  
In contrast thrombocytosis may occur secondary to some drugs or inflammatory 
cytokines.88 
Acquired thrombopathias generally occur secondary to underlying 
diseases/conditions like renal failure, infections, neoplasia and administration of such 
as non-steroidal anti-inflammatory drugs89 such as aspirin3 and clopidogrel.90,91  
Acquired vWD is uncommon but can be observed in people and animals due to 
other underlying diseases such as immune mediated, cardiac or neoplastic diseases 
or pretreatment with hydroxethyl starch.33,34  
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Coagulatiom components like prothrombin, FVII, FIX, FX, FXI, FXII, PC, PS, FV, 
FXIII, AT and plasminogen originate from the liver. So liver diseases and 
hepatobiliary disorders may lead to deficiencies or functional insufficiency of these 
components and result in different coagulation disorders.80,92-96 Moreover, in small 
animal clinical practice, bleeding disorders in association with rodenticide toxication 
is a common acquired coagulopathy. Coumadin and second-generation 
anticoagulant rodenticides inhibit the vitamin K epoxide reductase in the liver and 
thus the vitamin K cycle.10 Vitamin K is required for the synthesis of functional 
prothrombin, FVII, FIX and FX by carboxylation.10 In the absence of vitamin K, these 
coagulation componenets are circulating as inactive molecules in the plasma 
resulting in bleeding disorders.80  
Additonally, all these coagulation components can be influenced by drugs, vasculitis, 
renal disease, endocrinal diseases and can result in a variety of coagulopathies.80 DIC 
is also a common cause for acquired coagulopathy due to a consumption of 
coagulation platelets, coagulation factors and inhibitors of coagulation.97  
 
2.2.3. Hemostasis, sepsis and DIC 
DIC is an acquired coagulopathy, which disturbs the hemostatic balance and results 
in microthrombus formation and consumption of coagulation and fibrinolysis 
componenets. All this can lead to death. DIC is not a disease itself but arises from 
other underlying diseases, which increase the activation of coagulation components 
and affect generally severely ill patients.7,13,14,25,98-102 Reported underlying diseases 
include neoplasia, sepsis, endotoxemia, pancreatitis, IMHA which can be seen in 
different priorities in small animals, farm animals and horses.97,108-110 The knowledge 
about pathogenesis of DIC has been mainly gained from experimental studies.97,111,112  
At first, coagulation is initiated due to the massive endothelial injury associated with 
inflammation. Cytokines causes a TF expression, much more than in normal 
conditions and are responsible of TFPI insufficiency.97,113,116 The TF-FVIIa amount, 
which is responsible for thrombin formation, could not be regulated under these 
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circumstances. At this stage, natural anticoagulants are still enough for an inhibition 
of coagulation, however this phase is characterized by a hypercoagulable state.97,112,117 
The continuing imbalance cannot depress the thrombin formation, which leads to 
microvascular fibrin accumulations.97 At this time, inflammation initiates coagulation 
and coagulation triggers the inflammation in a complex mechanism.97,111,118-120 The 
persistent underlying disease results in the continous consumption of coagulation 
factors and inhibitors, which is also a cause of sustained inflammatory effects and 
can end with sepsis.97,111,118,121,123 With the consumption of this components a 
hypocoagulable state arises. Microthrombus formations is followed by  hypoxia in 
different tissues and organ failures.97 This state leads to spontaneous bleeding or 
prolonged bleeding times after injury. All this factors are life-threatining and DIC can 
end with death.  
In the majority of studies, the regulation of coagulation during the early course of a 
septic process has not been investigated. Although studying the early dynamic 
changes of coagulation after infection would be ideally carried out in canine patients 
with the naturally developing syndrome, there are ethical limitations to this 
approach. An alternative method is the use of endotoxin i.e., lipopolysaccharide 
(LPS) in research animals, like done here with low-dose LPS administration. 
However, the overwhelming induction of endotoxemia commonly used in 
experimental models is unlike the smoldering septic process typically seen in clinical 
patients. Thus, the application of information gained from a rapidly fatal, severe 
insult to a clinical patient with more smoldering disease has been considered to be 
difficult.124 
 
 
2.3. Diagnostic tests 
The most important aspect of diagnosis of hemostatic disorders is the collection and 
submission of an optimal sample for testing to avoid prenalytic errors due to poor 
sample collection and handling.12  
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2.3.1.Primary hemostasis 
Primary hemostasis tests include the evaluation of platelet count, platelet function, 
assessment of vWf and the buccal mucosal bleeding time (BMBT). For the evaluation 
of platelet numbers, EDTA as anticoagulant is preferred, because heparin may cause 
platelet clumping.125 
The platelet count can be estimated from a blood smear, where each platelet seen in a 
microscope field with the 100× oil immersion objective is nearly equivalent to 15,000 
platelets/µl.24 In many clinics, automated hematology analyzers are used, however, 
the automated results have to be confirmed on a blood smear in case of 
thrombocytopenia. Here, the ADVIA 2120™ with species specific software (Siemens 
Healthcare Diagnostics GmbH) was used,providing an accurate analysis of platelets 
and platelet activation indices due to sphering of platelets and two dimensional laser 
light scattering126, mentioned later. 
Regarding the assessment of platelet function, the most commonly used test is the 
buccal mucosal bleeding time, the BMBT.12 It is a simple clinical method and very 
useful. A small incision is made with a lancet at the oral mucosa. After this, a filter 
paper is hold to the incision rim and the time is taken until the blood is not 
permeating into the filter paper any more. This time is the BMBT.  
Aggregometry is a commonly used in vitro platelet function test. There are two types 
of aggregometry, i.e. impedance and optical methods.127 A platelet agonist is added 
to sample, which binds to platelet membranes and platelet aggregation is initiated.127 
Hematology analyzers such as the ADVIA 2120 might be used for assessment of 
platelet function, i.e. whole blood aggregometry by measuring the aggretion-induced 
decrease in platelet count after adding the agonist.128 Furthermore, the ADVIA 2120 
provides a unique methodology to specifically assess platelet activation status. 
During each measurement, a variety of platelet indices are routinely provided that 
are increasingly recognized as surrogate markers of platelet activation and include 
mean platelet volume (MPV), mean platelet mass (MPM), the mean platelet 
component concentration (MPC) and the platelet component distribution width 
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(PCDW).129-131 The MPC is a measure for platelet refractive index reflecting platelet 
granularity – and thus the activation status.126 The MPV is derived from the platelet 
volume histogram. The MPM is calculated from the platelet dry mass histogram, 
which means platelet volume ×platelet content/100. The PCDW is a measure of the 
variation in platelet shape change and is calculated by MPC × 100/standard deviation 
of MPC.  
Regarding the evaluation of vWf, functional, structural and quantitative 
measurements of vWf can be performed.12 Some functional assays have only been 
used in human medicine, so that they have to be adapted for their use in animal 
specimens.33  
 
2.3.2. Secondary hemostasis 
Assessment of secondary hemostasis includes tests for the evaluation of the extrinsic, 
intrinsic, and common pathway. Routinely used tests include the activated clotting 
time (ACT), prothrombin time (PT), activated partial thromboplastin time (aPTT), 
and fibrinogen. The ACT gives information about the intrinsic and common 
pathway.12 The ACT is performed by adding whole blood sample tubes, containing 
some subtrates, which initiate the coagulation by contact activation, and time is 
measured until a clot formation. The ACT gives information about the intrinsic and 
common pathway and can be used for monitoring of anticoagulant therapy 
(especially heparin).12  
Like the ACT, the aPTT reflects the intrinsic and common pathway. For 
measurement of the aPTT, the coagulation reaction is initiated by contact activation. 
In the actual study, kaolin was used as surface activator (STA APTT Kaolin, Roche 
Diagnostics GmbH, Mannheim, Germany) and results are reported as the 
coagulation time. Abnormal prolongations of aPTT are related with conditions 
affecting the intrinsic or common pathway, like congenital factor defects, drugs such 
as heparin, and a variety of other diseases.132-135  
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The PT is a screening test for the extrinsic and common pathways. Here a one-stage 
prothrombin-time (OSPT) measurement was performed. The OSPT is measured by 
adding calcium and thromboplastin into the citrated blood plasma and like the other 
tests the coagulation time is measured. Here, a combined thromboplastin, i.e. a 
reagent containing fibrinogen and FV in addition to thromboplastin was used (STA 
Neoplastin® Plus, Roche Diagnostics GmbH, Mannheim, Germany). The 
prolongation of the OSPT is an indicator of conditions affecting the extrinsic 
pathway, i.e. like hereditary or acquired factor VII deficiencies or inhibitors ( e.g. 
warfarin, high doses of heparin). 64,132-134,136  
Studies have shown that the shortening of OSPT did not indicate a hypercoagulable 
state.7,98,112 Another screening test for assessment of secondary hemostasis is the 
thrombin time (TT) reflecting the common pathway. TT is influenced by the 
conversion of fibrinogen to fibrin and fibrin polymerization. For the test, thrombin 
(STA Thrombin Reagenz, Roche Diagnostics GmbH, Mannheim, Germany) is added 
into citrated plasma sample. The prolongation of TT can induced by low fibrinogen 
plasma concentration, dysfibrinogenemia, hyperfibrinogenemia, or high 
concentrations of FDPs in the blood plasma.132,134,137-139 Shortening of TT have been 
detected due to errous sample handling.132,140  
Another variable routinely assessed is fibrinogen and there are several techniques as 
functional or immunochemical methods.132-134,141,142 The method used here is the 
Clauss-method, a modified TT.132 The test is performed by addition of a larger 
amount of thrombin than in the TT test (STA Fibrinogen, Roche Diagnostics GmbH, 
Mannheim, Germany) to reduce the interference by heparin therapy.132 Also here the 
clotting time is measured, but the results are converted into fibrinogen 
concentrations by a standard curve which is obtained by a serial dilution of human 
plasma calibration standard (STA Unicalibrator, Roche Diagnostics GmbH, 
Mannheim, Germany used here). Hyperfibrinogenemia can occur in acute phase 
responses.132,134,141 Hypofibrinogenemia can be caused by DIC, liver diseases, 
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hyperfibrinolytic syndrome and thrombolytic therapies.132,134 False low results by 
high FDP levels in dogs have been detected.132,143-146  
The measurement of FVIII is done by a chromogenic method and the test is 
traditionally performed with a one-stage clotting assay. The test is performed by 
adding a reagent including cogulation activators and phospholipids and a human- 
plasma deficient of the factor which should be evaluated, so that the only factor 
activity is from the patient plasma (STA Factor VIII, Roche Diagnostics GmbH, 
Mannheim, Germany).147 The method used here was a modified one-stage aPTT test. 
Results are compared with a standard curve derived from serially diluted pooled 
plasma from healthy people or dogs, respecitively. 
 
2.3.3. Tertiary hemostasis 
In humans, variables reflecting tertiary hemostasis include plasminogen, α2AP, PAI 
and tPA.132,134,148-151 In veterinary medicine, plasminogen, FDPs and D-dimer 
measurements are the most commonly used tests. α2AP, PAI and tPA are only used 
for research, because of their costs and unknown diagnostic use in  veterinary 
medicine.132,152,153 Plasminogen is assessed photometrically with a chromogenic assay 
(e.g, STA Plasminogen, Roche Diagnostics GmbH, Mannheim, Germany). An excess 
of streptokinase is added to the plasma so that plasminogen in the sample forms a 
complex with plasmin-like activity. After that, the activity of this complex is 
measured by its action on a chromogenic substrate which is added later. A low 
concentration of plasminogen might occur due to increased consumption (DIC, 
thrombolytic therapy) and decreased production, e.g. due to liver failure.132,134,149,150,154 
As a part of the fibrinolysis process, the fibrin split products such as FDPs and D-
dimers are generated, which can be measured with several point of care tests and 
bench top analyzers.110 In contrast to D-Dimers, FDP values can also be increased by 
plasma fibrinogen degradation or fibrin monomers so that the FDP test is less specific 
for diagnosing DIC.106 The D-dimer is formed by the degradation of the cross-linked 
fibrin clot by the effect of plasmin.107,132,156,157 There are different test methods for D-
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dimer evaluation includung turbidometry, latex agglutination, fluorescence 
immunoassay, and ELISA. Here we used the immunoturbidimetric assay (STA 
Liatest™ D-Dimer, Roche Diagnostics GmbH, Mannheim, Germany) and this 
method is currently the gold standard for assessment of D-dimer concentration 
assessment.132 Increased plasma levels of fibrin D-dimers have been observed in dogs 
with thromboembolism,13,14,25,98 disseminated intravascular coagulation (DIC),7,14 
terminal renal failure, neoplasia,13,99 immune mediated anaemia25 and other diseases 
which are associated with hypercoagulability. 
 
2.3.4. Assessment of thrombophilia and heparin effects 
Generally classified as tests for detection of thrombophilia are AT, PC and PS. AT is 
one of the most important protease inhibitors in regulation of blood coagulation.132 
The AT assay is performed in conditions associated with thrombophilia, DIC, and 
heparin therapy.132,158-162 Here, a chromogenic assay was used, which is generally 
preferred in veterinary medicine.132,163,164 Patient plasma is pipetted to the reagent 
containing excess FXa and a chromogenic substrate for FXa which is detected 
photometrically.132,134,165,166 
PC measurements are performed for detection of hypercoagulable states.132,134,165,166 
Here, an automated clotting test was performed. Contact activator, human PC 
deficient plasma and a specific PC activator (Protac®, a snake venom derivate of 
Southern Copperhead, Agkistrodon contortrix contortrix) were added to the prediluted 
citrate plasma sample. In this way PC is activated and determined indirectly by an 
aPTT test. APC cleaves FVa and FVIIIa which results in a prolongation of aPTT. The 
PC activity is directly proportional to the increase of aPTT in seconds. 132,134,170,171 
APC has an anticoagulant function and inactivates FVa and FVIIIa.172 In people, a 
poor anticoagulant response of APC is known as APC resistance (APCR) and results 
in thrombophilia and hypercoagulable state.173 In patients, APC ratio is calculated as 
follows to characterize APCR174: APC-ratio= [aPTT in presence of APC (aPTT2) / 
standard aPTT without APC (aPTT1)]. An APC ratio < 2.1 seconds has been 
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considered abnormal in man.175 APCR is detected via a modified aPTT in the 
presence and absence of APC. The APCR test used here is based on an unusually 
small prolongation of the clotting time of the sample in the presence of APC and 
calcified medium. FV deficient plasma and Crotalus viridis helleri venom is used 
which act as an activator of FX (STA-Staclot® APC-R, Roche Diagnostics GmbH, 
Mannheim; Germany). These all trigger the coagulation cascade downstream from 
FX so that an influence of all coagulation factors acting upstream could be ruled out.  
The PS activity was determined here also with a clotting test like PC. Protac® and 
bovine FVa are used and as PS is a cofactor of PC, the anticoagulatory effect of PC is 
soleyly increased by the PS activity in the sample and measured. The low results of 
PS in people are determined as thrombotic diseases.132,134,170,171 
One of the best known assays reflecting heparin activity is the measurement of anti-
FXa activity. Here, also a chromogenic assay was performed (STA-Rotachrom® 
Heparin, Roche Diagnostics GmbH, Mannheim, Germany). Bovine FXa and a 
chromogenic substrate are added to diluted patient plasma. The test is based on the 
inhibition of FXa by AT-heparin complex and hydrolysis of the chromogenic 
substrate by FXa which is detected spectrophotometrically.132  
 
2.3.5. Global tests (Thromboelastography) 
To be clinically useful, an assay must provide rapid and reliable information 
regarding a patient´s coagulatory state in an emergency situation (preferably as 
point-of-care test). TEG allows a rapid characterization of both hyper- and 
hypocoagulatory conditions. TEG has been utilized worldwide for evaluation of 
hemostasis in humans and the workup of dogs suspected of having a hemostatic 
disorder.177 Two different analyzers are commercially available, the ROTEM 
(Pentapharm, Germany) and TEG.132 There is only a small difference in the 
mechanical test procedure between this machines.132 As the TEG is used in the 
current studies, the principle is explained more detailed here.  
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Three types of TEG assays have been reported in veterinary medicine: native, human 
recombinant tissue factor activated (TF-activated; Innovin, Dade Behring) and 
kaolin-activated (Haemoscope)132, as used here. Kaolin (TEG® Hemostasis System 
Kaolin, Haemonetics Corporation; formerly Haemoscope Corporation; Braintree, 
MA, USA) is used for the activation of the sample by the intrinsic pathway.132  
The analyzer mainly has 3 parts: a sample cup (TEG® Hemostasis System Pins and 
Cups, Haemonetics Corporation; formerly Haemoscope Corporation; Braintree, MA, 
USA), a stationary pin, which is placed into the cup, and a mechanical-electrical 
tranceducer. After the placement of recalcified, kaolin-activated citrated whole blood 
sample into the cup, it moves in a constant speed and direction. The pin is set into 
the sample. With the beginning of the fibrin formation, a bound between pin and cup 
occurs. This bound leads to movement of the pin and cup together. The movement is 
related with kinetics, strength and dissolution of clot formation and is converted to 
electrical signals. (http://www.haemoscope.com/technology/teg_analyzer.html) 
Figure 1 shows a TEG result monitored by a computer. 
                                                                                                                      
 
Figure 1: A monitored TEG result in a dog. 
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A recent study using the computerized TEG has shown that TF-activated TEG G-
value correctly identified dogs with clinical signs of bleeding with a high positive 
and negative predictive value.178 Grading dogs with disseminated intravascular 
coagulation (DIC) in hyper-, normo-, or hypocoaguable state based on the TF-
activated TEG was reported to be of prognostic value.124 In 49 dogs with neoplasia, 
hypercoagulability was the most common finding, while hypocoagulability was 
consistently present in dogs with metastasis.175 In the majority of studies, five TEG 
variables (R, K, angle α, MA and G) have been evaluated: R is the reaction (or 
gelation) time and is measured from the commencement of the test until a preset 
fibrin formation, i.e. until the trace is 2 mm wide.179 R is primarily influenced by 
plasma clotting factors and natural anticoagulants / inhibitors of coagulation such as 
antithrombin, PC and PS activity. The R-value is prolonged by anticoagulants and 
clotting factor deficiencies and is shortened by hypercoagulable state.179 As fibrin 
polymerization proceeds, clot stability is increasing which is indicated by an 
increasing distance of the leaflets constituting the TEG curve. The coagulation time K 
is the time required from initial clot formation to achieve predetermined clot strength 
and is measured from the end of R until tracings reached an diversion of 20 mm. K is 
influenced by coagulation factors, fibrinogen plasma concentration, and the platelet 
count.179 Hyperfibrinogenemia – and to a lesser extent platelet hyperfunction – 
results in shortened K-value whereas K is decreased by anticoagulants affecting 
fibrin polymerization and platelet function.179 The angle α is closely related to the K-
value indicating the rapidity of fibrin cross linking and depends on fibrinogen 
plasma concentration and to a lesser degree on platelet count.179 Similar to the K-
value, the angle α is raised by hyperfibrinogenemia and increased platelet function. 
The maximal amplitude MA is a measure of the peak rigidity manifested by the clot. 
About 80% of the MA is dependent on platelet number and function.180 Fibrin 
contributes to a lesser extent to clot strength.179 For the computerized TEG G, a 
measure of clot rigidity and thus overall coagulation state (in dynes per square mm) 
is calculated as follows: G = (5000xMA)/(96-MA).179 As G is an exponentional 
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reflection of MA, it is more indicative of small changes in clot rigidity or fibrinolysis 
than the amplitude in millimeters.179 
 
2.4. Reference intervals for coagulation assays in dogs 
Reference intervals for routine coagulation parameters, AT, FVIII and PC have been 
established previously in dogs whereas reference ranges for PS, plasminogen, APC-
ratio and anti-FXa activity have not been determined before. However, even for 
routine coagulation parameters it is generally agreed upon that analyser- and 
method-specific reference intervals have to be established. Studies in people 
investigating eight different aPTT assays and modified aPTT assays for detection of 
APC resistance demonstrated that results are highly dependent on both the assay 
and the coagulation analyser so that reference intervals were not identical.181 The STA 
Compact has been used previously in dogs for measurement of routine coagulation 
parameters, AT, PC,8,24,182 and fibrin D-dimers183. Heparin test run on the STA 
coagulation analyser has been validated for its use for determination of anti-FXa 
activity for monitoring of heparin therapy in blood plasma of 12 healthy and 10 dogs 
with immune-mediated haemolytic anemia.8 In all these studies, healthy dogs served 
as controls and were compared to diseased patients. However, for routine use of STA 
Compact coagulation tests in veterinary laboratories, reference intervals have to be 
established. Generally, reference intervals are known to serve as the basis of 
laboratory testing and are helpful for differentiating between healthy and diseased 
patients.184 Canine reference intervals for a functional PC chromogenic assay run on a 
STA coagulation analyser have been published before, however a limitation of the 
previous study was that statistical methods for calculation of reference intervals were 
not given and only 30 dogs were included.25 
Also for routine use of TEG in veterinary practices, reference intervals have to be 
established. Mean and standard deviation180/range185 of several TEG variables have 
been reported for both TF-activated TEG180 and kaolin-activated TEG185 in 18 and 15 
healthy dogs respectively. In a further investigation, index of individuality and 
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biological variation of TEG variables have been assessed in eight dogs and – thus – 
provided useful information for interpretation of population based reference 
intervals.186 
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3. Material and Methods 
 
The study was separated in two parts, the reference study and the coagulation 
response in a canine model of toxaemia.  
 
3.1. Establishment of reference intervals for TEG and variables reflecting 
secondary and tertiary hemostasis run on the STA Compact analyzer 
The study was ethically approved by the Ethics Committee for animal welfare, 
Giessen, Germany (No. V54-19c20/15cGi18/17), January 2008. Before the reference 
study the repeatability and interferences were performed for TEG and measurements 
run on the STA Compact analyzer. Blood samples for both measurements were taken 
at the same time. Also for control of health, physical, hematological and clinical 
chemical examinations including complete blood cell count (CBC), kidney and liver 
parameters as well as electrolytes (sodium, potassium, ionized calcium and 
magnesium, phosphate), total protein, albumin, globulin, and fructosamine plasma 
concentration were performed. Complete hematological examinations were done 
with the ADVIA 2120 and clinical chemical examinations with the ABX Pentra 400 
(ABX Pentra 400, Horiba Diagnostics, France). Hematological and blood chemical 
examinations and the TEG analyses were run directly after blood collection.  
 
3.1.1. Evaluation of repeatability, interferences and the effect of anticoagulant 
Before the reference range study, the evaluation of repeatability, interferences and 
the effect of anticoagulant was done. Here the interference work includes the 
assessment of hemolysis and influence of lipemia. 
 
3.1.1.1. Repeatability of the TEG analysis 
The evaluation of intra-assay repeatability of the TEG analysis was performed sixty 
minutes after sampling and duplicate measurements were made from re-calcified 
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citrated blood with one TEG analyser (two channels per machine). A total of 6 
healthy dogs with a median age of 2.5 years (range 1-6 years) were studied. Three 
dogs were male, two were male-castrated and one was female. Intra-assay variation 
was assessed for TEG variables R; K; angle α; MA; and G by calculating the 
arithmetic mean and the pooled variance estimate, based on the differences in the 
duplicate determinations. The standard deviation required for calculation of the 
coefficient of variation was consistent with the root of the pooled variance estimate.  
 
3.1.1.2. Impact of anticoagulant in TEG analysis 
The comparison between TEG results obtained with native whole blood or citrated 
whole blood was performed in 16 healthy dogs with a median age of 3 years (range 
2-6 years). The study group included 10 male dogs, 3 female dogs, 3 neutered 
females. Sampling was performed as described above for the dogs included in the 
reference interval study with the only exception that one ml blood was given in a 
silicated kaolin-containing tube in addition to a citrated vial. The first 2 ml of the 
sampled blood were discarded (i.e., used for platelet count) to reduce the effects of 
tissue thromboplastin. The native blood in the kaolin containing tube was mixed by 
gentle inversion of the vial for 5 times. Then, 360 µl were pipetted in a pre-warmed 
TEG cup placed in the instrument holder and thromboelastography tracing was 
initiated. With the native whole blood specimens, TEG analysis was performed 
within 6 minutes of sampling whereas the citrated whole blood specimen was 
allowed to rest 1 hour at room temperature and TEG analysis was performed in re-
calcified blood as described for the samples used for establishment of the reference 
interval later. 
 
3.1.1.3. Effect of hemolysis on TEG analysis 
For the assessment of hemolysis on TEG results seventeen healthy dogs (fifteen 
Beagle dogs, one German shepherd dog, one Golden Retriever) with a mean age of 4 
years (range 3-5) were included. Six dogs were male, five male neutered, and six 
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were spayed females. The dogs were fasted at the time of blood sampling.Hemolytic 
samples were prepared with two techniques: mechanical stress (HM) as well as 
freeze and thawing (HF). Approximately 6 ml citrated whole blood was divided in 4 
aliquots a` 1.3 ml. One aliquot served as control; the other one was used for induction 
of mechanical hemolysis by rapid aspiration of an aliquot of the sample into a 
syringe with a 23 gauge needle followed by strong squeezing of blood into the test 
tube. This procedure was repeated 20 times. From the remaining two aliquots, 
hemolytic specimens were prepared by freeze and thawing: one aliquot was frozen at 
-80°C for one hour; the other one was stored at room temperature for the same time 
and was mixed with the first aliquot in equal parts after thawing at 37°C. TEG 
analyses were performed in all specimens approximately one hour after sampling 
(controls) or after induction of hemolysis. The TEG analyses were performed 
according to the manufacturers´ recommendations. 
 
3.1.1.4. Repeatability of the variables assayed on the STA compact 
The intra-assay repeatability on the STA Comapact was performed with 15 replicate 
measurements, made from plasma samples, thawed at 37°C in a water bath and 
centrifuged at 1500×g for 10 minutes to remove remnants of cryoprecipitate after 
thawing. One healthy dog was studied and the STA Compact analyzes were 
performed as described later for establishment of the reference interval. Intra-sample 
variation was estimated for OSPT, aPTT, TT, fibrinogen, fibrin D-dimers, 
Antithrombin III, PC, PS, APC resistance activity, Plasminogen, Factor VIII and anti-
factor Xa activity variables.   
 
3.1.1.5. Impact of hemolysis and lipemia on the variables measured on the STA 
compact 
To assess the influence of lipemia on secondary and tertiary hemostasis parameters, 
samples with three grades of lipemia were prepared by adding Liquigen® 
(Liquigen®, Pfrimmer Nutricia GmbH, Erlangen, Germany), a commercially 
35 
available fat emulsion in different dilutions (solutions “A”, “B” and “C”) to the 
samples of three healthy dogs. Solution “A” was obtained by adding Liquigen® to an 
equal volume of NaCl (1:1). Solutions “B” and “C” were consistent with a 1:4 and 
1:16 dilution of Liquigen® and NaCl. For preparation of samples with grade 1; 2; and 
3 lipemia, 20μl of solutions C; B; and A respectively were added to 1480 μl of citrated 
plasma resulting in final dilutions of 1:74 (grade 3), 1:296 (grade 2), and 1:1184 (grade 
1). In grade 1 lipemia, letters behind the tube could be read easily. In grade two 
lipemia, letters could be recognized whereas in grade three lipemia, recognition of 
letters behind the tube was impossible. Citrated plasma of the same dog to which 
20μl NaCl was added served as a control. 
The effects of hemolysis on coagulation parameters measured on the STA Comapact 
were done as follows. Hemolysis was achieved by subjecting whole blood to a freeze-
thaw cycle. Approximately 20ml citrated whole blood was obtained from three 
healthy dogs and was divided into two aliquots. One aliquot was frozen at -80°C to 
induce hemolysis, from the other aliquot citrated plasma was prepared as described 
above which was also stored at -80°C until analysis. After thawing at 37°C, 
hemolysed- and non-hemolysed aliquots were centrifuged at 850×g for 10 minutes 
and specimens with three grades of hemolysis were prepared. In samples with grade 
one hemolysis (ratio of hemolysed to non-haemolysed plasma 1:9), letters behind the 
tube could be read easily. In grade two (ratio of hemolysed to non-hemolysed plasma 
1:4) letters could be recognized whereas in grade three hemolysis (undiluted 
hemolysed plasma) recognition of letters behind the tube was impossible. 
Hemoglobin concentration was assessed colorimetrically using the species specific 
hematology analyser ADVIA 2120 and a cyanide-free reagent as described before.187 
 
3.1.2. Establishment of reference intervals 
The TEG measurements, as mentioned before, were run directly after blood 
collection but the STA compact evaluations were performed within 3 weeks after 
sampling, in the interval the samples were stored after processing at -80°C. But first 
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each human assay run on the STA Compact was validated for dogs. After that, assays 
that were not valid initially were modified and optimized for their use with canine 
specimens. The study was conducted in adult (> 1 year old, < 6years) dogs including 
staff-owned dogs, blood-donors, or healthy dogs presented at the Clinic for Small 
Animals, Surgery, Department of Veterinary Clinical Sciences, Faculty of Veterinary 
Medicine, Justus-Liebig-University Giessen, Germany for routine radiological 
examination to screen for hereditary hip (HD) or elbow dysplasia (ED). Inclusion 
criteria were a normal physical, haematological examination as well as normal 
results of serum biochemistry and coagulation profile and no history of a bleeding 
tendency or medication two weeks prior to presentation at the clinic. 
  
3.1.2.1. Sampling 
Sample taking was performed in fasted, resting dogs with a non-heparinized 18-
gauge venous catheter placed in the cephalic vein. Potassium-EDTA tubes were used 
for the complete hematological examinations with the ADVIA 2120. For clinical 
chemical examinations with the ABX Pentra 400, Lithium-Heparin tubes (Sarstedt 
AG&Co, Nümbrecht, Germany) were used, for these ones the first 2ml venous blood 
samples and afterwards samples for coagulation assays were taken. This sequencing 
was performed to reduce the effect of tissue thrombolastin on coagulation 
measurements. Blood was allowed to drop directly into the citrated tube or it was 
aspirated in a plain syringe. In the latter case, the specimen was gently placed into 
the citrate containing tube after removal of the needle from the syringe and the 
contents were mixed. The samples were carefully checked for proper filling and only 
specimens with an exact ratio of 9:1 blood to citrate anticoagulant were included. 
For TEG analysis, 1.17 ml venous whole blood was placed in a silicone-lined micro-
tube (40x1.8mm) containing 0.13 ml 3.18% trisodium citrate and was allowed to rest 
at room temperature for 1 hour. 
For measurement of coagulation parameters with the STA Compact, venous blood 
samples were drawn and anticoagulated in siliconized vacutainer tubes containing 
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3.18% trisodium citrate such that a ratio of 9:1 (vol/vol) was obtained. Blood was 
allowed to drop directly into the citrated tube or it was aspirated in a plain syringe. 
The samples were carefully checked for proper filling and only specimens with an 
exact ratio of 9:1 blood to citrate anticoagulant were included. Sodium-citrated whole 
blood was spun down at 850×g for 10 minutes within 1 hour after sampling. Citrated 
plasma was separated from the erythrocytes and centrifuged again at 850×g for 10 
minutes to remove all nonsedimented platelets prior to freezing as previously 
recommended.188 The supernatant was removed and stored at -80°C until analysis. 
Analysis was performed within 3 weeks after sampling. For all analytes, samples 
were proven to be stable over 12 months by re-analyzing 3 specimens approximately 
13 months after storage at -80°C. Directly prior to analysis, plasma samples were 
thawed at 37°C in a water bath as previously recommended178 to provide complete 
dissolving of cryoprecipitate. Afterwards, samples were centrifuged at 850×g for 10 
minutes so that plasma was mixed and non-dissolvable material was removed. 
 
3.1.2.2. Method – TEG 
Establishment of reference intervals for the TEG was performed with recalcified 
citrated whole blood according to the manufacturers´ recommendations. Briefly, 1 ml 
of citrated whole blood was placed in a silicated vial provided by the manufacturer 
which contained kaolin, buffered stabilizers and a blend of phospholipids. Mixing 
was ensured by gentle inversion of the kaolin-containing vials for 5 times. Pins and 
cups were placed in the TEG analyzer in accordance with the standard procedure 
recommended by the manufacturer. To each standard TEG cup, placed in the 37°C 
pre-warmed instrument holder 20 µl of 0.2 molar calcium chloride and 340µl kaolin-
activated citrated whole blood was added so that a total volume of 360 µl was 
reached in each cup. Internal quality control materials in two levels (normal and 
abnormal) Level 1®and Level 2® (TEG® Coagulation Control Level I and II, 
Haemonetics Corporation; formerly Haemoscope Corporation; Braintree, MA, USA) 
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were run each day. An electrical internal quality control (so called e-test) was 
performed in addition. 
 
3.1.2.3 Default settings and methods of human assays applied at the STA compact 
Directly prior to analysis, plasma samples were thawed at 37°C in a water bath and 
centrifuged at 1500×g for 10 minutes to remove remnants of cryoprecipitate after 
thawing. 
Coagulation screening tests OSPT, aPTT, and TT were measured automatically as 
clotting tests using commercial reagents, as mentioned before. Results were reported 
in seconds. Default settings for minimal/maximal measuring times for OSPT, aPTT, 
and TT were 6/180 seconds, 3/120 seconds and 13/240 seconds respectively. 
Fibrinogen was detected by the Clauss method using a human plasma calibration 
standard (STA Unicalibrator, Roche Diagnostics GmbH, Mannheim, Germany) 
provided by the manufacturer. Fibrin D-dimers were measured with the STA 
Liatest™ D-Di (STA Liatest™ D-Di, Roche Diagnostiscs, GmbH, Mannheim, 
Germany) immunoturbidimetric D-dimer assay as described before. The D-dimer 
result was reported as µg/ml fibrinogen equivalent units (FEU), i.e. the concentration 
of fibrin degradation products which are resulting from degradation of 1 mg/L 
fibrinogen. The assay was pre-calibrated and allowed a one-time testing on an 
automated analyser.189 According to the manufacturer, analytical interval of the assay 
ranged between 0.0 and 4.0 μg/ml. 
Antithrombin activity was detected based on its inhibition of thrombin with the 
chromogenic substrate kit (STA Antithrombin III, Roche Diagnostics GmbH, 
Mannheim, Germany). AT activity was reported as percentage of human plasma 
calibration standard. 
For measurement of PC, an automated clotting test was performed: Cephalin 
(phosphatidylethanolamine, a phospholipid serving as contact activator, 50 μl), 
human PC deficient plasma (50 μl) and 50 μl of a specific PC activator were added to 
50 μl the of patient sample prediluted 1:10 with diluent buffer (STA diluents buffer, 
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Roche Diagnostics GmbH, Mannheim, Germany). This resulted in an activation of PC 
within the sample and simultaneously an initiation of the intrinsic clotting system by 
contact activation. The PC activity was determined with a modified aPTT test using 
APC-deficient human plasma. Based on this method, the aPTT was depending solely 
on the PC activity in the sample as addition of PC-deficient human plasma. Activated 
PC cleaves FVa and VIIIa resulting in an increase in aPTT. Thus, PC activity was 
directly proportional to the increase in aPTT in seconds. 
Results could be reported as percentage of a human plasma calibration standard or in 
seconds. According to the manufacturer, analytical interval of the test was between 
3% and 150%. Default settings for minimal and maximal times of measurement were 
10 and 180 seconds respectively. In case of results < 10%, the test was automatically 
repeated with a dilution of 1:5. 
PS activity was also determined with an automated clotting test, the same test as 
used for the PC activity, as mentioned before. A total of 50μl human PS deficient 
plasma, 50μl human PC activated with Protac® and 50μl bovine factor Va were 
added to 50μl of the patient sample which was automatically diluted 1:10 with 
diluent buffer. As PS is a cofactor of PC, the anticoagulatory effect of PC was solely 
increased by the PS activity in the patient sample. For minimal and maximal times of 
measurement, 10 and 250 seconds respectively were set as a default. In case of results 
< 15%, the test was automatically repeated with a dilution of 1:5.  
The principle of assessment of APC resistance was based on an unusually small 
prolongation of the clotting time of the tested plasma in the presence of activated PC 
and in calcified medium. In the STA-Staclot® APC-R test system, 50 μl patient 
plasma was diluted 1:10 and coagulation was achieved in the presence of 50 μl factor 
V deficient plasma and 50 μl Crotalus viridis helleri venom. The result was reported in 
seconds. Based on the information of the manufacturer, analytical interval of the test 
was between 20 and 300 seconds.  
Plasminogen activity was determined photometrically with a chromogenic assay, 
explained before. An excess of streptokinase (100 μl of reagent 1 of the STA 
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plasminogen test kit containing approximately 5000 IU streptokinase/ml) was added 
to 100 μl of the patient sample which was diluted 1:20 with diluent buffer. A complex 
with a plasmin-like activity was formed between streptokinase and plasminogen. 
The quantity of streptokinase-plasminogen complex was assessed by its action on 100 
μl of a chromogenic synthetic substrate H-D-But-CHA-Lys-pNA x 2 AcOH in a 
concentration of 5.5 mol/ml. Quantification was achieved by the amount of p-
nitroaniline released which was photometrically detected at 405 nm. Results were 
reported as percentage of a human plasma calibration standard. A measuring range 
of 11-160% plasminogen activity compared to the human standard plasma was 
reported by the manufacturer.  
Measurement of FVIII was performed in a modified 1-stage aPTT with human FVIII 
deficient substrate plasma. Default setting for dilution of patient samples was 1:10 
with diluent buffer. In case of FVIII activity > 150%, measurement was automatically 
repeated in a dilution of 1:40. Default measuring range was between 1-600%. 
For measurement of anti-FXa activity, an automatic chromogenic assay was applied 
as described before. The test principle was based on a one-step reaction: 100 μl of 
bovine FXa (0.23 IU/ml) was added to a mixture of 50 μl patient plasma diluted 1:2 
with diluent buffer and a chromogenic substrate (MAPA-Gly-Arg-pNA x AcOH, 1.5 
μmol/ml). This resulted in an initiation of two reactions including the hydrolysis of 
the substrate by FXa and inhibition of FXa by the heparin-AT complex which was 
made up from the heparin and AT peculiar to the patient. After an incubation of 240 
seconds, the quantity of pNA released was measured photometrically and was 
inversely proportional to the heparin concentration in the test medium. Results were 
reported in IU/ml. According to the manufacturer, analytical range of the test was 
between 0.00 and 0.70 IU/ml. 
For all variables internal quality control material (normal and abnormal) provided by 
the manufacturer was run each day. STA PreciClot PlusI and II (STA PreciClot Plus I; 
II; III, Roche Diagnostics GmbH, Mannheim, Germany) was used for quality 
assurance of the majority of variables including OSPT, aPTT, TT, fibrinogen, AT, PC, 
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PS, FVIII, and plasminogen. A third level (STA PreciClotPlus III, also abnormal) was 
run in addition for OSPT, aPTT, fibrinogen, and AT. For internal quality control of 
fibrin D-dimer measurements, Liquicheck™ D-dimer control Levels I and II 
(Liquicheck™ D-Dimer control Level I and II, Roche Diagnostics GmbH, Mannheim, 
Germany) were used. In case of anti-FXa activity and APC response, materials for 
internal quality control STA Heparin Control (STA Heparin Control I and II, Roche 
Diagnostics GmbH, Mannheim, Germany) and STA-Staclot® APC-R(STA-Staclot® 
APC-R Control N and P, Roche Diagnostics GmbH, Mannheim, Germany) were 
included in each reagent package.  
 
3.1.2.4. Validation of human assays on the STA compact 
The majority of human assays (OSPT, aPTT, fibrinogen, AT, APC-ratio, fibrin D-
dimer) were valid for canine specimens. In 11/57 (19%) dogs, the TT was below the 
minimal measuring time of 13 seconds which was set as a default for the human 
assay. The most striking findings were the PC, PS and plasminogen activity being 
markedly lower than the concentrations in the human standard plasma (100% per 
definition). The PC and PS reference intervals determined with the clotting assay 
were markedly below the measurement range of the human assay whereas the 
canine reference interval for the plasminogen activity was slightly lower than the 
measurement range of the STA Plasminogen test. In contrast to this, the canine 
reference interval for FVIII activity was significantly higher than the concentrations 
in the human standard plasma and exceeded the upper limit of the measuring range 
of the FVIII assay. Based on the markedly different activities of FVIII, PC, PS, and 
plasminogen activity than in human assays, an adaptation of the human test 
protocols to the requirements of canine specimens was necessary. 
 
3.1.2.5 Modification of test methods applied at the STA compact 
Based on the results of the study, methods for measurement of TT, FVIII, PC, PS and 
plasminogen assays had to be optimized for their use with canine blood plasma. For 
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the TT, the minimal measuring time was defined as 8 seconds instead of 13 seconds 
set previously as a default. The eleven samples in which the TT was below 13 
seconds were reanalyzed with the new settings for the measuring time and yielded a 
result in all cases. 
Based on these results of the STA Compact method validation study, preparation of 
pooled plasma was necessary. Approximately 30 ml citrated whole blood was taken 
from 16 healthy adult dogs (8 female, 12 male, 2 female spayed) with a median age of 
3.5 years (range 1-8 years). Three Beagle dogs, two Malinois, Labrador Retrievers, 
French Bulldogs, Maremma Sheepdogs and German shepherd dogs were included as 
well as one Rottweiler, Staffordshire Bullterrier and mixed breed dog. The dogs were 
healthy based on the history, physical examination as well as on the haematological 
and clinical chemical examination. The dogs required for preparation of the pooled 
plasma were not included in the population used for establishment of the reference 
intervals. 
After the preperation of the canine pooled plasma the tests for FVIII, PC, PS and 
plasminogen were performed as described before with the difference of used serial 
dilutions (FVIII= 1:40; 1:60; 1:80; PC and PS= 1:5; 1:10; 1:20; 1:40; plasminogen= 1:100; 
1:40; 1:20) instead of human plasma calibration standard to obtain a species specific 
reference curve. Moreover, dilution of patient plasma was 1:40 for FVIII, 1:5 for 
PC/PS and 1:20 for plasminogen respectively. 
Internal quality control was performed in two levels (normal and low) with aliquots 
of citrated plasma obtained from one of the dogs included in the reference 
population. Plasma was stored at -80°C until analysis. Undiluted citrated plasma and 
plasma diluted 1:1 with saline served as normal control and low control respectively. 
 
3.2. Evaluation of the impact of endotoxemia on the coagulation process 
The study of the second section of this thesis work was performed at Uludag 
University, Bursa, Turkey whereas the sample analysis were performed at the 
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Central Laboratory, Faculty of Veterinary Medicine, Justus-Liebig-University 
Giessen, Germany. 
The prospective investigation was ethically approved by the Animal Care and Use 
Committee of the Uludag University, Bursa, Turkey (2009-01/08). The current 
investigation was performed to evaluate the early response to induction of 
endotoxemia on variables characterizing secondary hemostasis, physiological 
anticoagulants and markers of fibrinolysis compared with a control group. 
Coagulation analysis included a standard coagulation profile (OSPT, aPTT, TT, 
fibrinogen plasma concentration) as well as an extended profile including FVIII 
activity, natural inhibitors of coagulation (AT, PC, PS, APC-ratio) and markers of 
fibrinolysis (fibrin D-dimer plasma concentration). Kaolin-activated TEG analysis 
was performed in addition. Results were compared with laboratory-intern reference 
intervals which were established previously. Diagnosis of disseminated intravascular 
coagulation (DIC) was made when ≥ than 3 of the traditional coagulation tests were 
altered and consistent with a coagulation consumption disorder (thrombocytopenia 
and prolonged clotting times of OSPT, APTT, TT), together with an increment in 
plasma concentrations of D-dimers > 0.67 μg/L or consumption of the main 
coagulation inhibitor AT as published previously.187 
Ten adult clinically healthy mongrel dogs (4 males and 6 females) with a median age 
3 years (range 2 - 5 years) and a median body weight of 18 kg (range 15 - 22 kg), 
housed in the Animal Husbandry and Diseases Research and Application Centre of 
Uludag University were included in the study. Water was provided ad libitum, and 
the dogs were fed with standardized, pelleted diet twice daily before the experiment. 
The dogs were equally assigned into two groups. Dogs in the treatment group 
received endotoxin (LPS, Escherichia coli serotype 055:B5, purity 497%; Sigma, 
St.Louis, MO, USA) dissolved in sterile saline (0.9% NaCl solution; Baxter, Istanbul, 
Turkey) which was administered intravenously at a dosage of 0.02 mg/kg. Dogs in 
the control group received 0.2 ml/kg sterile 0.9% saline solution intravenously. Dogs 
were provided water 3 times a day, and food (the pelleted diet) twice a day during 
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the experiments which were performed in October. Dogs were monitored clinically 
and hematologically for 24 hours. 
 
3.2.1. Sampling  
Venous blood samples were collected before application of LPS or the placebo (0 
hour) and 1, 4, and 24 hours after treatment from the brachiocephalic vein. 
Specimens for hematology were collected into vacutainer tubes containing potassium 
Ethylendiamin-tetraacetate (K2EDTA. Sarstedt AG&Co, Nümbrecht, Germany). 
Hematological examination included measurement of white blood cells (WBCs) and 
platelet (PLT) count. The anticoagulant tubes were inverted several times 
immediately after sample acquisition to ensure adequate mixing. Hematological 
analysis was performed directly after the blood collection using an automatic 
analyzer with optical scatter and impedance methods (CELL-DYN 3500; Abott, 
Wiesbaden, Germany). Peripheral blood smears were not examined. For 
measurement of coagulation parameters, venous blood samples were drawn and 
anticoagulated in siliconized vacutainer tubes containing 3.18% trisodium citrate 
such that a ratio of 9:1 (vol/vol) was obtained. The first 2 ml were discarded to 
remove tissue thromboplastin and were used for hematological analysis. The 
samples were checked for proper filling and only specimens with an exact ratio of 9:1 
blood to citrate anticoagulant were included. Sodium-citrated whole blood was spun 
down at 850g for 10 minutes within 1 hour after sampling. Citrated plasma was 
separated from the erythrocytes and centrifuged again at 850g for 10 minutes. The 
supernatant was removed and stored at -80°C until analysis. Analysis was performed 
within 3 weeks after sampling. Sample stability was proven by the authors to be > 12 
months. For TEG analysis, 1.2 ml venous whole blood was placed in a silicone-lined 
tube containing 0.2 ml sodium citrate and was allowed to rest at room temperature 
for 1 hour. 
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4. Statistics 
 
Results were collected electronically and transferred manually to an excel spread 
sheet for statistical analysis. 
For statistical analysis, the following software packages were used: Graph Pad Prism 
(Graph Pad Software, San Diego, USA) and BMDP (BMDP Statitical software Inc., 
1440 sepulveda Blvd, Los Angeles, CA 90025 USA). Reference intervals were 
calculated with Analyse-it for Excel (Analyse-it Method validation Edition version 
2.12 - © 1997-2008, Analyse-it Software Ltd.). 
 
4.1. Statistical analysis for calculation of reference intervals for kaolin-activated 
TEG and coagulation variables 
 
4.1.1. Statistical analysis for the assessment of repeatability, interferences and effect 
of anticoagulant 
4.1.1.1. Repeatability of the TEG analysis 
Intra-assay variation was assessed by calculating the arithmetic mean and the pooled 
variance estimate, based on the differences in the duplicate determinations, for both 
analyzer parameters. The standard deviation required for calculation of the 
coefficient of variation (CV) was consistent with the root of the pooled variance 
estimate. 
 
4.1.1.2. Impact of anticoagulant and sex on TEG analysis 
The influence of the anticoagulant was assessed by using a paired t-test. An unpaired 
t-test or a comparable non-parametric test (Mann Whitney U test) was applied to 
investigate the effect of sex on TEG variables.  
Regarding the evaluation of the influence of hemolysis, a Kolmogorov Smirnov test 
was performed to verify the assumption of normality. The difference between results 
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obtained after HM and HF respectively was assessed with a one way ANOVA test 
and Tukey´s multiple comparison post test. In case of non-normal distribution or 
missing values, a Friedman test with Dunn´s multiple comparison post test or a Wald 
test with Student-Newman-Keuls test respectively were performed. The mean bias 
between hemolysed and non-hemolysed specimens was calculated with a Bland 
Altman Bias plot. After Bonferroni correction, significance was set at P < 0.01 for 
comparison of the influence of anticoagulant and sex. 
 
4.1.1.3. Effect of hemolysis on TEG results 
The difference between results obtained after HM and HF respectively was assessed 
with a one way ANOVA test and Tukey’s multiple comparison post test. In case of 
non-normal distribution or missing values, a Friedman test with Dunn’s multiple 
comparison post test or a Wald test with Student-Newman-Keuls test respectively 
were performed. The main bias between hemolysed and non-hemolysed specimens 
was calculated with a Bland Altman Bias plot. 
 
4.1.1.4. Influence of sex and repeatability of the variables assayed on the STA 
compact 
The influence of sex was assessed by using an unpaired t-test or a comparable non-
parametric test (Mann Whitney U test). After Bonferroni correction, significance was 
set at P<0.005 for comparison of the influence of sex.  
Fifteen-run intra-assay repeatability for normal values was calculated from a sample 
of a healthy dog. 
 
4.1.1.5. Impact of hemolysis and lipemia on the variables measured on the STA 
compact 
Student’s paired t-test was applied to investigate the effect of hemolysis and lipemia 
on coagulation parameters. After Bonferroni correction, significiance was set at 
P<0.0015 for assessment of the effect of interferences. 
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4.1.2. Statistical analysis for calculation of reference intervals 
An Anderson-Darling test was performed to verify the assumption of normality for 
both analyzer data.  
In case of normal distribution of data, double sided reference intervals were obtained 
by calculating the mean±1.96 SD (standard deviation) so that 95% of the reference 
population was included. The 90% confidence intervals of the upper and lower 
reference limit were calculated automatically with the Analyse-it software. If non-
normal distribution of data was present, a logarithmic transformation was performed 
and data were re-analysed with the Anderson-Darling test. In case of normal 
distribution after transformation, logarithmic data were analysed as described above. 
Data of TEG and coagulation parameters were depicted as histograms including the 
reference interval as well as the 90% confidence interval of the upper and lower 
reference limits as recommended by the IFCC.46 
 
4.2. Statistical analysis for the evaluation of the impact of endotoxemia on the 
coagulation process 
Results were analyzed with the Graph Pad Prism and BMDP statistical software. The 
differences between the study and control group were assessed with a two-way 
analysis of variance and repeated measures regarding the factor “group”, “time”, 
and interaction between both factors. Level of significance was set at P=0.05.  
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5. Results 
 
5.1. Establishment of reference intervals for TEG and variables reflecting 
secondary and tertiary hemostasis run on the STA Comapct analyzer 
 
5.1.1. Repeatability, interferences and the effect of anticoagulant 
5.1.1.1. Repeatability of  TEG analysis 
Intra-assay coefficients of variation for kaolin-activated TEG variables R;K;α;MA, 
and G were 7.6%;17.7%;7.4 %;2.9% and 6.6% resepctively. In table 1, the median and 
minimum and maximum values of intra-assay measurements are demonstrated.  
 
Table 1: Minimum and maximum values of intra-assay measurements (n=6 dogs). 
 
5.1.1.2. Impact of anticoagulant in TEG analysis 
The influence of the anticoagulant (native blood versus re-calcified citrate 
anticoagulated blood) on TEG R-value, angle α, K-value, MA and G-value is depicted 
in figure 2. As shown here in the figure, no significant effect of the anticoagulant was 
present, although the inter-individual variation of results was lower for the results 
obtained from citrated samples. 
Variable 
 
R-value 
(min) 
Α 
(degree) 
K-value 
(min) 
MA 
(mm) 
G-value 
(Kilo 
dyn/cm2) 
Median 22.4 14.3 35.8 6.6 16.1 
Range 16.1-43.3 5.0-27.7 20.2-52.3 3.7-10.7 8.5-22.5 
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Figure 2: Influence of the anticoagulant (native blood versus re-calcified citrate 
anticoagulated blood) in TEG variables (n= 16 dogs). 
 
The central box in figure 2 represents the values from the lower to upper quartile. 
The middle line represents the median. The horizontal lines indicate the minimum to 
the maximum values. The level of significance was set at 0.01 after Bonferroni 
correction.  
 
5.1.1.3 Effect of hemolysis on TEG results 
The TEG reaction time R reflecting secondary hemostasis was significantly shorter 
after HM than in the control specimens and after HF (table 2, P< 0.001).  
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Group/ 
Parameter(unit) 
R-value 
(min) 
K-value 
(min) 
α 
(degree) 
MA 
(mm) 
G-value 
(K dyn/cm2) 
Control 5.2±1.9 5.5 (1.7-16.9) 46.3±16.8 49.0±9.3 5.1±1.8 
HM 2.5±0.9 9.0 (2.3-20.7) 41.6±13.0 38.2±8.5 3.2±1.2 
HF 5.6±3.7 9.9 (5.6-33.2) 20.2±11.2 27.0±11.6 2.0±1.1 
 
Table 2: Change of TEG variables after induction of in vitro hemolysis by either HM 
or HF (n=17 dogs). Results are either depicted as mean ± standard deviation in case 
of normal distribution or as median and range if data were non-normally distributed. 
 
Following HM, a mean proportional bias of 2.7 minutes compared to the control 
samples was present. The K value tended to be higher after HM compared to the 
control group (table 2), however this trend was not statistically significant after 
Bonferroni correction (P<0.05). Following HF, a significantly reduced rapidity of 
fibrin cross linking was noted reflected by a significantly higher K value in 
comparison to the controls (P<0.01). After induction of hemolysis by freeze and 
thawing, the TEG-K value was not reported by the analyser in 4/17 samples (23.5%) 
because MA never reached the required 20 mm. In HM and HF, a mean constant bias 
of -4.0 and -9.8 minutes respectively was observed. 
Hemolysis resulted in a decrease in angle α also indicating a reduced rapidity of 
fibrin cross linking. The difference between the controls and hemolysed samples was 
highly significant for HF (P<0.001) but only small and insignificant for HM. There 
was a mean constant bias of 4.7 degrees after mechanical hemolysis, however, in 
individual dogs, a negative bias was present. After HF, a marked constant bias of 
26.1 degrees was observed. 
As detailed in table 2, hemolysis generally resulted in a decreased clot stability and 
overall coagulation ability indicated by a significantly lower MA and G value 
(between all groups: P<0.0001). A mean constant bias of 10.8 mm and 22.0 mm was 
present after HM and HF respectively. Similarly, hemolysis resulted in a highly 
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significant decrease in G value reflected by a mean constant bias of 1.9 
Kilo(K)dyn/cm2 after HM and 3.1 ± 1.9 Kdyn/cm2 after HF respectively. 
 
5.1.1.4. Repeatability of variables assayed on the STA compact 
Fifteen-run intra-assay repeatability of coagulation variables run on the STA 
Compact analyzer is shown in table 3. 
 
Table 3: Fifteen-run intra-assay repeatability for hemostasis variables (n=1 dog). 
Abbreviations: %cp: % compared to canine pooled plasma; %hs: % compared to 
human calibration standard. The symbol * means that is an outlier exceeding the 3-
fold standard deviation from the mean was removed.  
 
Variable  
 
Unit CV (%) Mean Range 
OSPT Sec 1.22 8.0 7.9-8.1 
aPTT Sec 1.02  10.8 10.6-11.0 
TT Sec 1.64 13.4 13.2-13.7 
Fibrinogen g/l 5.6%* 1.8 1.4-3.4 
Factor VIII %cp 3.89 108 99-114 
AT %hs 4.68 132 115-138 
Protein C %cp 2.36 85 82-90 
Protein S %cp 1.4* 110 58-118 
APC – ratio - 1.45 2.8 2.7-2.9 
Plasminogen %cp 20.16 66.8 46-94 
D- Dimer µg/ml 45.92 0.11 0.03-0.18 
Anti Factor Xa IU/ml 12.83 0.09 0.06-0.1 
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For the routine coagulation parameters aPTT, OSPT and TT a low CV was obtained 
ranging from 1.02% to 1.64%. FVIII activity, AT, PC, plasminogen, as well as the 
APC-ratio showed intra-assay CVs ranging from 1.45% to 4.68%, as you can see in 
table 3. For the fibrinogen concentration and PS activity, one outlier exceeding the 3-
fold standard deviation from the mean was present in the series of measurements. 
Removing the outlier resulted in an intra-assay CV of 5.6% for fibrinogen and 1.4% 
for PS. Variables with low plasma concentrations in healthy dogs such as fibrin D-
dimer plasma concentration and anti-FXa activity demonstrated high intra-assay 
CVs, as shown in table 3. 
 
5.1.1.5. Impact of hemolysis and lipemia on variables measured on the STA compact 
Hemoglobin concentration induced by freeze/thawing ranged from 0.6±0 mmol/L 
(grade 1 hemolysis) to 1.3 ± 0.06 mmol/L (grade 2 hemolysis) and 6.6 ± 0.06 mmol/L 
(grade 3 hemolysis), respectively. As depicted in table 4, hemolysis had a major 
impact on results obtained with the majority of coagulation tests run on the STA 
Compact.  
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% bias / Hb (mmol/l) 
and Variable 
0.6 1.3 6.6 
OSPT +10.0 +3.4 -21.9 
aPTT -4.6** -7.8***  +4.3 
TT -14.3** -20.6* -2.0 
Fibrinogen -9.1 -7.7 -32.1** 
Factor VIII -9.0** -4.9 -49.6* 
AT -19.1 -1.2 +94.3** 
Protein C +90.3 +61.4* +58.9* 
Protein S +46.6 +89.1 +143.2* 
APC-ratio +9.5* +15.5** +1.4 
D-dimer +106.0 Error Error 
Anti-Factor Xa +593.6*** +624.1*** +565.9*** 
 
Table 4: Bias after induction of three grades of hemolysis (n=3 dogs). 
%Bias=difference (hemolysed sample-control)/control × 100. *P<0.05; **P<0.01; 
***P<0.0015 = level of significance after Bonferroni correction. 
 
Anti-FXa activity was most susceptible to hemolysis demonstrating a highly 
significant increase of approximately 600% compared to the control (P=0.0002-0.0003 
for grades 1-3 hemolysis). Grade 1 hemolysis resulted in a false high measurement of 
fibrin D-dimers of approximately 100%. In plasma with a higher degree of hemolysis, 
measurement of D-dimers was not possible due to “technical errors” of the analyser. 
FVIII activity, AT, PC, PS, and APC ratio were overestimated in hemolytic plasma, 
whereas fibrinogen, TT, and aPTT tended to be underestimated compared to the 
control, as shown here in table 4. 
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In contrast to haemolysis, lipaemia generally did not significantly influence 
measurement of coagulation parameters except for the results obtained with the STA 
Liatest D-Di™ immunoturbidimetric D-dimer assay, here seen in table 5. In the 
presence of lipaemia, D-dimer results were markedly overestimated ranging from a 
bias of 32% (grade 1 lipaemia) to 160% (grade 3 lipaemia). Due to the lack of a valid 
test for canine specimens, the effect of haemolysis and lipaemia was not assessed for 
the plasminogen activity. 
 
% bias / ratio fat 
solution : blood 
plasma and variable  
1:1184 1:296 1:74 
OSPT -2.7 +1.4 -1.3 
aPTT -1.9 -1.7 -1.9 
TT -6.1 -2.1 -6.1 
Fibrinogen -0.5 -2.1 -2.1 
Factor VIII +10.5* +6.8 +5.2* 
AT -0.2 +0.0 -0.2 
Protein C -0.7 +1.2 +3.6 
Protein S +4.1 +6.0 +6.5 
APC-ratio -1.4 +0.4 +0.4 
D-dimer +32.4 +87.4 +165.5** 
Anti-FactorXa +3.7 +0.0 -11.7 
 
Table 5: Bias after induction of three grades of lipemia (n=3 dogs). % Bias=Difference 
(hemolysed sample-control)/control × 100. Statistically significant differences were 
assessed by Student’s paired t-test (*P<0.05; **P<0.001; ***P<0.0015 = level of 
significance after Bonferroni correction). 
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5.1.2. Results for reference intervals 
Fifty-six dogs (19 German Shepherd dogs, 15 Beagle dogs, 8 Golden Retriever dogs, 4 
Labrador Retriever dogs, 2 mixed breed dogs, 1 Hovawart, 2 Great Danes, 1 Saint 
Bernard dog, 1 English Springer Spaniel dog, 1 Bernese Mountain dog, 1 Boxer, and 1 
Giant Schnauzer) with a median age of 2 years (range 1 - 6 years) were included in 
the study. The sex was evenly distributed with 24 male, 20 female, 7 male neutered 
and 5 female neutered dogs. The dogs were healthy based on the clinical examination 
as well as the results of hematology, clinical chemistry and routine coagulation 
profile. 
Regarding the TEG results, the majority of variables were normally distributed 
except for results of the K-value demonstrating a right-skewed distribution of data 
(figure 3E) which could be normalized after logarithmic transformation. Reference 
intervals and 90% confidence intervals are displayed in table 6 and figure 3 below.  
 
Variable Unit 
Lower 
reference 
limit 
Upper 
reference 
limit 
90% CI 
interval 
lower 
90 % CI 
interval 
upper 
Distribution 
of data 
R Min 1.8 8.6 1.1 – 2.4 7.9 – 9.2 Non normal 
K Min 1.3 5.7 1.1 – 1.5 4.9 - 6.6 Log normal 
α Degree 36.9 74.6 33.3 – 40.5 71.0 – 78.2 Normal 
MA mm 42.9 67.9 40.5 – 45.3 65.5 – 70.3 Normal 
G K dyn/cm2 3.2 9.6 2.6 – 3.8 9.6 – 10.3 Normal 
 
Table 6: Reference ranges for kaolin-activated TEG variables and 90% confidence 
intervals of upper/lower reference limits determined in re-calcified whole blood 
(n=56 dogs). 
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Figure 3: Histograms demonstrating the distribution of TEG data obtained for 
calculation of reference intervals (n=56 dogs). The solid vertical line indicates the 
reference interval. The dotted lines indicate the 90% confidence interval of the upper 
and lower reference limit. The dotted curve indicates the Gauss curve in case of 
normal distribution. Log normal distribution is characterized by an absent Gauss 
curve but the confidence interval is shown, whereas in case of non normal 
distribution only the upper and lower reference limit are shown. 
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In table 7 is shown that TEG variables did not differ significantly between male and 
female dogs.  
 
Variable 
(unit)/ 
Sex 
R-value 
(min) 
α  
(degree) 
K-value 
(min) 
MA 
(mm) 
G-value 
(K dyn/cm2) 
Male 5.2±1.6 57.0±7.9 2.8±1.1 55.5±6.7 6.5±1.8 
Female 5.2±2.0 54.2±11.4 3.0±1.3 55.2±6.0 6.3±1.5 
P-value 0.9141 0.2747 0.5033 0.8743 0.7743 
 
Table 7: Influence of sex on results (mean±standard deviation) of different TEG 
variables (n=56 dogs). 
 
The majority of variables measured on the STA Compact were normally distributed 
as shown in table 8 and figure 4. In case of the fibrinogen concentration, the APC-
ratio, FVIII, PC and PS activities as well as the anti-FXa activity, a normal distribution 
was present. Results of aPTT and fibrin D-dimer measurements were normally 
distributed after logarithmic transformation whereas in case of OSPT, TT, AT, 
plasminogen activity, a non-normal distribution was observed. Reference intervals 
are displayed here in table 8. 
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Table 8: Reference intervals for variables reflecting secondary hemostasis, fibrinolysis 
and physiological anticoagulants (n=56 dogs). 
 
Variable Unit 
Lower 
2.5% 
reference 
limit 
Upper 
97.5% 
reference 
limit 
90% CI 
interval   
lower 
90% CI   
interval     
upper 
Data 
distribution 
OSPT Sec 5.7 8.1 - - 
Non 
normal 
aPTT Sec 10.0 14.3 9.7 - 10.4 13.9 - 14.9 Log normal 
TT Sec 11.9 18.3 - - 
Non 
normal 
Fibrinogen g/l 1.3 3.1 1.2 - 1.4 2.9 - 3.4 Normal 
FVIII 
%human 
standard 
283.9 1179.0 198.1-369.7 
1093.3 -
1264.8 
Normal 
FVIII 
% canine 
pooled 
plasma 
70.9 136.4 64.6 - 77.2 130.1-142.7 Normal 
AT 
%human 
standard 
107.9 128.0 - - 
Non 
normal 
PC 
%human 
standard 
-26.5 -19.0 
(-27.2) -      
(-25.8) 
(-19.7) - 
(18.3) 
Normal 
PC 
% canine 
pooled 
plasma 
75.5 118.9 71.3 - 79.7 114.7 - 123.0 Normal 
PS 
%human 
standard 
-47.3 -21.8 
(-49.8) -     
(-44.9) 
(-24.2) -       
(-19.3) 
Normal 
PS 
% canine 
pooled 
plasma 
74.4 160.5 66.2 - 82.7 152.3 - 168.8 Normal 
APC ratio - 2.0 3.0 1.9 - 2.1 2.9 - 3.1 Normal 
Plasminogen 
% human 
standard 
7.0 8.0 - - 
Non 
normal 
D-Dimer µg/ml 0.023 0.654 0.017-0.032 0.474 - 0.902 Log normal 
Anti-FXa IU/ml 0.04 0.259 0.019-0.061 0.238 - 0.280 Normal 
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Figure 4: Frequency histograms of data measured on the STA Compact 
demonstrating the distribution of data obtained for calculation of reference intervals 
(n=56 dogs). 
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Below the solid vertical line indicates the reference interval. The dotted lines are 
consistent with the 90% confidence interval of the upper and lower reference limit. 
For normally distributed data, frequency histogram and superimposed Gaussian 
curve (dotted lines) are shown. In case of non normal distribution only the upper and 
lower reference limit are detailed. 
 
5.2. Evaluation of the impact of endotoxemia on the coagulation process 
As expected, the dogs in the control group did not show any significant clinical 
abnormalities after application of the placebo. In the LPS group, all dogs showed 
clinical signs including lethargy (n=5/5), diarrhea (n=4/5), vomitus (n=4/5), abdominal 
pain during palpation (2/5) as well as a weak pulse and mild (n=2/5) to moderate 
(n=1/5) dehydration. The short-term effect after induction of endotoxemia on 
respiratory rate, heart rate and body temperature compared to the control group is 
depicted in figure 5.  
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Figure 5: Dynamic alterations in clinical parameters and hematology after placebo 
(solid line; n=5 dogs) and LPS injection (dotted line; n=5 dogs). The grey markings are 
consistent with the reference interval. Data are expressed as group mean±standard 
deviation.Level of significance was set at P<0.05. 
 
As shown infigure 5A, the respiratory rate of both groups was above the upper limit 
of the reference interval (34  breaths/min) in the majority of dogs. There was a trend 
towards a higher respiratory rate in the control group, however, the difference 
between the groups and between the time points of examination was not significant. 
The heart rate was also not significantly affected by the induction of endotoxemia. 
In all dogs of the study group, injection of LPS resulted in a significant increase in 
body temperature above the upper limit of the reference interval (38.0°C-39.2°C) 
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reaching a peak of 40.3±0.4°C at time point 4 hours. There was a significant difference 
between the groups, a significant effect of time as well as a significant interaction 
between time and group. After induction of endotoxemia, 5/5 dogs developed a 
marked leukopenia with mean leukocyte counts of 2.5±0.7x109/l at time point 1 hour 
as shown in figure 5D. In all dogs, leukopenia was followed by a severe leukocytosis 
24 hours after LPS administration with mean WBCs of 76.0±33.7x109/l. In 2/5 dogs of 
the control group, a transient increase in leukocyte count (35x109/l and 58x109/l 
respectively) was seen at time point 4 hours which, however, was not accompanied 
by fever or any other clinical sign of an inflammatory process. Unfortunately, blood 
smears were not available to evaluate leukocyte morphology and the number of 
band neutrophils. There was a highly significant effect of time and a significant 
interaction of group and time (both P<0.0001), i.e. a different development of 
leukocyte counts in both groups during the course of time. 
There was a mild but significant decrease in platelet count one hour after injection of 
LPS and the placebo respectively, presented in figure 5E. The mean platelet count 
was lower in the study group, however, the difference between the groups was not 
statistically significant. At time points 1; 4; and 24 hours after application of LPS, a 
moderate thrombocytopenia was present in 1/5 dogs with platelet counts ranging 
from 16-31x109/l (reference interval 150-500x109/l). Statistical analysis revealed a 
significant interaction between group and time, i.e. a different development of 
platelet count in study group and controls during the course of time. 
Throughout the study period, R-time was higher in the study group than in the 
controls indicating a lower activity of secondary hemostasis, however, the difference 
between the groups was not statistically significant as shown in figure 6 below. 
 
 
 
 
 
63 
 
 
 
 
 
Figure 6: Dynamic changes in TEG parameters after placebo (solid line; n=5 dogs) 
and LPS administration (dotted line; n=5 dogs). The grey area indicates the 
laboratory-intern reference interval. Data are shown as group mean±standard 
deviation. Level of significance was set at P<0.05.  
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Although there was a significant increase in R-time in both groups, the absolute 
alteration from baseline values was small and results remained within the reference 
interval. The K-value reflecting the rapidity of fibrin cross linking increased 
temporarily after induction of endotoxemia with maximum values at time point 4 
hours, however, there was no statistically significant effect of group, time or 
interaction between group and time. Angle α also indicative of fibrin cross linking 
dropped significantly after injection of LPS. Mean results were lower in the study 
group than in the control group indicating an impaired process of fibrin cross 
linking, however, the effect was not statistically significant. MA and G values mainly 
reflecting platelet function did not change in the control group during the period of 
follow-up examinations. In the study group, an endotoxemia-induced decrease in 
MA and G was observed with lowest values 4 hours after injection of LPS. In 2/5 
dogs, MA and G values below the lower limit of the reference interval were noted at 
time points 4 hours and 24 hours respectively. For both variables, statistical analysis 
revealed a significant effect of time but no significant interaction between the factors 
group and time. The application of LPS resulted in a rapid increase of OSPT, aPTT 
and TT with highest coagulation times 4 hours after induction of endotoxemia as 
shown in figure 7. 
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Figure 7: Dynamic alterations in plasma coagulation parameters after placebo (solid 
line; n=5 dogs) and LPS injection (dotted line; n=5 dogs). Data are shown as group 
mean±standard. The grey area is consistent with the laboratory-intern reference 
interval. Level of significance was set at P<0.05. Level of significance was set at 
P<0.05. 
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For OSPT and aPTT, statistical analysis did not reveal a significant difference 
between the treatment groups, however, there was a highly significant effect of time 
and interaction between group and time. Despite the trend towards an increase after 
application of LPS, TT did not differ significantly between the groups and the 
different time points of follow up examinations. In the study group, a significant 
decrease in fibrinogen plasma concentration was observed with lowest results after 4 
hours. Until time point 24 hours after injection of LPS, fibrinogen plasma 
concentration was rising again and thus exceeding the results of the control group 
and the upper limit of the reference interval (3.1 mg/L). 
Within one hour after induction of endotoxemia, a 2.2 fold increase of D-dimers from 
a mean baseline concentration 0.37±0.07 mg/L to 0.81±0.64 mg/L was seen. A second 
peak was observed at time point 24 hours. Mean D-dimer plasma concentrations 
were significantly higher than in the control group and remained > 0.67 μg/ml for the 
duration of the experiment. 
LPS administration induced a moderate decrease in AT plasma concentration by 16% 
from mean baseline activities of 146±11% to lowest results at time point 24 hours 
(mean 122±8%). At all time points, results in the study group were not below the 
lower limit of the reference interval of 108%. In the control group, a mild transient 
decrease of AT plasma concentration was noted 1 hour after injection of the placebo. 
Mean AT activities of the control group were ranging between 133±11% (time point 1 
hour) and 143±7% (time point 4 hours) and were thus exceeding the upper limit of 
the reference interval (128%). There was a significant effect of time and a significant 
interaction between group and time i.e., a different development of the AT plasma 
concentration during the study period. 
After LPS treatment, PC activity compared to canine pooled plasma decreased 
significantly by 68% from a mean baseline value of 81±15% to lowest measurements 
at time point 4 hours (mean 26±39%). At time points 4 and 24 hours, 4/5 dogs 
demonstrated PC plasma concentrations below the lower limit of the reference 
interval of 75%. There was a significant difference between the treatment groups as 
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well as between the different time points. A similar effect was seen for PS activity 
decreasing by 34% from a mean baseline value of 108±27% to mean results of 63±46% 
at time point 4 hours. In contrast to PC, the endotoxemia-induced decrease of PS was 
smaller and the difference between study group and control group was not 
statistically significant. However, there was a significant effect of time and a 
significant interaction between group and time. At time points 4 hours and 24 hours, 
PS plasma concentrations was below the reference interval (74%-161%) in 2/5 and 1/5 
dogs respectively. 
Endotoxemia induced an increase of APC-ratio from a mean baseline value 2.2±0.1 to 
2.5±0.2. Although the endotoxin-induced raise of APC-ratio was significantly higher 
than results obtained the controls, the majority of dogs in the study group 
demonstrated an APC-ratio within the reference interval (2.0-3.0). Only in 1/5 dogs of 
the endotoxin group, a decreased APC-ratio of 1.71 indicative of APC resistance was 
recognized 4 hours after application of LPS. 
For FVIII activity, a transient non-significant decrease by 38% was noted in the study 
group 4 hours after injection of LPS. 
Regarding the coagulation profile shown in figures 6 and 7, 3/5 dogs in the LPS 
group developed coagulation abnormalities consistent with DIC after endotoxin 
injection. 
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6.Discussion 
 
6.1. Establishment of reference intervals for TEG and variables reflecting 
secondary and tertiary hemostasis run on the STA Compact analyzer 
 
6.1.1. Repeatability, interferences and the effect of anticoagulant 
 
6.1.1.1. Repeatability of  TEG analysis 
Coefficients of variation of repeatability have been assessed for TF-activated TEG by 
calculating the arithmetic mean and the pooled variance estimate, based on the 
differences in the duplicate determinations after 30 minutes and 120 minutes 
respectively using canine citrated re-calcified whole blood.180 Mean CVs for both time 
points for R, K, angle α, and MA were 6.46%, 15.71%, 7.86%, and 4.30% 
respectively180 and – thus similar to the CVs for kaolin-activated TEG obtained here.  
 
6.1.1.2. Impact of anticoagulant in TEG analyses 
Based on the results of the current study, the anticoagulant did not have any 
significant impact on TEG measurements. In contrast to this, studies in adult healthy 
volunteers (n=30190 and n=10191) and healthy children (n=14)185 undergoing minor 
surgical procedures have demonstrated that TEG variables were significantly 
different when measured in re-calcified citrated whole blood (analysed 30 minutes 
after sampling) compared to native whole blood. In re-calcified citrated whole blood, 
R and K were significantly shorter than in native blood whereas angle α and MA 
were significantly higher.185 Other investigators did not demonstrate a significant 
difference between native whole blood samples and citrated re-calcified whole blood 
(n=8) when assessed after storage of 30 minutes at room temperature, however, after 
120 minutes, a significant decrease in K and an increase in angle α was observed.192 
These findings were in contrast to the results obtained in the dogs studied here. It has 
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to be taken into account that the number of dogs evaluated in this study was low and 
significant effects might have been missed but the number of patients included was 
even lower in the majority of human studies demonstrating significant differences 
between native whole blood samples and re-calcified citrate blood. The most 
probable reason for the trend in hypercoagulation of citrated blood with respect to 
the native blood has been highlighted by Camenzind et al.,190 who found that citrate 
does not completely inhibit thrombin formation so that activation of coagulation was 
not completely inhibited. In the cited human investigations, celite190 was used for 
TEG analysis or thromboelastography was performed without any activating 
substances185,191,192 so that it can be hypothesized that differences in activation of the 
coagulation process might be responsible for the different findings obtained in the 
current study. In people, kaolin is known to act as a stronger activator compared to 
celite as reflected by a significantly shorter R time (P=0.0052) and K time (P=0.0004).193 
If kaolin is capable to induce a strong activation even in native whole blood samples, 
a mild hypercoagulability due to incomplete inhibition of thrombin formation in 
citrated specimens would not have been detected. This theory is supported by 
previous investigations in humans demonstrating that routine coagulation assays 
using potent activators such as aPTT, PT, and TT are insensitive to minor thrombin 
generation during citrate storage.194,195 It is also possible that – in contrast to humans - 
thrombin formation is completely inhibited in canine specimens, however, there are 
no studies substantiating this hypothesis. 
It can be concluded that due to the higher inter-individual variation in native TEG, 
the use of citrated whole blood should be preferred especially for clinical studies. 
 
6.1.1.3. Effect of hemolysis on TEG results 
Previous studies in human specimens have shown that haemolysis resulted in an 
activation or significant alteration of coagulation.196,197 The etiology of hemolysis, and 
blood cell lysis in general, includes biochemical, immunologic, physical, and 
chemical mechanisms. In vivo blood cell lysis can arise from hereditary, acquired, 
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and iatrogenic conditions (such as autoimmune hemolytic anemia, severe infections, 
intravascular disseminated coagulation, or transfusion reactions).185 Here in the 
study, in vitro hemolysis was induced with two methods: First, the effect of severe 
shear stress on erythrocytes was evaluated by induction of mechanical hemolysis and 
second the impact of blood cell lysis on coagulation was assessed by induction of 
hemolysis by freeze/thawing. Causes for hemolysis due to mechanical destruction of 
erythrocytes include mainly pre-analytic factors such as prolonged application of the 
tourniquet, difficulty in locating the venous access, unsatisfactory sample acquisition, 
using a needle with a too small diameter or rapid flow of the blood in the test tube as 
well as vigorous mixing and shaking of the tube.185 In vivo mechanical hemolysis due 
to shearing of erythrocytes is known to occur in patients with DIC198 or 
microangiopathic hemolysis as reported in canine hemangiosarcoma. Mechanical 
hemolyis was rarely reported after incomplete closure of patent ductus arteriosus 
botalli in dogs with coils.199 Lysis of blood cell membranes by factors other than shear 
stress includes pre-analytic factors such as exposure of the blood to excessively hot or 
cold temperatures or transfer of alcohol-based desinfectant from the skin into the 
blood specimen.185 The current study clearly demonstrated that for the majority of 
variables hemolysis-induced changes were greater in samples with higher degree of 
hemolysis i.e., after HF. However, aprobable dose-depended behavior was not 
specifically addressed by producing several subgroups of hemolytic samples with 
several degrees of hemolysis. The latter was not performed as the analysis of three or 
more hemolytic subgroups for both HM and HF would have required several 
measurements after another or > 4 TEG analyzers which were not available in the 
laboratory. The results of TEG analyses demonstrated to be highly dependent on the 
storage time after sampling so that the number of assays was limited to those which 
could be performed at once one hour after sampling. 
The investigation clearly demonstrated that the overall effect was a decreased 
coagulatory ability as shown by a decrease in MA and G-value. A similar result has 
been reported for horses using thrombometry.200 The low number of erythrocytes 
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cannot be the only explanation for the low MA observed here and in the previous 
study in horses as an increased MA was observed in anemic human samples: Serially 
diluted human blood samples with preserved platelet count and unchanged 
concentration of coagulation factors demonstrated a hypercoaguable TEG curve 
which was characterized by a short R, increased angle alpha and MA.201 An increased 
Maximum Clot Firmness (consistent with MA) was also observed in patients with 
sickle cell anemia using Rotem thrombelastrometry.202 The presence of already 
activated – and thus hypo-reactive platelets – appears to be the most likely 
explanation for the low MA and G despite the evidence of increased secondary 
hemostasis. In anemic humans, the hypercoagulable thromboelastography curve was 
considered to be due to technical reasons rather than an in vivo finding as those 
patients possess a reduced number of erythrocytes so that a higher percentage of the 
sample is plasma. Therefore, more fibrinogen and platelets are in the 
thrombelastometer cup when the anemic blood is being analysed.202 This is also a 
probable explanation for the significantly higher reduction in R observed in the 
current study in samples after HM which was associated with a mild decrease in 
hematocrit value in comparison to HF associated with a marked decrease in the 
percentage of erythrocytes. A further explanation for the hemolysis-induced 
reduction of R may be the fact that many substances may be released from lysed 
erythrocytes which might activate coagulation.185 Intracellular and thromboplastic 
substances from either platelets or leukocytes are thought to be responsible for 
shortening of aPTT reported in investigations in human samples203 and might also be 
responsible for the activation of secondary hemostasis reflected by the decreased R 
value which was observed here. Regarding the current results, it can be further 
hypothesized that the decrease in platelet count noted after HF might contribute to 
hypocoagulability characterized by decreased MA and G values observed after 
hemolysis as about 80% of the TEG-MA value is dependent on platelet number and 
function. However, as MA was lowest in specimens after HF and platelet count did 
not change significantly in this group, a decrease in platelet count has to be 
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considered an unlikely cause for this finding. In contrast to the current study, the 
previous investigation in horses had shown that mechanically induced hemolysis 
resulted in an increase of platelet count. So it is seen that blood cell lysis has a 
significiant impact on TEG parameters and results should be carefully interpreted. 
 
6.1.1.4. Repeatability of variables assayed on the STA compact 
Intra-assay CVs for OSPT, aPTT, TT, FVIII, AT, PC and PS were comparable or even 
slightly lower than those reported by the manufacturer for human plasma samples. 
Twenty-one-run intra-assay-repeatability for human specimens was as follows: 
OSPT=2.8%; aPTT=0.6%; TT=2.8%; FVIII=6.5%; AT=2.6%; PC=4.6%, and PS 2.75% 
(Package insert of STA test kits). The functional chromogenic PC assay demonstrated 
similar intra-assay CVs in people (2.9%)25 when compared to the clotting assay used 
in here. Intra-assay CV was slightly higher for the fibrinogen concentration even after 
removal of an outlier (5.6% in dogs versus 2.3% in people). Variables with low 
plasma concentrations in healthy dogs such as fibrin D-dimer plasma concentration 
and anti-FXa activity demonstrated also high intra-assay CVs which were higher 
than those reported for human plasma. Intra-assay CV for fibrin D-dimers and anti-
FXa were 45.9% and 12.8% (table 3) in canine plasma compared to 13.7% and 4.4.% in 
human specimens. However, for interpretation it has to be considered that 
concentrations of fibrin D-dimers and anti-FXa activities were extremely low in 
healthy dogs which is well known to result in high intra-assay CVs.204 Six-run intra-
assay repeatability for fibrin D-dimers was reported to be 6.1% (range 2% to 10%) for 
the same method and analyzer when determined in canine plasma with increased 
fibrin D-dimer plasma concentrations ranging from 0.94 μg/ml to 3.08 μg/ml (n=6 
dogs).205 In the previous investigation evaluating the STA Rotachrom Heparin assay 
for measurement of activity in canine blood plasma, 15 run-intra-assay repeatability 
was 13% at low anti-FXa activities (mean 0.268 IU/ml) and thus comparable to the 
results obtained here.206 
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6.1.1.5. Impact of hemolysis and lipemia on variables measured on the STA compact 
In people, as mentioned above, it is well known that haemolysis does not cause 
interferences solely by the presence of haemoglobin as many substances may be 
released from lysed erythrocytes which might influence coagulation.197 The release of 
intracellular and thromboplastic substances from leukocytes and platelets was 
considered to be responsible for shortening of the aPTT as it was observed 
previously in human specimens207 and also in this study. In people, however, there 
was no definite agreement on this topic in the current literature.197 In patients, 
measurement of OSPT, aPTT, fibrinogen and D-dimer concentrations have been 
considered to be more susceptible to pre-analytic errors.208 A recent investigation 
evaluating 12 degrees of haemolysis on routine coagulation parameters in human 
specimens reported a significant increase in OSPT and D-dimers whereas a decrease 
in aPTT and fibrinogen was noted in samples containing more than 9% 
haemolysate.197 The impact of haemolysis on AT has been rarely investigated in 
people and dogs. Increasing concentrations of haemoglobin resulted in a linear 
decrease in AT activity detected in canine plasma164 which is in accordance with the 
results obtained in the current study. 
For assessment of the influence of haemolysis on laboratory analytes, haemolysed 
specimens are commonly achieved by freezing-thawing cycles as it was also 
performed in the canine specimens evaluated here and in the previous human 
study.197 A drawback of this method, however, was that naturally occurring 
haemolysis due to pre-analytic factors or diseases is associated with the generation of 
destroyed platelets and leukocytes as demonstrated in human samples.197 Thus, the 
results reported here may not representative for all causes for haemolysed specimens 
observed in clinical laboratories. 
According to the manufacturer, assays are insensitive to the following haemoglobin 
concentrations added to human plasma. A haemoglobin concentration up to 7.6 g/l 
(=4.7 mmol/l) for antithrombin, 5g/l (=3.1 mmol/l) for fibrin D-dimers and 2 g/l (=1.2 
mmol/l) for anti factor Xa activity did not interfere with the assay. For the APC assay, 
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resampling was recommended for haemolytic human samples. Regarding the other 
variables, information about the effect of haemolysis was not provided by the 
manufacturer. 
The effect of lipaemia on routine coagulation parameters (OSPT, aPTT, TT, 
fibrinogen) has been rarely investigated in dogs.140 In contrast to the current study, 
measurements were performed using a ball coagulometer. Severe lipaemia 
(>triglyceride concentration of 1.25 g/l) resulted in a slight but clinically not 
significant shortening of OSPT and TT in canine blood plasma.140 A decrease in 
fibrinogen concentrations by 15% have been reported in people, however, 
significantly false-low fibrinogen plasma levels were observed in the dogs evaluated 
here and in the previous investigation studying the effect of lipaemia on canine 
plasma.140 
According to the manufacturer, assays are insensitive to triglyceride concentrations 
up to 7.6 g/l for antithrombin, and 3.6 g/l for anti factor Xa activity added to human 
blood plasma. In people, lipaemia was reported to result in false-low D-dimer 
measurements, which was not in accordance with the current findings in canine 
specimens. 
 
6.1.2. Reference intervals 
According to the proposals of the IFCC, at least 40 reference values are needed to 
obtain the 0.025 and 0.975 percentiles.210 Given the proposal for establishment of 
human reference intervals, the number of values included should be preferable more 
than 120, but the quantity of samples required is strongly dependent on the 
confidence intervals.210 The number of dogs included here was lower than the 
optimal number recommended by the IFCC, however, even in humans, it is generally 
accepted that a smaller number of values may still serve a useful clinical purpose as a 
guide in the form of the list of all values.210 The use of the IFCC proposals in 
veterinary medicine is hampered by the fact that collection of samples and laboratory 
analyses are expensive and time-consuming and it is often difficult to identify the full 
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number of healthy subjects, so that alternative statistical methods have been 
evaluated to estimate reliable reference intervals even in a data set containing 
diseased animals.211 TEG has been rarely performed in healthy dogs. Mean and 
standard deviation209,212/range180 of TEG variables (R, K, angle α, MA)180,212 and G209 
have been published for both TF-activated TEG (n=18 dogs209; n=8 dogs212) and TEG 
performed with native recalcified citrated whole blood (n=15 dogs).180 It has to be 
considered that results of TF-activated TEG are not necessarily comparable to kaolin-
activated TEG performed here as the first represents the extrinsic coagulation 
pathway whereas the latter is consistent with the intrinsic pathway of the 
coagulation cascade. In people, reference intervals for kaolin-activated TEG were as 
follows: R=5.3-9.3 min; K=1.4-3.5 min; angle α=48.8-72.2 degree; MA=55.3-69.3 mm 
and G was not evaluated by the authors.213 MA and angle α were similar in humans 
(adults and children) and in the dogs investigated here but the lower reference limit 
of the R-value was considerably shorter in dogs (1.8 minutes in dogs versus 5.3 
minutes in man) indicating a higher activity of secondary haemostasis.213 This is 
supported by previous reports demonstrating that dogs show a higher coagulation 
activity of the extrinsic and intrinsic pathway compared to people.64 
Based on data obtained in 100 children of different age groups, age-related 
differences in kaolin-activated TEG were not indentified.213 However, establishment 
of reference intervals for TEG variables in newborns revealed that TEG reaction time, 
and G-value were significantly lower in neonates (P<0.001) than in adults.214 In the 
latter study, TEG was conducted without use of an activator. 
Comparable studies have not been performed in dogs, so that puppies or growing 
dogs have been excluded from the current investigation. 
TF-, kaolin- and celite-actived TEG has been conducted in human specimens 
investigating the in vitro effect of the novel kallikrein inhibitor DX88 on TEG using 
different types of activation compared to a control.215 R-time in the controls was 
shorter in kaolin activated-TEG than in TF-activated TEG. These results reinforce the 
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importance of consulting activator specific TEG reference intervals when interpreting 
results. 
The current study demonstrated that TEG parameters were similar in male and 
female dogs. In contrast to this, sex is known to have an impact on several variables 
of coagulation in people. Men were reported to have higher plasma antithrombin 
and PC concentrations216 whereas in woman higher D-dimer plasma concentrations 
were observed.203 An age-dependent decrease in prothrombin time was noted in men 
(r=-0.34; P<0.001) but not in woman (r=-0.04; P=0.47).217 Information about the 
influence of sex on TEG variables is lacking in people and dogs. The castration status 
was not taken into account here as the number of neutered dogs was comparatively 
low. 
A limitation of the current study was that predominantly samples from Beagle dogs 
and German shepherd dogs could be obtained. This was due to the fact that healthy 
dogs available at a university clinic are either blood donors (mainly medium-sized to 
large breed dogs and Beagle dogs) or healthy dogs presented for routine radiological 
examination to screen for hip dysplasia or elbow dysplasia which is known to affect 
large breed dogs. Due to the predominance of Beagle dogs and German shepherd 
dogs in the reference population, it has to be considered that the results obtained 
here, might not be representative for all breeds. Breed-specific differences in 
coagulation have rarely been investigated in dogs. In one study comparing kaolin-
activated TEG in 28 healthy Greyhounds and 15 non-Greyhound dogs, clotting 
kinetics were significantly slower and clot strength was significantly weaker in 
Greyhounds than in non-Greyhounds, except for R-time.209 Here, Greyhounds were 
not included.  
Previous investigations in canine citrated whole blood specimens have shown a 
significant trend towards hypercoagulability indicated by a decrease in R and K as 
well as an increase in angle α and MA when the storage time exceeded 120 
minutes.180 Thus, a fixed time point for measurements was recommended180 as 
performed in the current study. 
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Regarding the reference ranges established for the STA Compact, reference intervals 
for OSPT, aPTT, fibrinogen (Clauss method) were comparable to those detailed 
previously for manual tests applied in dogs.218 
Using a commercial coagulometric test, FVIII activity in canine plasma was reported 
to be 7.9 time higher compared with activities in human standard plasma which was 
in accordance with these results for the automated coagulation analyzer and was also 
demonstrated in less recent studies and case reports evaluating canine FVIII activity 
with coagulometry.198,219 It has been shown that all coagulation tests using human 
deficient plasma for measurement of coagulation factors in canine plasma were 
influenced by the very high activities of FVIII (9.3 fold higher than in human plasma) 
and FV which are typical for dogs.220 This was particularly the case when low 
dilutions of plasma were applied so that use of higher sample dilutions (> 1:20, e.g. 
1:40) were recommended to reduce this effect.220A similar finding has been reported 
in cats221 and cattle.222 
Reference intervals for a functional PC chromogenic assay have been previously 
reported in dogs to be 75%-135% compared to canine pooled plasma25 which was 
comparable to the result obtained here although the upper reference limit was 
slightly lower in this study (118%). Differences might be due to a different 
methodology (chromogenic versus clotting assay) and use of different pooled 
plasma. A limitation of the previous study was that statistical methods for 
calculation of reference intervals were not given and only 20 dogs were included.25 
To the author´s knowledge, this is the first study evaluating the PC and PS activity in 
healthy dogs with a functional clotting assay using Protac®, a single-chained 
glycoprotein derived from the venom of the southern copperhead snake, Agkistrodon 
contortrix contortrix as an activator of PC. PC activity has been determined previously 
in canine plasma with a Protac®-activated chromogenic assay, however, the results 
have been compared to canine pooled plasma rather than with the human standard.25 
The current study clearly demonstrated that PC and PS activities determined with 
the clotting test were markedly lower than in the human calibration standard. 
78 
Theoretically, this might have been due to a plasma concentration being lower in 
dogs than in people. As the clotting assay is a functional test, it might also be 
hypothesized that a decreased biological activity of PC and PS in dogs was the 
reason for different activities observed in people and dogs. However, given the 
physiology of the coagulation process, it is unlikely that dogs are lacking the natural 
anticoagulant PC. Moreover, an impaired activation of PC and PS in the clotting 
assay could have been responsible for different results obtained in people and dogs. 
A previous investigation demonstrated that canine PC was unresponsive for the 
activation with Protac® even when 3 times higher doses than in people were used.223 
Although canine PC was reported to show 72% homology with human PC molecule, 
the existent variations may account for the differences in the ability of Protac® to 
activate human and canine proteins. Surprisingly, dilution of the concentration of the 
contact activator even resulted in a shortening of the aPTT compared to the control 
(untreated canine blood plasma), whereas after dilution of both plasma and activator 
a minimal prolongation of aPTT was observed.223 A similar finding was reported in 
pigs and it was hypothesized that this effect could be attributed to the presence of PC 
inhibitors or anti-activators since Protac® did induce PC-related amidolytic activity 
when the sample was diluted.224,225 In contrast, PC-like amidolytic activity was not 
observed in canine plasma after activation with Protac® so that it was considered 
more likely that the snake venom extract, aPTT reagents, and canine plasma failed to 
produce astochiometric complex with strong PC activity.223 
 Despite these reports, there was evidence in the literature that at least a minimal 
activation of canine PC by Protac® is achieved because in this study and in another 
investigation, linearity of the test was proven from 0-100% when using a serial 
dilution of canine pooled plasma.25 In contrast to the current investigation, a 
functional chromogenic assay was used by de Laforcade et. al. which, however, also 
included an activation of PC with the venom of the copperhead snake in comparison 
to a canine pooled plasma sample obtained from 15 healthy dogs.25 Previous 
investigations in dogs have proven that functional PC assays are suitable to detect 
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significant differences between PC concentrations in patients with various diseases 
including sepsis25,182 and portosystemic shunting.226 
Regarding the resistance against activated PC, a reference interval for APC-ratio has 
not been evaluated in dogs. In people, an APC-ratio < 2.1 seconds has been 
considered abnormal175 which was comparable to the results in dogs. The clinical 
significance of this variable, however, has still to be elucidated for animals. 
The results of the current study clearly demonstrated that plasminogen activity was 
markedly lower in canine plasma than the human standard. Previous investigators 
found also lower plasminogen concentrations in dogs which were approximately 
50% of the activity present in the human control plasma. These investigators used a 
chromogenic assay which was working with an excess streptokinase concentration 
(8000 IU/ml) for activation of plasminogen (HemosIL™ Plasminogen, 
Instrumentation Laboratory Munich).227 However, these results were still higher than 
the reference interval obtained in the current study. A possible reason for the 
discrepancy found between different assays may be the fact that the concentration of 
streptokinase required for activation of plasminogen is species-specific. It was 
reported before that markedly higher amounts of streptokinase had to be applied in 
rats, rabbits and dogs than in humans.228 For this reason, different streptokinase 
concentrations used in the test kits (8000 IU/ml in the HemosIL™ Plasminogen 
assay227 versus 5000 IU/ml in the STA Plasminogen assay applied in the current 
study) may also be responsible for the differences between laboratories. Based on 
these findings, it was evident that human assays used for measurement of canine 
plasminogen activity were reflecting the capability of the fibrinolytic system to be 
activated by streptokinase rather than the plasminogen concentration itself.229 This is 
in accordance with a previous study in dogs reporting a low capability of 
streptokinase (4000 IU/ml) to activate canine plasminogen in a commercial assay 
which was adapted to a microtiter plate.154 Urokinase (20,000 IU/ml) demonstrated to 
be a more potent activator than streptokinase in canine specimens.154 Although 
commercial plasminogen test kits which were supplied with comparatively high 
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streptokinase concentrations such as the HemosIL™ Plasminogen assay showed a 
certain capability to activate canine plasminogen,227 substitution of streptokinase by 
urokinase appears to be preferable to achieve an expansion of the standard curve. In 
the current investigation, additional analysis of samples using urokinase or 
streptokinase in higher concentrations as activator was not performed due to an 
insufficient sample volume. 
Anti-FXa activity was evaluated before in 12 healthy dogs and 10 dogs with IMHA 
using the same assay, analyser and test protocol.206 Baseline anti-FXa activity ranged 
between 0.06-0.17 IU/l and thus was slightly lower than in the current investigation. 
This finding indicated that canine plasma contains endogenous FXa inhibitors at a 
higher concentration or increased activity compared with human plasma.206 
Therefore, a higher dilution of canine plasma (3:8 instead of the default setting of 1:2 
for human samples) was recommended for monitoring of heparin therapy in dogs to 
achieve a baseline activity close to zero. 
The impact of sex on coagulation parameters reflecting fibrinolysis and natural 
anticoagulants was not evaluated before. Previous investigations in dogs revealed 
significantly increased concentrations of fibrinogen and fibrin/fibrinogen 
degradation products (FDPs) under the influence of high peripheral progesterone 
concentrations whereas plasma antithrombin was decreased.230 The current 
investigation failed to demonstrate any significant impact of sex on coagulation 
parameters but the phase of the oestrus cycle was not determined here, so that effects 
specific for certain cycle phases might have been missed. The impact of sex on fibrin 
D-dimers, PC, PS, APC-ratio, plasminogen, and anti-FXa activity has not been 
evaluated in dogs. In people, several sex-specific findings were demonstrated. Men 
reported to have higher plasma AT and PC plasma concentrations216 whereas in 
women higher D-dimer plasma concentrations could be observed.231 
The samples were predominantly from Beagle dogs and German shepherd dogs 
whereas Greyhounds were not included as previously explained. Significant 
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differences between different breeds were reported for FVII232 which, was not 
investigated here. 
In summary it can be concluded that some human assays including the analysis of 
OSPT, aPTT, fibrinogen and AT, D-dimer concentrations were suitable for use with 
canine specimens without any further adaptation of the human test protocols 
whereas others such as the PC and PS clotting test can only be used when results are 
compared to canine pooled plasma due to species-specific characteristics of the 
coagulation process. With modifications, the commercial human PC, PS and FVIII 
test kits might serve to elucidate canine diseases associated with thrombophilia such 
as early phases of disseminated intravascular coagulation. The high costs of the 
assays, however, limit their application in routine practice. Based on the results of the 
current study, the STA plasminogen assay is not suitable for assaying plasminogen 
activity in canine samples most likely due to the low streptokinase concentration 
used in the test kit. 
 
6.2. Evaluation of impact of endotoxemia on the coagulation process 
This study documents the early systemic response to LPS administration in dogs. 
The peak of most severe coagulation abnormalities was accompanied by severe 
clinical and hematological signs of sepsis (fever and leukopenia). Here, respiratory 
rate and heart rate were no sensitive parameter to detect the early onset of a septic 
process. The respiratory rate was exceeding the reference interval in both groups 
which might have been caused by high ambient temperatures. However, maximal 
temperatures in Bursa, Turkey were ranging between 18.8°C and 23.6°C (Historical 
weather, Bursa, Turkey: http://www.tutiempo.net/en/Climate/Bursa/10-
2008/171160.htm) during the study period so that excitement of the dogs during the 
physical examination appears to be the most likely cause. 
Comparable to the results in the current study in dogs, transient leukopenia was 
observed 4 hours after application of LPS in dogs121 and in a feline model of low-dose 
endotoxemia.124 Others reported a nadir of leukocyte count 2 hours following the 
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application of 1 μg LPS in dogs.233 Like in the current investigation, leukopenia was 
followed by a leukocytosis 24 hours after administration of endotoxin in the previous 
study in dogs121 whereas in the other experimental investigations in dogs and cats, 
the study period was less than 5 hours233 and 6 hours124 respectively after 
administration of LPS so that a probable increase in leukocyte counts might have 
been missed. The transient leukocytosis recognized in two dogs of the control group 
was unexpected as this finding was not associated with any clinical signs or fever 
indicative of an acute inflammatory process. As it was not associated with 
coagulation abnormalities, its impact of the results of the study was considered to be 
not significant. 
The sepsis-induced changes in TEG variables observed here were in accordance with 
a previous experimental study in pigs (n=7) reporting a significant decrease in α and 
MA values (21%) in the first 4 hours after induction of sepsis, while R increased by 
63% at the end of the LPS injection (50 μg/kg given intravenously over 60 minutes). K 
rose steadily for 5 hours, increasing significantly by 66% at 6 hours. Fibrinolysis was 
not seen during the 6 hours period performing TEG of 1-hour length.234 In contrast to 
the results in dogs and pigs, infusion of 2 ng/kg LPS to human volunteers was 
followed by a significant decrease in clotting time (consistent with the TEG R value) 
when assessed with ROTEM thromboelastography whereas clot formation time 
(consistent with TEG K) and maximal clot firmness (consistent with TEG MA) were 
not affected by LPS application.235 
A probable reason for the discrepancy between the findings reported in people and 
dogs or pigs respectively might be the markedly lower dosage of endotoxin used in 
the human investigation. It can be hypothesized that application of higher dosages of 
endotoxin may result in a more rapid activation of coagulation which is followed by 
a fast consumption of coagulation factors and – thus a prolongation of R indicating 
an impaired secondary hemostasis. Lower LPS concentrations as used in the human 
study, however, appear to activate coagulation activity and fibrinolysis but there was 
no evidence of excessive consumption of coagulation factors. 
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Regarding the results of the current study, the diagnostic use of TEG as early marker 
of coagulation abnormalities in patients appears to be problematic as the majority of 
TEG parameters remained within the reference interval and changes are only 
detected if follow-up examinations are available. A similar finding was obtained in 
septic human patients without bleeding complications showing 
thromboelastography (ROTEM) variables within the reference interval, however, an 
improvement was seen after treatment.236 
The response to LPS administration has been reported previously in dogs for several 
coagulation parameters, however, in the previous study, a markedly higher LPS dose 
(6mg/kg) was applied so that the results are not entirely comparable to the findings 
reported here.121 In accordance to the current investigation, a transient 
hypofibrinogenemia followed by a hyperfibrinogenemia was noted in the previous 
study as well as a decrease in PC activity, antithrombin, factor VIII, platelets and the 
leukocyte count.122 Activation and subsequent consumption of PC has been also 
observed in septic human patients.237-239 
In the current study, the most significant endotoxin-induced change of coagulation 
parameters was demonstrated for PC activity and fibrin D-dimers. A similar result 
was recognized in people with naturally occurring sepsis.240 In accordance with the 
current study in dogs, a less pronounced decrease in PS compared to the AT and PC 
plasma activities was seen in people.241 In contrast to this, others reported that PS 
activity was not significantly different even in patients with severe sepsis when 
compared to the controls.240,242 For AT, mean results of the control group and baseline 
activities observed in the study group were exceeding the laboratory-intern reference 
interval established previously for the author´s laboratory. A probable reason for this 
may be the fact that only 2 of 56 dogs included for establishment of reference 
intervals were mongrel dogs. Moreover, German Shepherd dogs (n=19/56) and 
Beagle dogs (n=15/56) were overrepresented, so that the reference interval might be 
broader in mongrel dogs although to the author´s knowledge no breed-specific 
difference have been reported for AT. 
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The current study clearly demonstrated that application of endotoxin did result in a 
rapid change of mean results of all coagulation parameters studied. For TEG K and 
MA value as well as for coagulation times, fibrinogen, PC, PS and FVIII peak 
deviations from the baseline level are reached after 4 hours whereas for the other 
variables the deviations from the baseline level remained constantly changed during 
the study period. The results in dogs are in contrast to findings in people 
demonstrating a transient increase of FVIII activity 4 hours after experimentally 
induced endotoxemia after 4 ng/kg LPS given intravenously which was accompanied 
by unchanged PC and PS plasma activities.243 A probable reason for the discrepancy 
to the actual study in dogs might be the fact that the LPS dose administered in the 
human study was comparatively low so that it did not result in DIC with subsequent 
consumption of coagulation factors and natural inhibitors of coagulation such as PC 
and PS. The raise in FVIII activity reported in people is not surprising as it is an acute 
phase protein in humans and LPS demonstrated to activate the human FVIII 
promoter in cultured hepatocytes.244 FVIII is also an acute phase protein in 
horses245,246 but not in mice.244 The promoter region responding to LPS is well 
preserved in dogs compared to the human sequences which might suggest a similar 
importance of FVIII as acute phase proteins in dogs.244 The potential role of FVIII as a 
canine acute phase protein has not been demonstrated in clinical studies so that it has 
to be elucidated in future investigation if dogs show a similar increase of FVIII in 
response to inflammatory stimuli. 
Based on the results it can be concluded that the behavior of the APC-ratio is not 
comparable with its alterations in people observed during the course of 
inflammation. Except for 1/5 dogs, an increase of APC-ratio consistent with a 
decreased APC resistance was noted following the induction of endotoxemia. This 
result contrasts findings in people showing a decline of APC-ratio to 65% of the 
baseline levels and thus – an increased APC resistance.243 In the dogs evaluated here, 
the APC-ratio was generally within the reference interval so that this parameter can 
only interpreted when follow-up examinations are available. Based on the results of 
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this study, it can be concluded that – at least under experimental settings - the APC-
ratio is not of major use in the diagnostic workup of dogs with early 
sepsis/endotoxemia. 
In the previous experimental study in dogs, a markedly higher LPS dose (6 mg/kg) 
was applied resulting in the death of 2/5 patients.121 Sublethal LPS injection was 
chosen for the current investigation to avoid several pitfalls reported for high-dose 
bolus endotoxemia models, including acute overwhelming inflammation, induction 
of an immediate severe hypodynamic circulatory response, atypical massive cytokine 
production, and rapid mortality.247 Unlike models of high-dose endotoxemia 
resulting in rapid mortality, this model is more likely to provide clinically useful data 
for the evaluation of novel coagulation parameters in canine patients. The reaction to 
LPS appears to be species-specific as both low-dose (2 μg/kg/h i.v. for 4 hours)124 and 
high dose (3-10 mg/kg) LPS infusion248 did not produce significant coagulation 
abnormalities in cats. 
A potential downsides of IV endotoxin sepsis models – and also here - is that they 
are not necessarily representative for all situations of clinical disease as septic foci in 
patients generally seed the body with bacteria continuously rather than over a short 
period of time.247 Further limitations of the current study included the fact that the 
number of dogs examined was comparatively low so that significant effects might 
have been missed and that there was evidence of transient inflammation in the 2 of 
the control dogs. Nevertheless, coagulation parameters were not changed at this time 
point so that there was no apparent influence on the coagulation process. 
In this study, platelet aggregates or clumps could not be excluded as a contributing 
factor to the thrombocytopenia, as peripheral blood smears were not reviewed. Mild 
to moderate platelet clumping was reported to contribute to a decrease in platelet 
count when measured by the impedance method.249 However, in a recent study, 
platelets in canine blood collected in EDTA were minimally clumped in most blood 
smears and the interpretation of platelet count and platelet indices was not 
significantly affected, as compared with blood collected in citrate.250 
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 Overall, the study clearly demonstrated that a raise in fibrin D-dimers is the earliest 
indicator for sepsis-associated coagulation abnormalities followed by a significant 
increase in OSPT and a marked decrease in PC whereas alterations in PS, AT, FVIII 
were of minor severity in the early phase of a septic process. In contrast to humans, 
APC ratio did not appear to be a good screening parameter in canine septic patients 
but further studies are required to elucidate the diagnostic use of this parameter in 
dogs. TEG variables are often within the reference interval in early sepsis, so that 
follow-up examinations of the patient are essential to detect abnormalities of the 
coagulation system. 
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using the STA Compact automated analyzer. J Vet Diag Invest. 2009; 21(6): 
803-814. 
3) Bauer N., Eralp O., Moritz A.: Effects of hemolysis on canine kaolin-activated 
thromboelastography values and ADVIA 2120 platelet activation indices. Vet 
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4) Eralp O., Yilmaz Z., Failing K., Moritz A., Bauer N.: Effect of experimental 
endotoxemia on thromboelastography parameters, secondary and tertiary 
hemostasis in dogs. 2011, 25(3):524-531. 
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7. Summary 
 
Objective 
The first part of the study included method validation(intra-assay-repeatability, 
impact of hemolysis and lipaemia, effect of anticoagulant) and evaluation of 
reference intervals for dogs for kaolin-activated thromboelastography (TEG® 5000 
Thrombelastograph, Haemonetics Corporation; formerly Haemoscope Corporation; 
Braintree, MA, USA) and the automated coagulation analyzer STA Compact (STA 
Compact®, Roche Diagnostics GmbH, Mannheim, Germany).  
In a second part of the study, the response of the coagulation system in a canine 
model of endotoxemia was evaluated.  
Material and Methods 
Before the establishment of reference intervals, repeatability and interferences were 
assessed. Investigated variables included the TEG values R, K, α, MA and G as well 
and the coagulation variables one stage prothrombin time (OSPT), activated partial 
thromboplastin time (aPTT), thrombin time (TT), fibrinogen, Factor VIII (FVIII), 
antithrombin (AT), protein C (PC), protein S (PS), resistance against activated protein 
C (APC-ratio), plasminogen, D-dimer, anti-FXa run on the coagulation analyzer STA 
Compact. Intra-assay repeatability for TEG variables was performed in 6 healthy 
dogs with duplicate measurements. The standard deviation required for calculation 
of the coefficient of variation (CV) was consistent with the root of the pooled variance 
estimate. The comparison between TEG results obtained with native whole blood or 
citrated whole blood was performed in 16 healthy dogs. For assessment of hemolysis 
on TEG results,17 healthy dogs were included. Hemolytic samples were prepared 
with two techniques: mechanical stress (HM) and as well as freeze and thawing (HF). 
The intra-assay repeatability for variables assayed with the STA Compact was 
assessed with 15 replicate measurements in a sample taken from one healthy dog. 
The intra-assay variation was estimated for variables mentioned above. To assess the 
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influence of lipemia on measurements run on the STA Compact analyzer, samples 
with three grades of lipemia were prepared by adding Liquigen® (Liquigen®, 
Pfrimmer Nutricia GmbH, Erlangen, Germany) to the samples of three healthy dogs. 
The effect of hemolysis on these coagulation parameters was performed by treating 
whole blood in afreeze-thaw cycle and three grades of hemolysis were obtained. 
Establishment of reference intervals for TEG parameters and coagulation parameters 
measured on the STA Compact was performed with 56 healthy dogs. After 
evaluating the default settings of human assays applied on the STA Compact for 
canine specimens, some modifications of the test methods were needed. A standard 
curve has to be prepared with canine pooled plasma for PC, PS and FVIII. Also for 
both analyzer measurements the impact of sex on the results was established.  
In the second part of this investigation, the impact of endotoxemia on primary, 
secondary and tertiary hemostasis as well as TEG variables was evaluated in 10 
healthy Mongrel dogs. A control group (n=5 dogs) and a treatment group (n=5 dogs) 
was created. Dogs in the treatment group received endotoxin (LPS) dissolved in 
sterile saline 0.9% which was administered intravenously at a dosage of 0.02 mg/kg. 
The control group received 0.2 ml/kg sterile saline 0.9%. Venous blood samples were 
collected before application of LPS or placebo (0 hour), 1, 4 and 24 hours after 
treatment. 
Statistics 
Results were analyzed with the Graph Pad Prism (Graph Pad Software, San Diego, 
USA), Analyse-it Method evaluation (Analyse-it Method validation Edition version 
2.12 - © 1997-2008, Analyse-it Software Ltd.) and BMDP statistical software (BMDP 
Statitical software Inc., 1440 sepulveda Blvd, Los Angeles, CA 90025 USA).  
Intra-assay variation for TEG variables was assessed by calculating the arithmetic 
mean and the pooled variance estimate, based on the differences in the duplicate 
determinations. For variables measured on the STA compact fifteen-run intra-assay 
repeatability for normal values was calculated from a sample of a healthy dog. The 
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effect of anticoagulant and interferences was assessed by a paired t-test (or Wilcoxin 
signed rank sum test).  
For the establishment of the reference intervals, an Anderson Darling test was 
performed to verify the assumption of normality. In case of normal and log normal 
distribution of data, double sided reference intervals were obtained by calculating 
the mean±1.96 SD (standard deviation) so that 95% of the reference population 
wasincluded. If non-normal distribution of data was present, the non-parametric 
percentile method was applied. The 2.5 and 97.5 percentiles were calculated to obtain 
the 95% double sided reference interval. Data were depicted as histograms with the 
reference interval as well as the 90% confidence interval of the upper and lower 
reference limits. The influence of sex on the reference intervals was assessed by using 
an unpaired t-test or a comparable non-parametric test (Mann Whitney U test). 
The differences between control group and endotoxin treatment group were assessed 
with a two way analysis of varience and covariance with repeated measures. 
Results 
Intra-assay CVs for R; K; α; MA and G were 7.6%; 17.7%; 7.4%; 2.9% and 6.6% 
respectivley. Samples with hemolysis resulted in a significantlydecreased R value 
and decreased MA, G and α value (P<0.001 to <0.0001). Furthermore, a significantly 
high K value was seen compared to the control group (P<0.01). There was no 
significant impact of anticoagulant on TEG variables.Inter-individual variation was 
higher in native samples than in citrated whole blood. Intra-assay CVs for the 
coagulation parameters OSPT, aPTT, TT, fibrinogen, FVIII, AT, PC, PS, APC-ratio, 
plasminogen, D-dimer and anti-FXa were 1.22%, 1.02%, 1.64%, 5.6%, 3.89%, 4.68%, 
2.36%, 1.4%, 1.45%, 20.16%, 45.92% and 12.83%. FVIII-activity, antithrombin, 
proteinC, protein S, and APC-ratio were overestimated in haemolytic plasma, 
whereas fibrinogen, TT, and aPTT were underestimated. Lipemia resulted only in 
false high D-dimers. 
Reference intervals for the kaolin activated TEG were as follows: R=1.8-8,6min.; 
angleα=36.9-74.6 degrees; K=1.3-5.7 min.; MA=42.9-67.9 mm and G=3.2-9.6 
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Kdyn/cm2.Reference intervals for the STA Compact automated analyzer were as 
follows: OSPT=5.7-8.0 sec.; aPTT=10.0-14.3 sec.; TT=11.9-18.3 sec.; fibrinogen=1.3-3.1 
g/l; AT=107.9-128.0 %; D-dimer=0.023-0.65 µg/ml; anti-FXa=0.04-0.26 IU/L; APC-
ratio=2.0-3.0; PC=74.4-160.5 %; PS=75.5-118.9 % and FVIII=70.9-136.4 %. The results 
for PC, PS and FVIII have to be compared to a canine standard curve. There was no 
significant impact of sex on results of both analyzers.  
Second part of the study: The endotoxin-induced clinical signs included lethargy 
(n=5/5), diarrhea (n=4/5), vomitus (n=4/5) and abdominal pain (2/5).  
Regarding the evaluation of the impact of endotoxin on the coagulation process 
severe leukopenia (mean 2.5±0.7×109/l; P<.0001) and a significiant 2.2-fold increase in 
D-dimers (P=0.001) were observed at time point 1 hour. At time point 4 hours, a 
significant raise in body temperature (P=0.0006) and in OSPT (P=0.0042) was seen as 
well as a significant decrease in fibrinogen (P=0.0007), protein C (P=0.0021) and 
protein S (P=0.008). PLTs (P=.0284) and antithrombin (P=.0170) were lowest at time 
point 24 hours. TEG variables did not significantly differ between the groups. APC-
ratio was higher in the sepsis group (P=0.0348), however, remained within the 
reference interval in 4/5 dogs. 
Conclusion 
The data provided useful reference ranges for kaolin-activated TEG and for the STA 
Compact automated analyser but some human tests (e.g., Protein C,  protein S and 
factor VIII) have to be modified.  
Regarding the impact of endotoxemia on the hemostatic system, the earliest indicator 
of sepsis-associated coagulation abnormalities were D-dimers which were followed 
by increased OSPT and decreased protein C. APC-ratio and TEG variables were not 
considered to be good screening variables in early sepsis/endotoxemia. 
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8. Zusammenfassung 
 
Ziel der Studie 
Das Ziel des ersten Teils der Studie war die Methodenevaluation (inklusive intra-
assay Wiederholbarkeit, Einfluss von Hämolyse, Lipämie und Antikoagulant) sowie 
die Referenzwertbestimmung für Hunde für kaolin-aktivierte Thrombelastographie 
(TEG® 5000 Thrombelastograph, Haemonetics Corporation; formerly Haemoscope 
Corporation; Braintree, MA, USA) und das automatisierte Gerinnungsanalysegerät 
STA Compact (STA Compact®, Roche Diagnostics GmbH, Mannheim, Germany). 
Im zweiten Teil der Studie soll der Einfluss von Endotoxämie auf den 
Gerinnungsprozess bei  einem Hunde-Endotoxinmodell untersucht werden.  
Material und Methoden 
Vor der Etablierung der Referenzwerte wurden die Wiederholbarkeit und 
Interferenzen auf die Untersuchungen durchgeführt. Die evaluierten 
Gerinnungsparameter umfassten die TEG Parameter R, K, α, MA und G sowie die 
Koagulationsparameter Prothrombinzeit (PT), aktivierte partielle Thromboplastinzeit 
(aPTT), Thrombinzeit (TT), Fibrinogen, Faktor VIII (FVIII), antithrombin (AT), 
Protein C (PC), Protein S (PS), Resistenz gegen aktiviertes Protein C (APC-ratio), 
Plasminogen, D-dimer und anti-FXa, die am STA Compact gemessen wurden. Die 
Wiederholbarkeit für die TEG-Parameter wurde mit Doppelmessungen bei 6 
Hunden durchgeführt. Die Standardabweichung, die für die Berechnung des CV 
erforderlich war, war mit der Wurzel der gepoolten Varianz übereinstimmend. Der 
Vergleich von TEG Ergebnissen mit nativem und Zitrat antikoaguliertem Vollblut 
wurde bei 16 gesunden Hunden durchgeführt. Für die Beurteilung der Hämolyse auf 
TEG Ergebnisse wurden 17 gesunde Hunde eingeschlossen. Hämolytische Proben 
wurden mit zwei Verfahren hergestellt: mechanischer Stress (HM) und sowie 
Einfrieren und Auftauen (HF). 
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Die intra-assay Wiederholbarkeit für die am STA Compact gemessenen Parameter 
wurde bei einer von einem gesunden Hund entnommenen Probe mit 15 
Wiederholungsmessungen durchgeführt. Um den Einfluss von Lipämie auf die 
Resultate der Messungen beim STA Compact zu bestimmen, wurden drei 
verschiedene Grade von Lipämie vorbereitet, indem Liquigen® (Liquigen®, 
Pfrimmer Nutricia GmbH, Erlangen, Germany) in die Proben gemischt wurde. Die 
Auswirkungen von 3 verschiedenen Stufen von Hämolyse auf die 
Gerinnungsparameter wurde durch Gefrieren/Auftauen von Vollblut untersucht.  
Die Referenzwertbestimmung für die TEG Parameter und die am STA Compact 
gemessenen Gerinnungsparameter wurde mit 56 gesunden Hunden durchgeführt. 
Die ersten Untersuchungen zeigten, dass einige humane Gerinnungstests für die 
Anwendung für Hundeblutproben modifiziert werden mussten. So war für PC, PS 
und FVIII die Etablierung einer Standardkurve mit Hundepoolplasma notwendig. 
Weiterhin wurde das Vorhandensein möglicher geschlechtsabhängiger Unterschiede 
der Referenzwerte untersucht..  
Die Auswirkung der Endotoxämie auf pimäre, sekundäre und tertiäre Hämostase 
sowie TEG Werte wurden bei 10 gesunden Mischlingshunden ausgewertet. Eine 
Kontrollgruppe (n=5 Hunde) und eine Behandlungsgruppe (n=5 Hunde) wurde 
untersucht. Die Hunde in der Behandlungsgruppe erhielten in 0,9% sterile 
Kochsalzlösung gelöstes Endotoxin (LPS) intravenös in einer Dosis von 0,02 mg/kg 
injiziert. Die Kontrollgruppe erhielt eine intravenöse Injektion von 0,2 ml/kg 0,9% 
steriler Kochsalzlösung. Venöse Blutproben wurden vor der LPS- oder Placebo-
Applikation (0 Stunde), sowie 1., 4. und 24. Stunden nach der Behandlung 
entnommen. 
Statistik 
Die Ergebnisse wurden mit dem Graphpad Prism (Graph Pad Software, San Diego, 
USA), Analyse-it Methoden Bewertung (Analyse-it Method validation Edition 
version 2.12 - © 1997-2008, Analyse-it Software Ltd.) und BMDP Statistik Software 
93 
(BMDP Statitical software Inc., 1440 sepulveda Blvd, Los Angeles, CA 90025 USA) 
analysiert. 
Die Intra-Assay-Varianz (Variationskoeffizient, CV) wurde für die am STA Compact 
gemessenen Parameter mittels Berechnung des arithmetrischen Mittelwertes und der 
Standardabweichung bestimmt. Für die TEG Parameter erfolgte die Berechnung 
durch eine Schätzung der gepoolten Varianz basierend auf den Unterschieden von 
Doppelbestimmungen. Die Wirkung von Antikoagulanz und Interferenzen auf die 
Messergebnisse wurde mit Hilfe eines gepaarten T-tests (oder Wilcoxin signed rank 
sum Tests) beurteilt.  
Für die Bestimmung der Referenzwerte und der Überprüfung der Normalverteilung 
wurde ein Anderson Darling Test durchgeführt. Beim Vorliegen einer 
Normalverteilung oder logarithmischer Normalverteilung der Daten, wurden 
doppelseitig Referenzbereiche durch Berechnung der mittleren ±0,96 SD 
(Standardabweichung) berechnet, so dass 95% der Referenzpopulation einbezogen 
wurde. Lagen nicht-normal verteilte Daten vor, wurde die nicht-parametrische 
Perzentil-Methode angewendet; hier erfolgte eine Berechnung der 2,5 und 97,5 
Perzentile, um das 95% doppelseitige Referenz-Intervall zu erhalten. Die Daten 
wurden als Histogramme mit dem Referenz-Intervall und den 90%-
Konfidenzintervalle der oberen und unteren Referenzgrenzen dargestellt. Der 
Einfluss des Geschlechts auf die Referenzintervalle wurde mittels eines ungepaarten 
t-Test oder einem vergleichbaren nicht-parametrischen Test (Mann-Whitney-U-Test) 
beurteilt. 
Im zweiten Teil der Studie wurden die Unterschiede zwischen der Kontrollgruppe 
und der mit Endotoxin behandelten Gruppe mittels einer zweifaktoriellen Analyse 
von Varianz und Kovarianz und Messwiederholung  untersucht. 
Ergebnisse 
Für die TEG Parameter R; K; α; MA und G konnten die folgenden 
Variationskoeffizienten von7.6%; 17.7%; 7.4%; 2.9% und 6.6% festgestellt werden. 
Proben mit Hämolyse führten zu einem signifikant erniedrigten R, MA, G und α 
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Wert (P<0.001 bis P>0.0001). Darüber hinaus konnte ein signifikant höherer K Wert 
im Vergleich zur Kontrollgruppe festgestellt werden (P<0.01). Es war  kein 
signifikanter Einfluss  des Antikoagulanzes auf die TEG-Ergebnisse nachweisbar, 
jedoch war die interindividuelle Variationin nativen Proben höher als im Zitratblut. 
Die Intra-Assay CVs für die Gerinnungsparameter PT, aPTT, TT, Fibrinogen, FVIII, 
AT, PC, PS, APC-ratio, Plasminogen, D-dimer und Anti-FXa waren 1.22%, 1.02%, 
1.64%, 5.6%, 3.89%, 4.68%, 2.36%, 1.4%, 1.45%, 20.16%, 45.92% und 12.83%. Die FVIII-
Aktivität, Antithrombin, PC, PS und APC-ratio wurdenin hämolytischem Plasma 
falsch hoch gemessen, während Fibrinogen, TT und aPTT falsch niedrig waren. 
Lipämie führte lediglich zu falsch hohen D-dimer Werten. 
Folgende Referenzbereiche konnten für das Kaolin aktivierte TEG etabliert werden: 
R=1.8-8,6min.; α=36.9-74.6 Grad; K=1.3-5.7 min.; MA=42.9-67.9 mm und G=3.2-9.6 
Kdyn/cm2. Für die am STA Compact gemessenen Parameter wurden folgende 
Referenzbereicheerstellt: OSPT=5.7-8.0 sek.; aPTT=10.0-14.3 sek.; TT=11.9-18.3 sek.; 
Fibrinogen=1.3-3.1 g/l; AT=107.9-128.0 %; D-dimer=0.023-0.65 µg/ml; anti-FXa=0.04-
0.26 IU/l; APC-ratio=2.0-3.0; PC=74.4-160.5 %; PS=75.5-118.9 % und FVIII=70.9-136.4 
%. Die Ergebnisse für PC, PS und FVIII mussten dabei jeweils mit einer Hunde-
Standardkurve verglichen werden. Es gab keinen signifikanten Einfluss auf die 
Ergebnisse der beiden Analysatoren.   
Zweiter Teil der Studie: Die endotoxin-induzierten klinische Symptome umfassten 
Lethargie (n=5/5), Durchfall (n=5/4), Erbrechen (n=5/4) und Bauchschmerzen (n=2/5).   
Eine Stunde nach der Injektion von Endotoxin konnte eine hochgradige Leukopenie 
(Mittelwert 2.5±0.7×109/L; P<0.0001) und ein signifikanter 2.2-fach Anstieg der D-
dimere (P=0.001) beobachtet werden. Zum Zeitpunkt 4. Stunden war eine deutliche 
Erhöhung der Körpertemperatur (P=0.0006) und der PT (P=0.0042) sowie ein 
signifikanter Abfall der Fibrinogen Plasmakonzentration (P=0.0007), des PC 
(P=0.0021) und des PS (P=0.008)nachweisbar . PLTs (P=o.0284) und AT (P=0.0170) 
waren am niedrigsten zum Zeitpunkt 24 Stunden. Die TEG Parameter unterschieden 
sich nicht signifikant zwischen den Gruppen. Die APC-ratio war höher in der 
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Endotoxin-Gruppe (P=o.0348), blieb jedoch innerhalb des Referenz-Intervalls bei 4/5 
Hunden.  
Schlussfolgerung 
Insgesamt konnten nützliche Referenzwerte für das kaolin-aktivierte TEG und das 
automatische Gerinnungsanalysegerät STA Compactetabliert werden, jedoch 
mussten einigehumane Testmethoden (Protein C, Protein S und Factor VIII) zuvor 
für den Hund modifiziert werden.  
Die Untersuchung des Einflusses von Endotoxämie auf die Gerinnung zeigte, dass 
erhöhte D-Dimere der früheste Indikator für Endotoxämie sind, denen später eine 
Verlängerung der PT und ein Absinken von Protein C folgt. Die APC-ratio und TEG 
Parameter waren in der aktuellen Studie keine gute Indikatoren für das Erkennen 
einer frühen Sepsis/Endotoxämie.  
96 
9. Reference List 
 
(1) Dahlback B.: 2008, Advances in understanding pathogenic mechanisms of 
thrombophilic disorders. Blood 112:19-27.  
(2) Schaer BD, Hackner SG. Thrombotic disorders. In: Weiss DJ, Wardrop KJ. Eds. 
Schalm’s Veterinary Hematology. 6thedn. Iowa: Blackwell Publishing, 2010, pp. 668-
678. 
(3) Franz RC, Coetzee WJ.: The thromboelastographic diagnosis of hemostatic 
defects. Surg Annu 1981;13:75-107. 
(4) Donahue SM, Otto CM.: Thromboelastography: a tool for measuring 
hypercoagulability, hypercoagulability, and fibrinolysis. J of Vet Emergency and Crit 
Care. 2005;15(1):9-16. 
(5) Brainard BM, Meredith CP, Callan MB, et al.: Changes in platelet function, 
hemostasis, and prostaglandin expression after treatment with nonsteroidal anti-
inflammatory drugs with various cyclooxygenase selectivities in dogs. Am J Vet Res 
2007;68(3):251-257. 
(6) Wiinberg B, Jensen AL, Johansson PI, Rozanski E, Tranholm M, Kristensen AT: 
Thromboelastographic evaluation of hemostatic function in dogs with disseminated 
intravascular coagulation. J Vet Intern Med. 2008;22(2):357-365. 
(7) Otto CM, Rieser TM, Brooks MB, et al. Evidence of hypercoagulability in dogs 
with parvoviral enteritis. J Am Vet Med Assoc 2000; 217(10):1500-1504. 
(8) Toulza O, Center SA, Brooks MB, et al. Evaluation of plasma protein C activity 
for detection of hepatobiliary disease and portosystemic shunting in dogs. J Am Vet 
Med Assoc 2006; 229: 1761-1771. 
(9) Kristensen AT, Wiinberg B, Jessen LR, et al.: Evaluation of human 
recombinant tissue factor-activated thromboelastography in 49 dogs with neoplasia. J 
Vet Int Med 2008;22:140-147. 
97 
(10) Smith AS. Overview of hemostasis, In: Weiss DJ, Wardrop KJ. Eds. Schalm’s 
Veterinary Hematology. 6thedn. Iowa: Blackwell Publishing, 2010, pp. 635-653. 
(11) Smith S.A.: The cell-based model of coagulation. J Vet Emerg Crit Care. 
2009;19(1):3-10. 
(12) Stokol T., Cornell University, College of Veterinary Medicine. Hemostasis: 
Introduction, Tests of hemostasis, Disorders of hemostasis, Transfusion medicine. 
http://ahdc.vet.cornell.edu/clinpath/modules/coags/coag.htm 
(13) Furie B, Furie BC. Molecular basis of blood coagulation, In: Hoffman R. Ed. 
Hematology: Basic Principles and Practice. New York: Churchill-Livingstone; 2000, 
pp. 1783-1803. 
(14) Brooks J. Coagulopathiesand thrombosis, In: Ettinger SJ, Felman EC. Eds. 
Textbook of Veterinary Internal Medicine, 5th edn. Philadelphia: WB Saunders, 2000, 
pp. 1829-1841. 
 (15) Colman W. Contact activation (kallikrein - kinin) pathway: multiple 
physiologicand pathophysiologic activities. In: Hemostasis and Thrombosis:Basic 
Principles and Clinical Practice. Philadelphia: Lippincott Williams and Wilkins, 2006; 
107–130. 
(16) Brown N.J., Gainer J.V., Stein C.M., Vaughan D.E.: Bradykinin stimulates 
tissue plasminogen activator release in human vasculature. Hypertension. 
1999;33:1431-1435. 
(17) Gailani D, Renne T. The intrinsic pathway of coagulation: a target for treating 
thromboembolic disease? J Thromb Haemost 2007; 5: 1106–1112. 
(18) Muller F, Renne T. Novel roles for factor XII - driven plasma contact 
activationsystem. Curr Opin Hematol 2008; 15: 516–521. 
(19) Roberts HR, Hoffman M, Monroe DM.: A cell-based model of thrombin 
generation. Seminars in Thromb Hemostasis. 2006; 32:32-38. 
(20) Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb 
Haemostasis 2003; 1: 1504–1514. 
98 
(21) Wolberg A.S.: Thrombin generation and fibrin clot structure. Blood Reviews. 
2007;21:131-142. 
(22) Crawley JT, Zanardelli, Chion CK, et al. The central role of thrombin in 
hemostasis. J Thromb Haemost 2007; 5: 95–101. 
(23) Wiman B., Collen D.: Molecular mechanism of physiological fibrinolysis. 
Nature. 1978;272:549-550. 
(24) Stockham SL, Scott MA. Hemostasis. In: Fundamentals of Veterinary Clinical 
Pathology, 2nd ed. Ames: Blackwell, 2008; 223–257. 
(25) De Laforcade A, Freeman LM, Shaw SP, et al. Hemostatic changes in dogs 
with naturally occuring sepsis. J Vet Intern Med 2003; 17(5):674-679. 
 (26) Bock SC. Antithrombin III and heparin cofactor II. In: Hemostasis and 
Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott Williams 
and Wilkins, 2006; 235–248. 
(27) Tollefsen DM, Zhang L. Heparin and vascular proteoglycans. In: Hemostasis 
and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott 
Williams and Wilkins, 2006; 271–283. 
(28) Bajaj MS, Birktoft JJ, Steer SA, et al. Structure and biology of tissue factor 
pathway inhibitor. Thromb Haemostasis 2001; 86:959–972. 
(29) Mast AE, Broze GJ. Physiological concentrations of tissue factor pathway 
inhibitor do not inhibit prothrombinase. Blood 1996; 87:1845–1850. 
(30) Rosing J, Maurissen LF, Tchaikovski SN, et al. Protein S is a cofactor for tissue 
factor pathway inhibitor. Thromb Res 2008; 122: 60–63. 
(31) Esmon CT. Protein C, protein S, and thrombomodulin. In: Hemostasis and 
Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott Williams 
and Wilkins, 2006; 249–270. 
(32) Oliver JA, Monroe DM, Church FC, et al. Activated protein C cleaves factor Va 
more efficiently on endothelium than on platelet surfaces. Blood 2002; 100:539–546. 
(33) Brooks MB, Catalfamo JL. Von Willebrand disease, In: Weiss DJ, Wardrop KJ. 
99 
Eds. Schalm’s Veterinary Hematology. 6th edn. Iowa: Blackwell Publishing, 2010, pp. 
612-618. 
(34) Sadler JE. New concepts in von Willebrand disease. Annu Rev Med 2005; 56: 
173–91. 
(35) Johnson GS, Turrentine MA, Kraus KH. Canine von Willebrand ’s disease: a 
heterogeneous group of bleeding disorders. Vet Clin N Am 1988; 18: 195–229. 
(36) Favaloro EJ. Laboratory identifi cation of von Willebrand disease: technical 
and scientific perspectives. Semin Thromb Hemost 2006; 32: 456–471. 
(37) James PD, Notley C, Hegadorn C, et al. The mutational spectrum of type 1 von 
Willebrand disease: results from a Canadian cohort study. Blood 2006; 109: 145–154. 
(38) Rodeghiero F, Castaman G, Tosetto A, et al. The discriminant power of 
bleeding history for the diagnosis of type 1 von Willebrand disease: an international 
multicenter study. J Thromb Haemost 2005; 3: 2619–2626. 
(39) Sabino BP, Erb HN, Catalfamo JL. Development of a collagen binding activity 
assay as a screening test for type II von Willebrand disease in dogs. Am J Vet Res 
2005; 67: 242–249. 
(40) Brooks M, Dodds WJ, Raymond SL. Epidemiologic features of von 
Willebrand’s disease in Doberman pinschers, Scottish terriers, and Shetland 
sheepdogs. J Am Vet Med Assoc 1992; 200: 1123–1127. 
(41) Brooks M, Raymond S, Catalfamo J. Severe recessive von Willebrand’s disease 
in German wirehaired pointers. J Am Vet Med Assoc 1996; 209: 926–929. 
(42) Brooks MB, Erb HN, Foureman P, et al. Von Willebrand disease phenotype 
and marker genotype in Doberman pinscher dogs. Am J Vet Res 2001; 62: 364–369. 
(43) Kramer JW, Venta PJ, Klein SR, et al. A von Willebrand’s factor genomic 
nucleotide variant and polymerase chain reaction diagnostic test associated with 
inheritable type-2 von Willebrand’s disease in a line of german shorthaired pointer 
dogs. Vet Pathol 2004; 41: 221–228. 
100 
(44) Rieger M, Schwarz HP, Turecek PL, et al. Identification of mutations in the 
canine von Willebrand factor gene associated with type III von Willebrand disease. 
Thromb Haemost 1998; 80: 332–337. 
(45) Venta PJ, Li J, Yuzbasiyan-Gurkan V, et al. Mutation causing von Willebrand’s 
disease in Scottish terriers. J Vet Intern Med 2000; 14: 10–19. 
(46) Rathgeber RA, Brooks M, Bain FT, et al. Von Willebrand disease in a 
thoroughbred broodmare and foal. J Vet Intern Med 2001; 15: 63–66. 
(47) Patterson MM, Jackson LR, Brooks MB, et al. Type 3 von Willebrands disease 
in a Rhesus monkey. Comp Med 2002; 52: 368–371. 
(48) French TW, Fox LE, Randolph JR, et al. A bleeding disorder (von Willebrand ’s 
disease) in a Himalayan cat. J Am Vet Med Assoc 1987; 190: 437–439. 
(49) Sullivan PS, Grubbs ST, Olchowy TW, et al. Bleeding diathesis associated with 
variant von Willebrand factor in a Simmental calf. J Am Vet Med Assoc 1994; 205: 
1763–1766. 
(50) Fuster V, Griggs TR. Porcine von Willebrand disease: implications for the 
pathophysiology of atherosclerosis and thrombosis. Prog Hemost Thromb 1986; 8: 
159–183. 
(51) Lemmerhirt HL, Broman KW, Shavit JA, et al. Genetic regulation of plasma 
von Willebrand factor levels: quantitative trait loci analysis in a mouse model. J 
Thromb Haemost 2007; 5: 329–335. 
(52) Cheville NF. The grey collie syndrome. J Am Vet Med Assoc 1968; 152(6): 620-
630. 
(53) Thomas JS. Non-immune mediated thrombocytopenia In: Weiss DJ, Wardrop 
KJ. Eds. Schalm’s Veterinary Hematology. 6th edn. Iowa: Blackwell Publishing, 2010, 
pp. 596-604. 
(54) Boudreaux MK. Inherited intrinsic platelet disorders In: Weiss DJ, Wardrop 
KJ. Eds. Schalm’s Veterinary Hematology. 6th edn. Iowa: Blackwell Publishing, 2010, 
pp. 619-625. 
101 
 (55) Santoro SK, Garrett LD, Wilkerson M. Platelet concentrations and platelet 
associated IgG in greyhounds. J Vet Intern Med 2007; 21: 107-112. 
(56) Brooks MB, Catalfamo JL, Friese P, et al. Scott syndrome dogs have impaired 
coated - platelet formation and calcein - release but normal mitochondrial 
depolarization. J Thromb Haemost 2007; 5: 1972–1974. 
(57) Ayers JR, Leipold HW, Padgett GA. Lesions in Brangus cattle with Chediak - 
Higashi syndrome. Vet Pathol 1988; 25: 432–436. 
(58) Benson KF, Li FQ, Person RE, et al. Mutations associated with neutropenia in 
dogs and humans disrupt intracellular transport of neutrophil elastase. Nat Genet 
2003; 35: 90 – 96. 
(59) Honda N, Ohnishi K, Fujishiro I, et al. Alteration of release and role of 
adenosine diphosphate and thromboxane A2 during collagen – induced aggregation 
of platelets from cattle with Chediak - Higashi syndrome. Am J Vet Res 2007; 88: 
1399–1406. 
(60) Brooks MB, Catalfamo JL, Brown HA, et al. A hereditary bleeding disorder of 
dogs caused by a lack of platelet procoagulant activity. Blood 2002; 99: 2434–2441. 
(61) Brooks MB. Hereditary coagulopathies In: Weiss DJ, Wardrop KJ. Eds. 
Schalm’s Veterinary Hematology. 6th edt. Iowa: Blackwell Publishing, 2010, pp. 661-
667. 
(62) Furie B, Furie BC. Molecular basis of hemophilia. Semin Hematol 1990;27: 270–
285. 
(63) Brooks M. A review of canine inherited bleeding disorders. J Hered 1997; 90: 
112–118. 
(64) Dodds WJ. Hemostasis. In: Kaneko JJ, ed. Clinical Biochemistry of Domestic 
Animals, 4th ed. San Diego: Academic Press, 1989; 274–315. 
(65) Wilkerson MJ, Johnson GS, Stockham S, et al. Afibrinogenemia and a 
circulating antibody against fibrinogen in a Bichon Frise dog. Vet Clin Pathol 2005; 
34: 148–155. 
102 
(66) Callan MB, Aljamali MN, Margaritis P, et al. A novel missense mutation 
responsible for factor VII deficiency in research Beagle colonies. J Thromb 
Haemostasis 2006; 4: 2616–2222. 
(67) Kaae JA, Callan MB, Brooks MB. Hereditary factor VII deficiency in the 
Alaskan Klee Kai dog. J Vet Intern Med 2007; 21: 976–981. 
(68) Cook AK, Werner LL, O ’ Neill SL, et al. Factor X deficiency in a Jack Russell 
Terrier. Vet Clin Pathol 1993; 22: 68–71. 
(69) Gookin JL, Brooks MB, Catalfamo JL, et al. Factor X deficiency in a cat. J Vet 
Intern Med 1997; 211: 576–579. 
(70) Knowler C, Giger U, Dodds WJ, et al. Factor XI deficiency in Kerry Blue 
Terriers. J Am Vet Med Assoc 1994; 205: 1557–1561. 
(71) Marron BM, Robinson JL, Gentry PA, et al. Identification of a mutation 
associated with factor XI deficiency in Holstein cattle. Anim Genet 2004; 35: 454–456. 
(72) Troxel MT, Brooks MB, Esterline ML. Congenital Factor XI deficiency in a 
domestic shorthair cat. J Am Anim Hosp Assoc 2002; 38: 549–553. 
(73) Geor RJ, Jackson ML, Lewis KD, et al. Prekallikrein deficiency in a family of 
Belgian horses. J Vet Intern Med 1990; 197: 741–745. 
(74) Kier AB, Bresnahan JF, White FJ, et al. The inheritance pattern of factor XII 
(Hageman) deficiency in domestic cats. Can J Comp Med 1980; 44: 309–314. 
(75) Turrentine MA, Sculley PW, Green EM, et al. Prekallikrein deficiency in a 
family of miniature horses. Am J Vet Res 1986; 47: 2464–2467. 
(76) Brooks MB, de Wilde LA. Feline factor XII deficiency. Compendium 2006; 28: 
148–156. 
(77) Johnson JS, Soute BA, Olver CS, et al. Defective gamma glutamyl carboxylase 
activity and bleeding in Rambouillet sheep. Vet Pathol 2006; 43: 726–762. 
(78) Mason DJ, Abrams - Ogg A, Allen D, et al. Vitamin K - dependent 
coagulopathy in a black Labrador Retriever. J Vet Intern Med 2002; 16: 485–488. 
103 
(79) Soute BA, Ulrich MM, Watson AD, et al. Congenital deficiency of all vitamin 
K-dependent blood coagulation factors due to a defective vitamin K-dependent 
carboxylase in Devon Rex cats. Thromb Haemostasis 1992; 68:521–525. 
(80) Brooks MB, De Laforcade A. Acquired Coagulopathies In: Weiss DJ, Wardrop 
KJ. Eds. Schalm’s Veterinary Hematology. 6th edn. Iowa: Blackwell Publishing, 2010, 
pp. 654-660. 
(81) Abrams K, Yunusov MY, Slichter S, et al. Recombinant human macrophage 
colony-stimulating factor-induced thrombocytopenia in dogs. Br J Haematol 2003; 
121: 614–622. 
(82) Weiss DJ. Hemophagocytic syndrome in dogs: 24 cases (1996 – 2005). J Am Vet 
Med Assoc 2007; 230: 697–701. 
(83) Schouten M, Wiersinga WJ, Levi M, et al. Inflammation, endothelium, and 
coagulation in sepsis. J Leuk Biol 2008; 83: 536–545. 
(84) Brietschwerdt EB. Infectious thrombocytopenia in dogs. Comp Cont Educ 
Pract Vet 1988; 10: 1177–1190. 
(85) Foley J, Drazenovich N, Leutenegger CM, et al. Association between 
polyarthritis and thrombocytopenia and increased prevalence of vectorborne 
pathogens in Californian dogs. Vet Rec 2007; 160: 159–162. 
(86) Russell KE, Grindem CB. Secondary thrombocytopenias. In: Feldman BF, 
Zinkl JG, Jain NC, eds. Schalm ’ s Veterinary Hematology, 5th ed. Baltimore: 
Lippincott Williams & Wilkins, 2000; 487–495. 
(87) Waner T, Leykin I, Shinitsky M, et al. Detection of platelet-bound antibodies in 
beagle dogs after artificial infection with Ehrlichia canis. Vet Immunol 
Immunopathol 2000; 23: 145–150. 
(88) Stokol T. Essential thrombocythemia and reactive thrombocytosis In: Weiss 
DJ, Wardrop KJ. Eds. Schalm’s Veterinary Hematology. 6th edn. Iowa: Blackwell 
Publishing, 2010, pp. 605-611. 
104 
(89)  Fry MM. Acquired platelet dysfunction In: Weiss DJ, Wardrop KJ. Eds. 
Schalm’s Veterinary Hematology. 6th edn. Iowa: Blackwell Publishing, 2010, pp. 626-
631.  
(90) Hogan D.F., Brooks M.B.Treatment of hemostatic disorders, In: Weiss DJ, 
Wardrop KJ. Eds. Schalm’s Veterinary Hematology. 6thedn. Iowa: Blackwell 
Publishing, 2010, pp. 695-207. 
(91) Mellett A.M., Nakamura R.K., Bianco D.: A prospective study of clopidogrel 
therapy in dogs with primary immune-mediated hemolytic anemia. J Vet Intern 
Med. 2011;25:71-75. 
(92) Caldwell SH, Hoffman M, Lisman T, et al. Coagulation disorders and 
hemostasis in liver disease: pathophysiology and critical assessment of current 
management. Hepatology 2006; 44: 1039–1046. 
(93) Tripodi A, Manucci PM. Abnormalities of hemostasis in chronic liver disease: 
reappraisal of their significance and need for clinical and laboratory research. J 
Hepatol 2007; 46: 727–733. 
(94) Center SA, Warner K, Corbett J, et al. Proteins invoked by vitamin K absence 
and clotting times in clinically ill cats. J Vet Intern Med 2000; 14: 292–297. 
(95) Lisciandro SC, Hohenhaus A, Brooks M. Coagulation abnormalities in 22 cats 
with naturally occurring liver disease. J Vet Intern Med 1998; 12: 71–75. 
(96) Toulza O, Center SA, Brooks MB et al. Evaluation of protein C activity for 
detection of hepatobiliary disease and portosystemic shunting in dogs. J Am Vet Med 
Assoc 2005; 229: 1761–1771. 
(97) Stokol T. Disseminated intravascular coagulation In: Weiss DJ, Wardrop KJ. 
Eds. Schalm’s Veterinary Hematology. 6th edn. Iowa: Blackwell Publishing, 2010, pp. 
679-688. 
(98) Palmer KG, King LG, Van Winkle TJ. Clinical manifestations and associated 
disease syndromes in dogs with cranial vena cava thrombosis: 17 cases (1989-1996). J 
Am Vet Med Assoc 1998; 213(2):220-224. 
105 
(99) Whalen J, Tuman K. Monitoring hemostasis. Int Anesthesiol Clin 1996; 
34(3):195-213. 
(100) Rasedee a, Feldman BF, Washabau R. Naturally uccuring canine nephrotic 
syndrome is a potentially hypercoagulable state. Acta Vet Scand 1986; 27:369-377. 
(101) Bick RL, Kaplan H. Syndromes of thrombosis and hypercoagulabiliğty: 
congenital and aquired causes of thrombosis. Med Clin North Am 1998; 82(3):409-
458. 
(102) Green RA, Thomas JS. Hemostatic disorders: coagulopathies and thrombosis, 
In: Ettinger SJ, Feldman EC. eds. Textbook of Veterinary Internal Medicine, 4th edn. 
Philadelphia: WB Saunders; 1995, pp. 1946-1963. 
(103) Estrin MA, Wehausen CE, Jessen CR, Lee JA. Disseminated intravascular 
coagulation in cats. J Vet Intern Med 2006; 20: 1334–1339. 
(104) Scott-Moncrieff JC, Treadwell NG, McCullough SM, Brooks MB. Hemostatic 
abnormalities in dogs with primary immune-mediated hemolyticanemia. J Am Anim 
Hosp Assoc 2001; 37: 220–227. 
(105) Stokol T, Brooks M, Erb H, Mauldin GE. Evaluation of kits for the detection of 
fibrin(ogen) degradation products in dogs. J Vet Intern Med 1999; 13: 478–484. 
(106) Stokol T, Brooks MB, Erb HN, Mauldin GE. D - dimer concentrations in 
healthy dogs and dogs with disseminated intravascular coagulation. Am J Vet Res 
2000; 61: 393–398. 
(107) Thomas JS, Green RA. Clotting times and antithrombin III activity in cats with 
naturally developing diseases: 85 cases (1984 – 1994). J Am Vet Med Assoc 1998; 213: 
1290–1295. 
(108) Armengou L, Monreal L, Tarancon I, et al. Plasma D-dimer concentration in 
sick newborn foals. J Vet Intern Med 2008; 22: 411–417. 
(109) Dolente BA, Wilkins PA, Boston RC. Clinicopathologic evidence of 
disseminated intravascular coagulation in horses with acute colitis. J Am Vet Med 
Assoc 2002; 220: 1034–1038. 
106 
(110) Stokol T, Erb HN, De Wilde L, et al. Evaluation of latex agglutination kits for 
detection of fibrin(ogen) degradation products and D-dimer in healthy horses and 
horses with severe colic. Vet Clin Pathol 2005; 34: 375–382. 
(111) Levi M, van der Poll T. Two-way interactions between inflammation and 
coagulation. Trends Cardiovasc Med 2005; 15: 254–259. 
(112) Taylor FB Jr., Toh CH, Hoots WK, et al. Towards defi nition, clinical 
andlaboratory criteria, and a scoring system for disseminated intravascular 
coagulation . Thromb Haemostasis 2001; 86: 1327–1330. 
(113) Franchini M, Lippi G, Manzato F. Recent acquisitions in the pathophysiology, 
diagnosis and treatment of disseminated intravascular coagulation. Thromb J 2006; 4: 
4. 
(114) Hopper K, Bateman SW. An updated view of hemostasis: mechanisms of 
hemostatic dysfunction associated with sepsis. J Vet Emerg Crit Care 2005; 15: 83–91. 
(115) Gando S, Kameue T, Morimoto Y, et al. Tissue factor production not balanced 
by tissue factor pathway inhibitor in sepsis promotes poor prognosis. Crit Care Med 
2002; 30: 1729–1734. 
(116) Rapaport SI, Rao LV. Initiation and regulation of tissue factor–dependent 
blood coagulation. Arterioscler Thromb 1992; 12: 1111–1121. 
(117) Taylor FB Jr., Wada H, Kinasewitz G. Description of compensated and 
uncompensated disseminated intravascular coagulation (DIC) responses (non-overt 
and overt DIC) in baboon models of intravenous and intraperitoneal Escherichia coli 
sepsis and in the human model of endotoxemia: toward a better definition of DIC. 
Crit Care Med 2000; 28: S12–19. 
(118) Toh CH, Downey C. Back to the future: testing in disseminated intravascular 
coagulation. Blood Coag Fibrinol 2005; 16: 535–542. 
(119) Borensztajn K, Stiekema J, Nijmeijer S, et al. Factor Xa stimulates 
proinflammatory and profibrotic responses in fibroblasts via protease–activated 
receptor-2 activation. Am J Pathol 2008; 172: 309–320. 
107 
(120) Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 
2000; 407: 258–264. 
(121) Madden RM, Ward M, Marlar RA. Protein C activity levels in endotoxin-
induced disseminated intravascular coagulation in a dog model. Thromb Res 1989; 
55: 297–307. 
(122) Roemisch J, Gray E, Hoffmann JN, Wiedermann CJ. Antithrombin: a new look 
at the actions of a serine protease inhibitor. Blood Coag Fibrinol 2002; 13: 657–670. 
(123) Weiss DJ, Rashid J. The sepsis-coagulant axis: a review. J Vet Int Med 1998; 12: 
317-324. 
(124) Declue AE, Williams KJ, Sharp C, et al. Systemic response to low-dose 
endotoxin infusion in cats. Vet Immunol Immunopathol. 2009; 132: 167-74. 
(125) Shojania A.M., Turnbull G.: Effect of heparin on platelet count and platelet 
aggregation. Am J of Hematology. 1987;26(3):255-262. 
(126) Moritz A. Der Einsatz lasergestützter Hämatologiesysteme in der 
Veterinärmedizin ”the diagnostic use of laser-based hematology systems in 
veterinary medicine”. Habilitation Giessen, Germany; 2000. 
(127) Tarnow I., Kristensen A.T. Evaluation of platelet function, In: Weiss DJ, 
Wardrop KJ. Eds. Schalm’s Veterinary Hematology. 6thedn. Iowa: Blackwell 
Publishing, 2010, pp. 695-207. 
(128) Simon C. Vollblutaggregation beim Hund: Vergleich der Methode nach Born 
mit einer erreichten Aggregation nach Thrombozytenzählung mittels konventioneller 
Hämatologiesysteme. Dissertation Giessen, Germany;2009. 
(129) Ahnadi CE, Sabrinah CE, Lepine M, et al. Assessment of platelet activation in 
severaldifferent anticoagulants by the Advia 120 Hematology System, fluorescence 
flowcytometry, and electron microscopy. Thromb Haemost. 2003;90:940-8. 
(130) Boos CJ, Beevers GD, Lip GY. Assessment of platelet activation indices using 
the ADVIATM 120 amongst 'high-risk' patients with hypertension. Ann Med. 2007; 
39: 72-8. 
108 
(131) Giacomini A, Legovini P, Antico F, et al. Assessment of in vitro platelet 
activation by 24 Advia 120 platelet parameters. Lab Hematol. 2003; 9: 132-7. 
(132) Lubas G, Caldin M, Wiinberg BO, Kristensen AT. Laboratory testing of 
coagulation disorders In: Weiss DJ, Wardrop KJ. Eds. Schalm’s Veterinary 
Hematology. 6th edn. Iowa: Blackwell Publishing, 2010, pp. 1082-1100. 
(133) National Committee for Clinical Laboratory Standards. One–stage 
prothrombin time (PT) test and activated partial thromboplastin time (APTT) test. 
NCCLS document-Wayne A, PA: NCCLS, 1996. 
(134) Van Cott EM, Laposata M. Coagulation. In: Jacobs DS, Oxley DK, DeMott WR, 
eds. The Laboratory Test Handbook, 5th ed. Cleveland: Lexi-Comp. 2001; 327–358. 
(135) Miletich JP. Activated partial thromboplastin time. In: Beutler E, Lichtman 
MA, Coller BS, Kipps TJ, eds. Williams Hematology, 5th ed. New York: McGraw-
Hill, 1995; L85–L86. 
(136) Miletich JP. Prothrombin time. Ch. L33. In: Beutler E, Lichtman MA, Coller BS, 
Kipps TJ, eds. Williams Hematolog , 5th ed. New York: McGraw-Hill, 1995; L82–L84. 
(137) Dawson NA, Barr CF, Alving BM. Acquired dysfibrinogenemia: 
paraneoplastic syndrome in renal cell carcinoma. Am J Med 1985; 78: 682–686. 
(138) Galanakis DK. Plasma thrombin time and related tests. In: Beutler E, Lichtman 
MA, Coller BS, Kipps TJ, eds. Williams Hematology, 5th ed. New York: McGraw 
Hill, 1995; L91–93. 
(139) Mischke R, Wolling H. Influence of fibrinogen degradation products on 
thrombin time, activated partial thromboplastin time and prothrombintime of canine 
plasma. Haemostasis 2000; 30: 123–130. 
(140) Moreno P, Ginel PJ. Effects of haemolysis, lipaemia and bilirubinaemia on 
prothrombin time, activated partial thromboplastin time and thrombin time in 
plasma samples from healthy dogs. Res Vet Sci 1999; 67: 273–276. 
(141) Bovill EG, Tracy RP. Methods for the determination of the plasma 
concentration of fibrinogen. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ eds. 
Williams Hematology, 5th edt. New York: McGraw-Hill , 1995; L87–88. 
109 
(142) Gentry PA. Comparative aspects of blood coagulation. Vet J 2004; 168: 238–
251. 
(143) Clauss A. Gerinnungsphysiologische schnellmethode für die bestimmung des 
fibrinogens. Acta Haematol 1957; 17: 237–246. 
(144) Mischke R. Commercial variants of the prothrombin time test as a screening 
test of acquired coagulation factor II, VII, and X deficiencies in dogs. Res Vet Sci 2002; 
73: 165–170. 
(145) Mischke R, Menzel D, Wolling H. Comparison of different methods to 
measure fibrinogen concentration in canine plasma with respect to their sensitivity 
towards the fibrinogen degradation products X, Y, and D. Haemostasis 2000; 30: 131–
138. 
(146) National Committee for Clinical Laboratory Standards. Procedure for the 
Determination of Fibrinogen in Plasma. NCCLS document - A2. 2nd ed. Wayne, PA: 
NCCLS, 2001. 
(147) Peetz D. Factor VIII Methods: Which assay principle for which indication. 
Scharrer I, Schramm W. Eds. 36th hemophilia symposium. Hamburg 2005 © Springer 
Verlag Heidelberg 2007. 
(148) Bovill EG, Tracy RP. 1995a. Euglobulin clot lysis time. In: Beutler E, Lichtman 
MA, Coller BS, Kipps TJ, eds. Williams Hematology, 5th ed. New York: McGraw-
Hill, 1995; L102–103. 
(149) Tracy RP, Bovill EG. Plasminogen and alpha-2 antiplasmin. In: Beutler E, 
Lichtman MA, Coller BS, Kipps TJ, eds. Williams Hematology, 5th ed. New York: 
McGraw-Hill, L106–107. 
(150) Tracy RP, Bovill EG. Tissue-type plasminogen activator. In: Beutler E, 
Lichtman MA, Coller BS, Kipps TJ, eds. Williams Hematology, 5th ed. New York: 
McGraw-Hill, 1995; L108–109. 
(151) Tracy RP, Bovill EG. Plasminogen activator inhibitor-1. In: Beutler E, Lichtman 
MA, Coller BS, Kipps TJ, eds. Williams Hematology, 5th ed. New York: McGraw-
Hill, 1995; L110–111. 
110 
(152) Lanevschi A, Kramer JW, Greene SA, et al. Evaluation of chromogenic 
substrate assays for fibrinolytic analytes in dogs. Am J Vet Res 1996; 57: 1124–1130. 
(153) Lang IM, Marsh JJ, Konopka RG, et al. Factors contributing to increased 
vascular fibrinolytic activity in mongrel dogs. Circulation 1993; 87: 1990–2000. 
(154) Kolde HJ. Haemostasis: Physiology, Pathology, Diagnostics , 2nd ed. Basel , 
Switzerland: Pentapharm, 2004; 66–74, 78–135. 
(155) Caldin M, Furlanello T, Lubas G. Sensitivity and specificity of citrated plasma 
FDPs and D-dimer in the diagnosis of disseminated intravascular coagulation (DIC) 
in dogs. J Vet Int Med 1998; 12: 236(abstract). 
(156) Caldin M, Furlanello T, Lubas G. Validation of an immunoturbidimetric D-
dimer assay in canine citrated plasma. Vet Clin Pathol 2000; 29: 51–54. 
(157) Stokol T. Plasma D-dimer for the diagnosis of thromboembolic disorders in 
dogs. Vet Clin N Am Small Anim Pract 2003; 33: 1419–1435. 
(158) Brazzell JL, Borijesson DL. Evaluation of plasma antithrombin activity and D-
dimer concentration in populations of healthy cats, clinically ill cats and cats with 
cardiomyopathy. Vet Clin Pathol 2007; 36: 79–84. 
(159) Green RA. Pathophysiology of antithrombin III deficiency. Vet Clin N Am 
Small Anim Pract 1988; 18: 95–104. 
(160) Pusterla N, Braun U, Forrer R, et al. Antithrombin-III activity in plasma of 
healthy and sick cattle. Vet Rec 1997; 140: 17–18. 
(161) Raymond SL, Dodds WJ. Plasma antithrombin activity: a comparativestudy in 
normal and diseased animals. Proc Soc Exp Biol Med 1979; 161: 464–467. 
(162) Topper MJ, Prasse KW. Use of enzyme-linked immunosorbent assay to 
measure thrombin-antithrombin III complexes in horses with colic. Am J Vet Res 
1996; 57: 456–462. 
(163) Feldman BF, Madewell BR, O ’ Neill S. Disseminated intravascular 
coagulation: Antithrombin, plasminogen and coagulation abnormalities in 41 dogs. J 
Am Vet Med Assoc 1981; 179: 151–154. 
111 
(164) Van der Merwe L, Reyers F. The effect of hemolysis on plasma antithrombin 
activity as determined by a chromogenic method. Vet Clin Pathol 2007; 36: 55–59. 
(165) Fareed J, Messmore HL, Walenga JM, et al. Laboratory evaluation of 
antithrombin III: A critical review of currently available methods for antithrombin III 
measurement. Semin Thromb Haemostasis 1982; 8: 288–301. 
(166) Hultin MB. Antithrombin III assays. In: Beutler E, Lichtman MA, Coller BS, 
Kipps TJ, eds. Williams Hematology, 5th ed. New York: McGraw-Hill, 1995; L101–
102. 
(167) Esmon CT. The protein C pathway. Chest 2003; 124 (Suppl 3 ): 25S–32S. 
(168) Esmon CT. Structure and functions of the endothelial cell protein C receptor. 
Crit Care Med 2004; 32 (Suppl): S298–S301. 
(169) Weinstein RE, Walker FJ. Species specificity of the fibrinolytic effects of 
activated protein C. Thromb Res 1991; 63: 123–131. 
(170) Comp PC. Protein C and protein S. In: Beutler E, Lichtman MA, Coller BS, 
Kipps TJ, eds. Williams Hematology, 5th ed. New York: McGraw-Hill, 1995; L99–100. 
(171) Tripodi A, Mannucci PM. Laboratory investigation of thrombophilia. Clin 
Chem 2001; 47: 1597–1606. 
(172) Walker FJ, Fay PJ. Regulation of blood coagulation by the protein C 
system.1992; FASEB J 6:2561-2567. 
(173) Harris JM, Abramson N. Evaluation of recurrent thrombosis and 
hypercoagulability. Am Fam Physician 1997; 56:1591-1592. 
(174) Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a 
previously unrecognized mechanism characterized by poor anticoagulant response 
to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad 
Sci USA 1993; 90:1004-1008. 
(175) Svensson PJ, Zoller B, Dahlback B. Evaluation of original and modified APC- 
Resistance tests in unselected outpatients with clinically suspected thrombosis and in 
healthy controls. Thromb Haemost 1997; 77:332-335. 
112 
(176) Ornstein DL, Cushman M. Cardiology patient page. Factor V Leiden. 
Circulation 107:e94-e97; 2005. 
(177) Klein MK, Dow SW, Rosychuk RAW. Pulmonary thromboembolism 
associated with immune-mediated hemolytic anemia in dogs: ten cases (1982-1987). J 
Am Vet Med Assoc 1989; 195:246-250. 
(178) Bruhn HD, Schambeck CM, Hach-Wunderle V. Häufige 
Fehlerursachen[common sources of error]. In: Hämostaseologie für die Praxis 
[haemostaseology for the practice] Bruhn HD, Schambeck CM, Hach-WunderleV. 
eds. 2007;1st edt, 29. Schattauer, Stuttgart. 
(179) Anonymous: TEG® design and principles of operation. In: TEG® 5000 User´s 
Manual. 1 edt.2001; pp. 1-15. Haemoscope Cooperation, Niles IL USA. 
(180) Wiinberg B, Jensen AL, Rojkjaer R, et al.Validation of human recombinant 
tissue factor-activated thromboelastography on citrated whole blood from clinically 
healthy dogs. Vet Clin Pathol 2005; 34:389-393. 
(181) Kappert G.: 2002, Vergleichbarkeit der Methoden zur Bestimmung der 
aktivierten partiellen Thromboplastinzeit und der Resistenz gegen aktiviertes 
ProteinC [Comparability of methods for measurement of activated partial 
thromboplastin time and resistance against activated protein C]. Heinrich-Heine 
University, Duesseldorf. English abstract. 
(182) De Laforcade AM, Rozanski EA, Freeman LM, Li W.: 2008, Serial evaluation of 
protein C and antithrombin in dogs with sepsis. J Vet Intern Med 22:26-30. 
(183) Bauer N, Moritz A. Evaluation of three methods for measurement of 
hemoglobin andcalculated hemoglobin parameters with the ADVIA 2120 and 
ADVIA 120 in dogs,cats, and horses. Vet Clin Pathol. 2008;37:173-9. 
(184) Horn PS, Pesce AJ.: 2003, Reference intervals: an update. Clin Chim Acta 
334:5-23. 
(185) Rajwal S, Richards M, O'Meara M. The use of recalcified citrated whole blood -
a pragmatic approach for thromboelastography in children. Paediatr Anaesth 2004; 
14:656-660. 
113 
(186) Wiinberg B, Jensen AL, Kjelgaard-Hansen M, et al.: 2007, Study on biological 
variation of haemostatic parameters in clinically healthy dogs. Vet J 174:62-68. 
(187) Monreal L. D-dimer as a new test for the diagnosis of DIC and 
thromboembolic disease. J Vet Intern Med. 2003;17:757-9. 
(188) Bruhn HD, Schambeck CM, Hach-Wunderle V. Verarbeitung von 
Citratplasma [preparation of citrated plasma]. In: Hämostaseologie für die Praxis 
[haemosteology for the practice]. Bruhn HD, Schambeck CM, Hach-Wunderle V. eds. 
1st edt, 2007; pp. 28-29. Schattauer, Stuttgart. 
(189) Oger E, Leroyer C, Bressollette L, et al. Evaluation of a new, rapid, and 
quantitative D-Dimer test in patients with suspected pulmonary embolism. Am J 
Respir Crit Care Med 1998; 158:65-70. 
(190) Camenzind V, Bombeli T, Seifert B, et al. Citrate storage affects 
Thrombelastograph analysis. Anesthesiology 2000; 92:1242-1249. 
(191) Harris JM, Abramson N. Evaluation of recurrent thrombosis and 
hypercoagulability. Am Fam Physician 1997; 56:1591-1592. 
(192) Bowbrick VA, Mikhailidis DP, Stansby G. The use of citrated whole blood in 
thromboelastography. Anesth Analg 2000; 90:1086-1088. 
(193) Pivalizza EG, Pivalizza PJ, Gottschalk LI, et al. Celite-activated 
thrombelastography in children. J Clin Anesth 2001; 13:20-23. 
(194) Adcock D, Kressin D, Marlar RA. The effect of time and temperature variables 
on routine coagulation tests. Blood Coagul Fibrinolysis1998; 9:463-470. 
(195) Papp AC, Hatzakis H, Bracey A, Wu KK. ARIC hemostasis study--I. 
Development of a blood collection and processing system suitable for multicenter 
hemostatic studies. Thromb Haemost 1989; 61:15-19. 
(196) Stief TW. Influence of the surface on thrombin generation. Int J Lab Hematol 
2008; 30:269-277.  
(197) Lippi G, Montagnana M, Salvagno GL, Guidi GC. Interference of blood cell 
lysis on routine coagulation testing. Arch Pathol Lab Med 2006; 130:181-184. 
114 
(198) Couto CG. Disorders of hemostasis.In: Nelson RW, Couto C G, eds. Small 
animal internal medicine. 3rd edt. Mosby: ST. Louis; 2003:1185-99. 
(199) Corash L, Costa JL, Shafer B, et al. Heterogeneity of human whole blood 
platelet subpopulations. III. Density-dependent differences in subcellular 
constituents. Blood. 1984;64:185-93. 
(200) Paltrinieri S, Meazza C, Giordano A, Tunesi C. Validation of 
thromboelastometry in 12 horses. Vet Clin Pathol. 2008;37:277-85. 
(201) Iselin BM, Willimann PF, Seifert B, et al. Isolated reduction of haematocrit 
does not compromise in vitro blood coagulation. Br J Anaesth. 2001;87:246-9. 
(202) Spiezia L, Radu C, Marchioro P, et al. Peculiar whole blood 
rotationthromboelastometry (Rotem) profile in 40 sideropenic anaemia patients. 
ThrombHaemost. 2008;100:1106-10. 
(203) Garton S, Larsen AE. Effect of hemolysis on the partial thromboplastin time. 
Am J Med Technol. 1972; 38: 408-10. 
(204) Reed GF, Lynn F, Meade BD. Use of coefficient of variation in assessing 
variability of quantitative Assays. Clinical and Diagnostic Laboratory Immunology 
2002; 9:1235-1239. 
(205) Bauer N, Moritz A. Evaluation of the Cardiac reader® as a point-of-care 
instrument for measurement of fibrin D-dimers in dogs. Tierärztliche Praxis, 2009; 5: 
319-325. 
(206) Brooks MB. Evaluation of a chromogenic assay to measure the factor Xa 
inhibitory activity of unfractionated heparin in canine plasma. Vet Clin Pathol 2004; 
33:208-214. 
(207) Lippi G, Guidi GC. Effect of specimen collection on routine coagulation assays 
and D-dimer measurement. Clin Chem 2004; 50:2150-2152. 
(208) Wiwanitkit V. Rejection of specimens for prothrombin time and relating 
preanalytical factors in blood collection. Blood Coagul Fibrinolysis 2002; 13:371-372. 
115 
(209) Vilar P, Couto CG, Westendorf N, et al. Thromboelastographic tracings in 
retired racing greyhounds and in non-greyhound dogs. J Vet Intern Med 2008; 
22:374-379. 
(210) Solberg HE. Approved recommendation on the theory of reference values. 
Part 5.Statistical treatment of reference values. Determination of reference limits. J 
Clin Chem Clin Biochem 1987; 25:645-656. 
(211) Dimauro C, Bonelli P, Nicolussi P, et al. Estimating clinical chemistry 
reference values based on an existing data set of unselected animals. Vet J 2008; 178: 
278-281. 
(212) Wiinberg B, Jensen AL, Kjelgaard-Hansen M, et al. Study on biological 
variation of haemostatic parameters in clinically healthy dogs. Vet J 2007; 174:62-68. 
(213) Chan KL, Summerhayes RG, Ignjatovic V, et al. Reference values for kaolin-
activated thromboelastography in healthy children. Anesth Analg 2007; 105:1610-3, 
table. 
(214) Edwards RM, Naik-Mathuria BJ, Gay AN, et al. Parameters of 
thromboelastography in healthy newborns. Am J Clin Pathol 2008; 130: 99-102. 
(215) Tanaka KA, Szlam F, Katori N, et al. Evaluation of a novel kallikrein inhibitor 
on hemostatic activation in vitro. Thromb Res 2004; 113:333-339. 
(216) Dolan G, Neal K, Cooper P, et al. Protein C, antithrombin III and plasminogen: 
effect of age, sex and blood group. Br J Haematol 1994; 86:798-803. 
(217) Sakata T, Okamoto A, Morita T, et al. Age- and gender-related differences of 
plasma prothrombin activity levels. Thromb Haemost 2007; 97: 1052-1053. 
(218) Mischke R. Hämostase [hemostasis]. In: Kraft W, Dürr UM. eds. Klinische 
Labordiagnostik in der 54. Tiermedizin. 6 edt, pp. 115-144. Schattauer, Stuttgart. 
Article in German. 
(219) Murtaugh RJ, Dodds WJ. Hemophilia A in a female dog. J Am Vet Med Assoc 
1988; 193:351-352. 
116 
(220) Mischke R. Optimization of coagulometric tests that incorporate human 
plasma for determination of coagulation factor activities in canine plasma. Am J Vet 
Res 2001; 62:625-629. 
(221) Lutze G, Kutschmann K. The plasma coagulation system of domestic cats. Berl 
Munch Tierarztl Wochenschr 1991; 104:53-57. English abstract. 
(222) Lutze G, Hartung KJ, Kutschmann K.Determination of the activity of single 
coagulation factors in clinically healthy swine and cattle. Berl Munch Tierarztl 
Wochenschr 1992; 105:411-414. English abstract. 
(223)  Johnstone IB, Martin CA. Comparative effects of the human protein C 
activator, Protac, on the activated partial thromboplastin clotting times of plasmas, 
with special reference to the dog. Can J Vet Res 2000; 64: 117-122. 
(224) Stocker K, Fischer H, Meier J, et al. Protein C 1 activators in snake venoms. 
Behring Inst Mitt 1986; 37-47. 
(225) Stocker K, Fischer H, Meier J, et al. Characterization of the protein C activator 
Protac from the venom of the southern copperhead (Agkistrodon contortrix) snake. 
Toxicon 1987; 25:239-252.  
(226) Toulza O, Center SA, Brooks MB, et al. Evaluation of plasma protein C activity 
for detection of hepatobiliary disease and portosystemic shunting in dogs. J Am Vet 
Med Assoc 2006; 229: 1761-1771. 
(227) Wilke K. Untersuchungen zur Beurteilung der fibrinolytischen Aktivität im 
Plasma von verschiedenen Spezies (inklusive Mensch) und Korrelation mit der in 
vivo fibrinolytischen Wirkung von therapeutisch wirksamen Prinzipien [Evaluation 
of fibrinolytic activity in the plasma of different species (including man) and 
correlation with the in vivo fibrinolytic effect of therapeutic principles]. Thesis work, 
Justus- Liebig-University Giessen, 2008. English Abstract. 
(228) Hedlin AM, Monkhouse FC, Milojevic SM. A comparative study of fibrinolytic 
activity in human, rat, rabbit, and dog blood. Can J Physiol Pharmacol. 1972; 50:11-
16. 
117 
(229) Karges HE, Funk KA, Ronneberger H. Activity of coagulation and fibrinolysis 
parameters in animals. Arzneimittelforschung 1994; 44: 793-797. 
(230) Gunzel-Apel AR, Hayer M, Mischke R, et al. Dynamics of haemostasis during 
the oestrous cycle and pregnancy in bitches. J Reprod Fertil Suppl.1997; 51:185-193. 
(231) Hughes R, Thomson K, Hopkins R, et al. Determinants of plasma D-dimer 
levels in a traveling population. J Thromb Haemost.2005; 3:2445-2448. 
(232) Mischke R. Activity of coagulation factors II, V, VII and X in healthy dogs 
dependence on age, sex and breed. Berl Munch Tierarztl Wochenschr. 1994; 107: 289-
294. English abstract. 
(233) Declue AE, Cohn LA, Lechner ES, et al. Effects of subanesthetic doses of 
ketamine on hemodynamic and immunologic variables in dogs with experimentally 
induced endotoxemia. Am J Vet Res. 2008;69:228-32. 
(234) Nates JL, Doursout M-F, Weavind LM, Chelly JE. A thromboelastographic 
study of LPS induced coagulation abnormalities induced coagulation abnormalities 
in a pig endotoxemic shock model. Abstract poster presentation; Critical Care 
Medicine. 27(12) Supplement: A102, Dec 1999. 
(235) Spiel AO, Mayr FB, Firbas C, et al. Validation of rotation thrombelastography 
in a model of systemic activation of fibrinolysis and coagulation in humans. J 
Thromb Haemost.2006;4:411-6. 
(236) Daudel F, Kessler U, Folly H, et al. Thromboelastometry for the assessment of 
coagulation abnormalities in early and established adult sepsis: a prospective cohort 
study. Crit Care. 2009;13:R42. 
(237) Hesselvik JF, Malm J, Dahlback B, Blomback M. Protein C, protein S and 
C4b22 binding protein in severe infection and septic shock. Thromb Haemost. 
1991;65:126-9. 
(238) Yan SB, Helterbrand JD, Hartman DL, et al. Low levels of protein C are 
associated with poor outcome in severe sepsis. Chest.2001;120:915-22. 
(239) Alcaraz A, Espana F, Sanchez-Cuenca J, et al. Activation of the protein C 
pathway in acute sepsis. Thromb Res. 1995;79:83-93. 
118 
(240) Mavrommatis AC, Theodoridis T, Economou M, et al. Activation of the 
fibrinolytic system and utilization of the coagulation inhibitors in sepsis: comparison 
with severe sepsis and septic shock. Intensive Care Med. 2001;27:1853-9. 
(241) Fourrier F, Chopin C, Goudemand J, et al. Septic shock, multiple organ failure, 
and disseminated intravascular coagulation. Compared patterns of antithrombin III, 
protein C, and protein S deficiencies.Chest. 1992; 101: 816-23. 
(242) Lorente JA, Garcia-Frade LJ, Landin L, et al. Time course of hemostatic 
abnormalities in sepsis and its relation to outcome. Chest.1993;103:1536-42. 
(243) de Pont AC, Bakhtiari K, Hutten BA, et al. Endotoxaemia induces resistance to 
activated protein C in healthy humans. Br J Haematol.2006;134:213-9. 
(244) Begbie M, Notley C, Tinlin S, et al. The Factor VIII acute phase response 
requires the participation of NFkappaB and C/EBP. Thromb Haemost. 2000;84:216-22. 
(245) Topper MJ, Prasse KW. Analysis of coagulation proteins as acute-phase 
reactants in horses with colic. Am J Vet Res. 1998;59:542-5. 
(246) Prasse KW, Topper MJ, Moore JN, Welles EG. Analysis of hemostasis in horses 
with colic. Am J Vet Res 1998; 59:542-545. 
(247) Deitch EA. Animal models of sepsis and shock: a review and lessons learned. 
Shock.1998;9:1-11. 
(248) Lucas WE, Kitzmiller JL. The role of intravascular coagulation in feline 
endotoxin shock. Surg Gynecol Obstet. 1972;134:73-7. 
(249) Koplitz SL, Scott MA, Cohn LA. Effects of platelet clumping on platelet 
concentrations measured by use of impedance or buffy coat analysis in dogs. J Am 
Vet Med Assoc. 2001;219:1552-6. 
(250) Stokol T, Erb HN. A comparison of platelet parameters in EDTA- and citrate 
anticoagulated blood in dogs. Vet Clin Pathol. 2007;36:148-54. 
  
119 
10. Acknowledgements 
 
There are several people who I would like to thank for their various support: 
- Dr. Natali Bauer;  I couldn’t think anything without her. 
- Prof. Dr. Andreas Moritz and his beautiful family; without their help nothing    
would be possible. 
-  Prof. Dr. Zeki Yılmaz; who always encouraged me, supports me in all matters 
and gives me the chance to learn from him 
-  Prof. Dr. Nilüfer Aytug, whose support I can feel everytime and everywhere, 
like a mother’s love 
-  Prof. Dr. Hasan Batmaz; giving me the chance to work in Giessen 
-  Prof. Dr. Wilhelm Schoner and Katrin Schoner; everytime they entertained me 
so kindly  
-  All the collegues at the small animal clinic; Internal Medicine, Radiology and 
Laboratory in Giessen 
-  All my collegues at the Animal Hospital; Internal Medicine and Laboratory in 
Bursa, Turkey 
-  Tokra Medikal, Ankara, Turkey 
-  Aycan Özcan and Hakan Bulun ; who were always good friends abroad 
And I want to thank my dad, mum and sisters Berin and Büsra for their devotions 
and love to support me. My husband Kivanc – he is everything; and his family. Halit 
and Zehra as the best aunt and uncle. 
 
 
 
 
 
 
120 
„Ich erkläre: Ich habe die vorgelegte Dissertation selbständig und ohne unerlaubte 
fremde Hilfe und nur mit den Hilfen angefertigt, die ich in der Dissertation 
angegeben habe. Alle Textstellen, die wörtlich oder sinngemäß aus veröffentlichten 
oder nicht veröffentlichten Schriften entnommen sind, und alle Angaben, die auf 
mündlichen Auskünften beruhen, sind als solche kenntlich gemacht. Bei den von mir 
durchgeführten und in der Dissertation erwähnten Untersuchungen habe ich die 
Grundsätze guter wissenschaftlicher Praxis, wiesie in der „Satzung der Justus–
Liebig-Universität Gießen zur Sicherung guter wissenschaftlicher Praxis“ 
niedergelegt sind, eingehalten.“ 
       Oya Eralp Inan    
       Tierärztin aus Schwelm/Deutschland 
 
O
Y
A
 
E
R
A
L
P
 
I
N
A
N
 
 
 
 
 
 
C
O
A
G
U
L
A
T
I
O
N
-
T
E
G
-
S
T
A
 
C
O
M
P
A
C
T
-
E
N
D
O
T
O
X
E
M
I
A
-
D
O
G
VVB VVB LAUFERSWEILER VERLAG
édition scientifique
9 7 8 3 8 3 5 9 5 8 4 9 4
VVB LAUFERSWEILER VERLAG
STAUFENBERGRING 15
D-35396 GIESSEN
Tel: 0641-5599888 Fax: -5599890
redaktion@doktorverlag.de
www.doktorverlag.de
VVB LAUFERSWEILER VERLAG
édition scientifique
ISBN: 978-3-8359-5849-4
Establishment of Reference Intervals for  Kaolin-
activated TEG  and the STA Compact Automated
Analyzer for Dogs and Coagulation Response 
in a Canine Model of Endotoxemia
Oya Eralp Inan 
INAUGURAL-DISSERTATION zur Erlangung des Grades eines Dr. med. vet.
beim Fachbereich Veterinärmedizin der Justus-Liebig-Universität Gießen
